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Abstract 
Background: Cancer associated fibroblasts (CAFs) are known to stimulate crosstalk 
between stroma and cancer via paracrine signalling and promote cancer progression 
through matrix remodelling, angiogenesis and immunosuppression. CAFs arise from 
many sources and display different markers and characteristics in the tumour 
stroma; their presence in head and neck cancers is associated with poor prognosis. 
This study examines the differences in secretome of myofibroblasts and senescent 
fibroblasts in the context of their ability to recruit and polarise macrophages, with the 
aim of establishing which phenotype recruits more macrophages, which 
chemokine/receptor is primarily employed and which way are the macrophages 
polarised. 
Methods: Normal oral fibroblasts (NOFs) were transdifferentiated to myofibroblasts 
(MF) using TGF-β1, or senesced using cisplatin. MF phenotype was confirmed by 
expression of α-smooth muscle actin (α-SMA), fibronectin with extra domain A 
(FNEDA), and collagen type 1 alpha 1 (COL1A1) using RT-qPCR, western blot and 
immunofluorescence. Senescence was confirmed by senescence associated β-
galactosidase assay, RT-qPCR for p16INK4A and p21CIP1/WAF-1. Primary monocytes 
were allowed to migrate towards conditioned medium (CM) from MFs, senescent 
fibroblasts (SFs) and patient CAFs in a Boyden chamber assay. The involvement of 
chemokine receptors were scrutinised using CCR2 antagonist and pertussis toxin. 
Macrophages were also polarised in the same CM, as assessed by qPCR. Levels of 
The secretome of MFs, SFs and patient-derived CAF was examined using ELISA, 
cytokine array and mass spectrometry. 
Results: CCL2 secretion correlated with monocyte migration through CCL2/CCR2 
axis towards CM from SF, MF and most patient CAFs. SFs secreted more IL-6 and 
CCL2 than MFs, in which secretion declined with longer duration of TGF-β1 
treatment. Cytokine array detected more cytokines secreted by MF than SF, while 
MS revealed more collagen interacting proteins secreted by SF, while both secreted 
several types of collagen. MF, SF and patient CAF CM also polarised macrophages 
towards M2 phenotype, increasing CD206 mRNA compared to normal firboblasts 
CM. While CM from unpolarised (M0) macrophages induced highest expression of α-
SMA expression 
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Conclusion: SF recruits more monocytes through CCL2/CCR2 axis and secreted 
more collagen interacting proteins than MF. However, both seem to polarisation 
macrophages towards M2 phenotype. Collectively the data identify differences and 
similarities in the secretome of MF and SF, and one or both can be potentially 
targeted to manipulate immune cell populations in tumour stroma to improve 
prognosis. 
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Chapter 1 
1. Review of literature 
1.1 Introduction to Cancer 
Cancer has become a major cause of morbidity and mortality around the world 
irrespective of region or race. World Health Organisation outlines in World Cancer 
Report 2014 that nearly 14 million new cases and 8 million cancer related deaths 
occurred in 2012 (McGuire, 2016). The report also highlights high incidence rates of 
all cancers combined in high income countries of North America, Western Europe 
(along with Australia, Japan, New Zealand, and Republic of Korea) compared to 
Central and South America, Eastern Europe, Africa, and South Asia (McGuire, 
2016). However, cancer related mortality is higher in developing countries (McGuire, 
2016). 
1.2 Head and neck cancer 
While lung, prostate, and breast cancers have the highest incidence, head and neck 
cancer (HNC) is the fifth common cancer worldwide. It is the most common 
malignant disease in Central Asia (Marcu and Yeoh, 2009). Squamous cell 
carcinoma predominates, making up over 95% of all HNC cases, while the rest (4-
17 
 
5%) are mainly melanoma or salivary gland adenocarcinoma (Vikram et al., 1984). 
HNC includes cancers of the larynx, pharynx (nasopharynx, oropharynx, and 
hypopharynx), nasal cavity, paranasal sinuses, oral cavity, tongue, and salivary 
glands (fig.1.1). The main risk factors for HNC are excessive exposure to alcohol, 
tobacco (including chewing tobacco) and human papilloma virus infection (Mathers, 
2006, Boyle, 2008). However, genetic predisposition can increase risk of HNC in 
non-consumers of alcohol, and tobacco, and so can poor oral hygiene (Rosenquist, 
2005). In developing countries such as the Indian sub-continent, and South East 
Asian countries chewing of areca nut has been linked to cancer (Sankaranarayanan 
et al., 1998). 
Oral cancer is sub-type of HNC, and manifests itself on the lip or the oral cavity, as 
described previously. Oral cancer is often referred to as oral squamous cell 
carcinoma as 90% of the cancers occurring in the oral cavity arise histologically from 
squamous cells (Lingen et al., 2008). The frequency of occurrence of oral cancer is 
in South East Asia (India, Pakistan, Sri Lanka, and Taiwan), France, Eastern Europe 
(Hungary, Slovenia, and Slovakia), and Latin America and Carribean 
18 
 
(Warnakulasuriya, 2009). Similar to other parts of head and neck, majority of cases 
of oral cancer are caused by chewing/smoking of tobacco, alcohol consumption, 
chewing of areca nut, poor nutrition (especially from poor socio-economic status), 
HPV infections, and poor oral hygiene (Johnson et al., 2011, Secretan et al., 2009, 
Conway et al., 2008, Doll and Peto, 1981, Syrjänen et al., 2011, Guha et al., 2007). 
With such a vast epidemiological spread and poor treatment options, this thesis 
dwells further in to biology of oral cancer to propose future treatment targets. 
 
 
 
 
 
 
 
19 
 
 
Figure 1.1 Regions common to cancers of the head and neck. (For the National 
Cancer Institute © 2012 Terese Winslow LLC, U.S. Govt. has certain rights, 
permission granted for use in this thesis) 
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Survival rates for HNC, including oral cancer are still quite poor at only 50% overall 
with no significant improvement for several decades, particularly for advanced 
disease (Döbróssy, 2005, Haddad and Shin, 2008). Disease outcome is improved if 
diagnosed early, with survival rates as high as 75% at five years, however patients 
frequently present with metastasis to lungs, bone, mediastinal lymph node, and 
adrenal gland (Chin et al., 2005, Wiegand et al., 2015). 
Current treatment options for HNC include surgery, frequently involving removal of 
cervical lymph nodes to remove local metastases, combined with radiotherapy as 
well as chemotherapy. Therefore, there is a clear need to develop novel treatment 
strategies for HNC. 
1.2.1  Therapies in HNC 
Some of the new emerging therapies include the use of viruses; Gendicine is 
a non-replicating adeno-virus engineered to contain a human wild-type p53 
expression cassette propelled by Rous sarcoma virus promoter. Intra-tumoral 
injections of Gendicine restores expression of p53, which is often down-
regulated or mutated, in cancer cells to induce cell cycle arrest, and apoptosis 
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in humans (Hughes et al., 2015a). In phase III clinical trials, Gendicine 
demonstrated a response rate of 96% when used in conjunction with 
radiotherapy, compared to 80% when radiotherapy was used alone (Peng, 
2005). Although Gendicine has been approved for use in China, it failed to get 
approval in the U.S.A and Europe (Pearson et al.) H101 is an oncolytic virus 
modified to only replicate in cancer cells; in phase III with cisplatin and 5-
flurouracil, it has achieved 78.8% response rate compared to 39.6% with 
chemotherapy alone (Xia et al., 2004). 
Another upcoming therapy makes use of epidermal growth factor receptor 
(EGFR) inhibitors. EGFR is implicated in several cancers like pancreatic, 
breast, lung, HNCs (Shostak and Chariot, 2015). However, EGFR inhibitors 
are often seen to provoke drug resistance, with second generation of EGFR 
inhibitors showing some advancement in breast, pancreatic, lung, and HNC 
(Lee et al., 2014a). EGFR inhibitors have shown to induce autophagy, which 
promotes recycling of organelles and cellular components providing nutrients 
to cancer cells; therefore autophagy inhibitor may prove to be cytotoxic to 
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cancer cells in this case. However, if autophagy inducers are administered, it 
could lead to autophagic cell death; hence tilting the scale either way – 
inhibiting or up-regulating autophagy may prove to be therapeutic (Cui et al., 
2014). 
Current therapies targeting EGFR include a chimeric IgG1 mAb called 
Cetuximab, approved in 2006 to treat locally or regionally advanced head and 
neck squamous cell carcinoma (HNSCC) in combination with radiation 
therapy (Santuray et al., 2018). Phase III clinical trials combining Cetuximab 
and radiation therapy showed significant improvement in median overall 
survival from 14.9 months for radiation alone to 24.9 months (Bonner et al., 
2006). After another study, Cetuximab was approved as first line of treatment 
in combination with platinum based therapy in local or metastatic HNSCC as 
median overall survival improved from 7.4 to 10.1 months, however it was 
also approved to be used as single agent treatment in platinum based therapy 
resistant HNSCC where it reported a response rate of 13% (Vermorken et al., 
2008).  
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Unfortunately, resistance towards Cetuximab is increasing, and other EGFR 
inhibitors like Pantinumab and Zalutumumab are in trials (Santuray et al., 
2018). 
Our body’s natural immune system is capable of recognising neoplastic cell 
antigens, along with other costimulatory and inhibitory molecules, in order to 
eliminate those cells. However, cancer cells manipulate immune check points 
in the body to evade anti-tumour immunity (Pardoll, 2012). Immune check 
points are numerous inbuilt pathways to prevent auto-immune reactions, and 
modulate duration and magnitude of required immune reactions (Pardoll, 
2012). Some of the well-known immune check points are cytotoxic T 
lymphocyte associated protein-4 (CTLA-4), and programmed cell death 
protein-1 (PD-1). PD-1 plays a role at a later stage of immune response in the 
infected tissue, where it binds with its ligand – PD-1 ligand (PDL-1) to regulate 
the activity of effector T cells to limit additional tissue damage (Santuray et al., 
2018, Pardoll, 2012). Currently, Pembrolizumab, a monoclonal antibody 
(mAb) directed against PD-1, and was first authorised to be used to treat 
24 
 
metastatic melanoma. In August 2016, it was approved to be used in recurrent 
or metastatic HNSCC with or after platinum chemotherapy (Santuray et al., 
2018). In tumour with 50% or more the cells expressing PDL-1, the overall 
survival improved from 7.9 months to 11.6 months with use of Pembrolizumab 
(Cohen, 2017). In another study, patients with unmanageable 
metastatic/recurrent HNSCC after both platinum and cetuximab, showed an 
overall response of 16% (Bauml et al., 2017). 
Nivolumab is another mAb approved to treat metastatic/recurrent HNSCC with 
or after platinum chemotherapy. Compared to standard therapy 
(methotrexate, cetuximab, or docetaxel), Nivolumab increased 1 year survival 
rate from 16% to 36% (Ferris et al., 2016).  
Although Pembrolizumab and Nivolumab show response rates below 20%, 
they show better overall survival than standard of care, and are being trialled 
with other drug combinations to increase their response rate (Santuray et al., 
2018). 
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Meanwhile, CTLA-4 is normally expressed on regulatory T (Treg) cells, but is 
upregulated in conventional T cells in tumour microenvironment (Pardoll, 
2012, Syn et al., 2017). CTLA-4 is sequestered in intracellular vesicles, and 
not surfaced until the T cell receptors (TCR) are activated, where its 
expression increases with stronger TCR activation, and also binds with CD80 
and CD86 on antigen presenting cells to dampen immune response (Santuray 
et al., 2018, Pardoll, 2012).  
In HNSCC patients with tumours with surplus infiltration of CTLA-4 expressing 
Treg cells, could be the reason behind dysfunction of effector cells (Albers et 
al., 2005). Furthermore, a study with cetuximab treated HNSCC patients with 
higher frequency of circulating CTLA-1 has poorer clinical outcome (Jie et al., 
2015).  
Currently there are no CTLA-4 inhibitors in clinic but Ipilimumab, a mAb 
against CTLA-4, has been approved to treat metastatic melanoma, is being 
trialled as single agent as well as in combination with Nivolumab to treat 
HNSCC (Larkin et al., 2015). 
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Alternatively, nanoparticles (versatile particles of 1-100 nm in diameter) are 
also being exploited to use as cancer therapy. Nanoparticles easily 
accumulate in tumour tissues due to leaky vasculature and inefficient 
lymphatic drainage, where they can extravasate though blood vessels and 
capillaries to deposit therapeutic agents and target cancer cells more 
efficiently (Wu and Zhou, 2015). Since nanoparticles are foreign bodies and 
will be attacked and cleared by the immune system, they’re coated with 
biodegradable polyethylene glycol to reduce being phagocytosed.  
Nanoparticles can be used to deliver anti-sense oligonucleotides, and small 
interfering RNA aimed at degradation of targeted mRNA to prevent expression 
of proteins like GLUT-1, EGFR, survivin, protein kinase CK2, ribonuclease 
reductase M2 amongst many to halt cancer growth (Wu and Zhou, 2015). 
1.3 Inflammation and cancer 
1.3.1 Acute inflammation 
Acute inflammation is initiated as a mechanism to resolve infections and 
injurious stimuli. Inflammation is a complex reaction involving the resident 
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macrophages, dendritic cells, circulating leukocytes and neutrophils, connective 
tissue cells, and extracellular fibrous proteins and glycoproteins recruited to the 
site of infection/injury (Beck, 2013). The process of inflammation can damage 
the surrounding cells of the tissue if continued for too long, hence resolution of 
inflammation is an important aspect of maintaining homeostasis. The initial step 
towards resolution involves terminating pro-inflammatory mediators, and their 
catabolism, followed by clearance of immune cells present at the site of 
infection/injury. The leukocytes can either return back into systemic circulation 
or undergo apoptosis/necrosis resulting in phagocytosis/efferocytosis by 
macrophages (Gilroy and De Maeyer, 2015). Dying cells display surface 
markers that are recognised by macrophages which then phagocytose them. In 
the process these macrophage release anti-inflammatory molecules, such as 
IL-10 and TGF-β1 (Huynh et al., 2002). It’s also been observed that when 
monocytes are exposed to glucocorticoids, they differentiate into highly 
phagocytic macrophages with elevated cell surface CD163 (Giles et al., 2001, 
Philippidis et al., 2004). Most macrophages then return back to the lymphatic 
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system while the remaining few undergo apoptosis themselves (Gilroy et al., 
2003). 
1.3.2  Chronic Inflammation and cancer 
When either the inflammatory response is not short lived, or resolution of 
inflammation is inadequate, it can lead to chronic inflammation. Other reasons 
for chronic inflammation can be exposure to a toxic agent, for example 
tobacco or silica in lungs (Cohen and Pope, 1995), auto-immune disorders 
such as inflammatory bowel disease which can lead to colon cancer 
(Francescone et al., 2015), and obesity predisposing to liver cancer (Calle 
and Kaaks, 2004). However, infection plays the greatest role in chronic 
inflammation and related cancers with up to 20% of cancers worldwide 
associated with microbial infection, such as Helicobacter pylori causing gastric 
cancer or mucosa associated lymphoid tissue lymphoma (Kuper et al., 2000, 
De Falco et al., 2015).  Prolonged inflammation also results in accumulation of 
metabolic products such as reactive oxygen species and reactive nitrogen 
species which potentially damage DNA by activating oncogenes and/or 
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inactivating tumour suppressor gene or mismatch repair mechanisms as 
depicted in fig. 1.2 (Ohnishi et al., 2013, Beck, 2013). 
 
 
 
 
 
 
 
30 
 
 
Figure 1.2: Relationship between inflammation and various stages of cancer development 
& progression. Inflammatory factors such as ROS, RNS, COX2, other cytokines when 
secreted chronically can alter DNA expression leading to activation of oncogenes, and 
deactivation of tumour suppressor genes, allowing uncontrolled proliferation of 
transformed cells. The same inflammatory factors can further fuel cancer progression and 
metastasis. 
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1.3.3 Role of COX2 in inflammation and cancer  
One of the many inflammatory molecules implicated in promoting cancer is 
cyclooxygenase 2 (COX-2), which mediates immune responses by catalysing 
the production of prostaglandins and prostanoids and plays a vital role in 
angiogenesis, cell proliferation, inhibition of apoptosis, and cell motility. 
Moreover, COX-2 is found at sites of inflammation released by epithelial, 
mesenchymal and inflammatory cells in response to cytokines, environmental 
factors and infective agents (O'Byrne and Dalgleish, 2001). Consequently, 
COX-2 induces production of Th2 cytokines, IL-4 and IL-10, which are known 
to be immuno-suppressive and in turn suppress production of Th1 cytokines. 
Therefore, the site of inflammation may promote mutagenic changes in cells 
and provides an immuno-suppressive environment for these cells to evade 
host’s immune surveillance and pass the mutations down to the next 
generation of cells while developing more mutations leading to neoplasia and 
eventually to a malignant tumour development (Kundu, 2008). 
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According to (Wu et al., 2014), COX-2 upregulated urokinase type 
plasminogen activator and its receptor which are involved in degrading extra-
cellular matrix to promote metastasis in osteosarcoma.  
COX-2 was also found to be upregulated and secreted by senescent 
fibroblasts, and regulates microRNA-335 which, further enhances secretion of 
IL-6, CCL2, and MMP-2 creating a pro-inflammatory secretome, which 
stimulated migration of H357 cells (HNC cell line) in an in vitro model (Kabir et 
al., 2016) 
1.3.4 Role of IL-6 in inflammation and cancer 
Another prominent molecule in inflammation is IL-6, which is a multifaceted 
cytokine. During inflammation, it is secreted by monocytes, macrophages, 
neutrophils, endothelial cells, fibroblasts, T-cells, and smooth muscle cells 
(Rose-John, 2012). IL-6 has a similar protein structure to IL-11, IL-27, IL-31, 
ciliary neurotrophic factor, cardiotrophin-1, cardiotrophin like cytokine, 
leukemia inhibitory factor, and oncostatin M, and these are all part of the IL-6 
cytokine family. The IL-6 cytokine family, with exception of IL-31, activates the 
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JAK/STAT3 pathway, MAPK/ERK pathway, and PI3K pathway through their 
unique signalling receptors and glycoprotein 30 which increases transcription 
and translation of many downstream proteins promoting cell survival, 
proliferation, differentiation (Poncet et al., 2011, Hov et al., 2009, Guo et al., 
2012, Yao et al., 2014), migration (Ara and Declerck, 2010, Walter et al., 
2009, Foran et al., 2010), invasion (Walter et al., 2009, Lin et al., 2007, Huang 
et al., 2011, Sullivan et al., 2009, Yadav et al., 2011), angiogenesis (Middleton 
et al., 2014, Xu et al., 2005, Shinriki et al., 2011), metabolism, and 
inflammation (Tanaka et al., 2014).  
In HNC patients, IL-6 has found to be elevated in blood samples, and 
distinctly predict tumour metastasis, recurrence and survival (Duffy et al., 
2008, Riedel et al., 2005, Chen et al., 1999). IL- 6 is also known to promote 
malignant growth of SCC through complex cytokine and protease network 
(Lederle et al., 2011). IL-6 has also been associated with HNC progression 
where serum levels of IL-6 in stage IV were significantly different from stage 
I/II/III (Mojtahedi et al., 2011). It is also a powerful inducer of EMT via 
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JAK/STAT3/SNAIL, confirmed by up-regulation of vimentin, and down-
regulation of E-cadherin; addition of recombinant IL-6 to tumour cell culture 
produced similar results (Yadav et al., 2011, Scherzad et al., 2015). Through 
persistent activation of STAT3 pathway by IL-6, target genes responsible for 
proliferation, migration, invasion, survival, cancer stem cell expansion, EMT 
and chemo-resistance expressed (Su et al., 2011, Yadav et al., 2011, Stanam 
et al., 2015). Evidence has shown that targeting IL-6/STAT3 pathway by 
inhibiting IL-6 receptor by an antibody led to decrease in mRNA of serpin 
B3/B4 (known to promote cell survival in HNC), enhancing tumour cell 
apoptosis (Ahmed and Darnell, 2009). IL-6 is also capable of altering CpG 
promoter, responsible for DNA methylation, and repress tumour suppressor 
genes like GATA5, PAX6, and CHFR (Gasche et al., 2011). With such diverse 
roles of IL-6 in HNC, its production by two CAF phenotypes are examined in 
this thesis further. 
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1.3.5 Role of CCL2 in inflammation and cancer 
CCL2 is produced by several cells, such as, fibroblasts, endothelial cells, 
mesangial, smooth muscle, astrocytic and glial cells, with 
monocyte/macrophage as the major source of the chemokine (Deshmane et 
al., 2009). It is one of the many prevalent cytokines found at the site of 
inflammation, where it recruits monocytes through the CCL2/CCR2 axis, 
which then differentiate into macrophages to phagocytose invading 
pathogens, and to clear prevailing immune cells at the end of an acute 
inflammatory phase. It is also serves as a chemoattractant for memory T 
lymphocytes and natural killer (NK) cells (Deshmane et al., 2009). However, 
CCL2 has been found in tumours and their environment, and levels of CCL2 
correlate with the presence of tumour associated macrophages and poor 
prognosis in prostate and breast cancer (Zhang et al., 2010, Ueno et al., 
2000). A gene study from human monocytes as well as murine bone marrow 
derived macrophages has shown CCL2 is also able to selectively polarise 
these macrophages to a M2 phenotype in the presence of M-CSF with 
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upregulated expression of CD206, and increased secretion of IL-10 (Sierra-
Filardi et al., 2014). Qian et al reported that monocytes recruited by tumour 
derived CCL2, stimulated extravasation of tumour cells via monocyte-derived 
endothelial growth factor (Qian et al., 2011). CCL2 is also able to bind to 
CCR4, recruiting T regulatory cells, building an immuno-suppressed 
environment in tumours (Lim et al., 2016). CCR2 expressing cancer cells 
respond to CCL2 through MEK-p42/44MAPK, and increasing the secretion of 
MMP9 resulting in increased cell motility and cell survival (Fang et al., 2012, 
Tang and Tsai, 2012). CCL2 has also been shown to assist mammary cancer 
cell proliferation and cell survival (Hembruff et al., 2010, Lim et al., 2016). 
CCL2 has also been associated with metastasis and cancer stem cells (Lu 
and Kang, 2009, Loberg et al., 2007, Tsuyada et al., 2012b, Kudo-Saito et al., 
2013). It has also been observed in vitro that mesenchymal stem cell derived 
osteoblasts secrete high levels of CCL2, aiding migration of breast cancer 
cells, suggesting a role in bone metastasis in breast cancer by CCL2 (Molloy 
et al., 2009). Another study showed that human bone marrow endothelial cells 
also secrete high levels of CCL2 compared to dermal and cardiac endothelial 
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cells and attract prostate cancer cells using CCL2 in vitro (Loberg et al., 
2006). Serum levels of CCL2 have been found to high in patients with 
prostate cancer with bone metastasis; when CCL2 production in prostate 
cancer cells was knockdown, it hampered osteoclast formation and upon 
transplantation in SCID mice tibia, reported reduced tumour growth (Lu et al., 
2009)  A study showed that blockade of CCL2, enhanced the chemosensitivity 
of ovarian cancer cells to paclitaxel, and carboplatin (Moisan et al., 2014).  
CCL2 has been implicated in the cancers of HNC as well. In oral squamous 
cell carcinoma (OSCC), significantly lower serum levels of CCL2 was 
observed compared to healthy participants, and the ratio of CCL2/CCL3 
correlated with disease progression, suggesting these can serve as potential 
biomarkers in OSCC (Ding et al., 2014b). CCL2 has also demonstrated to 
induce EMT and increased motility in head and neck cancer cells in vitro via 
activation of AKT pathway (Lee et al., 2015, Ji et al., 2014). Another in vitro 
study reported HNSCC cells educated macrophage to M2-like phenotype via 
CCL2, which in turn secreted EGF, enhancing invasion properties of HNSCC 
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cells by invadopodia which degraded ECM and allowing metastasis (Gao et 
al., 2016). Apart from HNC cells, cancer associated fibroblasts also secrete 
CCL2 when in vicinity of cancer cells in vivo or co-cultured in vitro, further 
enhancing production of endogenous reactive oxygen species which caused 
oxidative stress in HNC cells and fuelled production of cell cycle progression 
proteins promoting proliferation, migration and invasion (Li et al., 2014b). 
Recent evidence also shows that CCR4, found on Treg cells are attracted to 
the tumour microenvironment by CCL2, and impeding CCL2/CCR4 pathway 
reduced this recruitment, allowing effector T cells to evoke anti-tumour 
immunity (Sun et al., 2016).  
With such an array of data implicating CCL2 in HNC, this study looks at 
cancer associated fibroblasts as a source, and macrophage recruitment by 
the resulting CCL2. 
1.3.6 Role of IL-8 in inflammation and cancer 
Another molecule secreted during inflammation is IL-8 (CXCL8). It has also 
been linked with chronic inflammation and cancer. Initially it is responsible for 
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neutrophil recruitment and degranulation to destroy invading pathogens 
(Waugh and Wilson, 2008). However, in cancer it has been observed to be 
secreted by cancer cells themselves, mesenchymal cells, and macrophages 
(Singh et al., 2013). Breast cancer patients display higher serum levels of IL-8 
which is correlated with early metastasis, and its involvement in metastasis 
could be mediated by COX2 (Benoy et al., 2004, Singh et al., 2006).   
The above highlights only a few factors that illustrate the marriage between 
inflammation and cancer. This thesis goes on to highlight more factors, and 
some will be described in detail. 
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1.4 Importance of the tumour microenvironment 
Tumours are not a homogenous group of cells causing disease, but rather a 
heterogeneous population of non-malignant cells, immune cells, expanding network 
of blood vessels, extra cellular matrix, and signalling molecules coordinating together 
and disrupting normal physiological processes as seen in fig. 1.3 (Quail and Joyce, 
2013, Junttila and de Sauvage, 2013). The importance of the tumour 
microenvironment has been the focus of intense research in recent years with 
emphasis on fibroblasts, leukocytes, natural killer cells, Treg cells, myeloid-derived 
suppressor cells, which co-evolve with cancer cells to contribute numerous signals in 
a paracrine fashion having pleiotropic effects on tumour progression, immune-
evasion and metastasis (Curry et al., 2014). The tumour manipulates these cells in to 
changing the ECM around it for easier invasion, stifle attacks by cytotoxic T cell, 
macrophages, and NK cells, create a metabolically supportive environment, and 
allow formation of new blood and lymph vessels (Curry et al., 2014). By 
understanding the stroma around a tumour, and added benefit of stromal cells being 
more genetically stable compared cancer cells, one or more stromal component can 
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be targeted for a more accurate prognosis and treatment options. The importance of 
different aspects, including cells of the tumour microenvironment are described in 
sections after this. 
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Figure 1.3: Diagrammatic representation of tumour microenvironment: A comparison of 
normal stroma vs tumour stroma where the extracellular matrix is stiffer and organised 
differently, epithelial cells are transformed to a malignant state, number of fibroblasts and 
immune cells increases with pro-tumorigenic phenotypes, and vasculature consisting of 
leaky irregular blood vessels. There are also various soluble signalling molecules being 
secreted by tumour cells and stromal cells, through which crosstalk occurs.  
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1.4.1 Extracellular matrix in TME  
Patients usually visit the doctor upon feeling a lump suggesting the rigidity of 
the cancerous mass is more than its surrounding tissue. With this in mind, and 
increasing evidence, rigidity of TME can be considered another hallmark of 
cancer (Jonietz, 2012). 
Radiological examination such as chest x-rays and mammography show that 
cancerous lesions are denser than surrounding tissue, which is a result of an 
increased deposition of extracellular matrix components like collagen and 
fibronectin, and can serve as an independent prognostic tool (Martin and 
Boyd, 2008, Aerts et al., 2014). 
Evidence also suggests that mechanical properties of ECM alter cells’ ability 
to invade. Provenzano et al showed that murine mammary epithelial cells 
displayed more invasive behaviour in stiffer matrix (~44 kPa) compared to 
softer matrix of (~25 kPa) (Provenzano et al., 2009). While Paszek et al 
demonstrated human mammary epithelial cells organised themselves in to 
organotypic acinar structures on soft gels (170 Pa), but this morphology is 
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disrupted and the cells lose their polarity on gels of increasing stiffness (up to 
~1200 Pa) (Paszek et al., 2005). Chaudhuri et al reported similar findings 
where mammary epithelial cells cultured on stiffer substrates lost their 
polarisation, ability to arrest growth, and invaded the matrix (Chaudhuri et al., 
2014). However mechanical forces do not transform cell phenotype 
permanently, and the resulting changes can be reversed with a less rigid ECM 
(Chaudhuri et al., 2014). 
Evidence also suggests a correlation of cancer aggressiveness and 
invasiveness with stiffening of ECM. Acerbi et al reported notable deposition 
of collagen I and ECM remodelling in more aggressive forms of breast cancer 
such as human EGFR2 and Basal-like, in which the ECM were stiffer than 
Luminal A and B types; and at the invasive front of the tumour (Acerbi et al., 
2015). 
Further analysis of the stiffer invasive front of tumours revealed an infiltration 
of CD45, CD68 and CD163 positive macrophages, which further secrete TGF-
β and stimulate production of ECM components such as collagen from the 
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stromal cells and activate lysyl oxidase causing cross-linking of collagen 
(Acerbi et al., 2015, Shanley et al., 1997). Collagen cross-linking caused by 
lysyl oxidase further induces activation of FAK (focal adhesion kinase)/Src 
pathways giving cancer cells a more proliferative and invasive phenotype 
(Baker et al., 2013).  
Having observed the importance of ECM in tumour microenvironment; it is 
important to shed some light on the major source of these ECM components 
– fibroblasts. In the vicinity of cancer cells they’re commonly known as cancer 
associated fibroblasts (CAFs). These CAFs possess the ability to produce, 
deposit and reorganise ECM proteins like collagen (Tuxhorn et al., 2002, 
Yang et al., 2011). One such study by Gaggioli et al demonstrated using 
reflectance imaging which captures a series of images with the object lit at 
variable angles, and transmission electron microscopy, that CAFs paved a 
path, using protease and force mediated matrix remodelling dependent on 
integrins α3 & α5 and regulation of Rho mediated myosin light chains, for 
cancer cells to follow on to invade (Gaggioli et al., 2007). 
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1.4.2 Angiogenesis in TME 
With cancer cells proliferating quickly and forming a mass, they have an 
increased requirement for oxygen, nutrients, and waste removal, which is 
difficult to come by without sufficient blood vessels serving the growing 
tumour. This calls for an urgent need for angiogenesis, and vascular 
endothelial growth factor (VEGF) plays a pivotal role in the process of meeting 
these needs (Ferrara and Davis-Smyth, 1997, Shibuya and Claesson-Welsh, 
2006).  VEGF-A, a sub-type of VEGF family which plays a crucial role in 
formation of blood vessels, is implicated in development and several cancers 
(Matsumoto and Ema, 2014). Current evidence suggests that not only cancer 
cells, but also stromal cells such as CAFs and macrophages secrete VEGF, 
platelet derived growth factor, fibroblast growth factor, insulin-like growth 
factor, angiopoietins, TGF-β1, MMP-9 and several other chemokines to 
promote angiogenesis through endothelial cell invasion and blood vessel 
formation (Hlatky et al., 1994, Sakurai and Kudo, 2011, Murdoch et al., 2008, 
Albini et al., 2005). This, therefore, makes CAFs and macrophages good 
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targets to attempt to inhibit angiogenesis in tumours as a form of cancer 
therapy. 
1.4.3 Immune cells in TME 
It has been long observed that the tumour microenvironment is a home to 
several types of immune cell, and these immune cells are exploited by cancer 
cells to promote cancer progression by providing an immunosuppressed 
environment, stimulating angiogenesis, and metastasis (Gajewski et al., 
2013). T cell populations have been found at invasive tumour fronts and 
draining into lymphoid organs (Restifo et al., 2012). Amongst the T cell 
population in TME, there are CD8+ memory T cells and CD4+ T helper 1 cells 
which provide an anti-tumour effect by secreting IFN-γ, and improve 
prognosis (Fridman et al., 2012). On the other hand, regulatory T cells 
(CD4+CD25+Foxp3+) and Th17 cells are shown to promote tumour growth, 
mainly by suppressing activation of effector immune cells which present self-
antigen, and by secreting TGF- β1 (Chen et al., 2003, Curiel et al., 2004, Kim 
et al., 2007, Littman and Rudensky, 2010).  
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Other immune cells in the TME include but are not limited to; myeloid-derived 
suppressor cells, which promote angiogenesis, disrupt natural killer (NK) cell 
cytotoxicity; also minimise antigen presentation by dendritic cells, and T cell 
activation against cancer cells (Bochet et al., 2013). Another commonly found 
immune cell in the TME is the neutrophil. Neutrophils are capable of acquiring 
different phentotypes under the influence of respective cytokine environment.  
Tumour associated neutrophils promote genetic instability through production 
of reactive oxygen species (ROS), tumour cell proliferation via neutrophil 
elastase, angiogenesis through VEGF-A, MMP-9 and hepatocyte growth 
factor and tumour invasion through cytokines as demonstrated in in vivo mice 
models of mesothelioma (Fridlender et al., 2012, Curry et al., 2014). 
1.4.4 Tumour associated macrophages (TAMs) 
Circulating monocytes are recruited to the site of injury and/or infection, where 
they differentiate in to ‘M0’ or unpolarised macrophages in tissue. Their 
primary role at this stage is to phagocytose damaged cells, invading bodies, 
microbes,  and present resulting antigens to activate T cells resulting 
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inflammation (Navegantes et al., 2017). While a second subset of 
macrophage at the site of inflammation later aims to reduce inflammation   
while remodelling tissue to heal wounds (Mills, 2012).  They are also found in 
and around tumours and this presence is often associated with poor prognosis 
in most cancers including head and neck (Gajewski et al., 2013, Bingle et al., 
2002, Chen et al., 2005, Ryder et al., 2008, Zhu et al., 2008), with exceptions 
of certain cancers like non-small cell lung cancer where high density of 
macrophages are reported to improve prognosis (Kim et al., 2008). This 
conflicting role of TAM could be due to macrophages undergoing polarisation 
exhibiting different secretory phenotypes and markers in response to the 
cytokine environment in their surroundings. Figure 1.4 depicts differential 
activation of macrophages. 
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Figure 1.4. Macrophage activation and polarisation in response to their cytokine 
environment: Depending on the cytokine environment, macrophages can polarise towards 
inflammatory M1 or anti-inflammatory M2, which further sub-divides in to M2a, M2b, M2c, 
and M2d, secreting their own sets of cytokines. M1 activated macrophages respond to 
injury/infection to phagocytose cellular debris, and microbes, while presenting antigens to T 
cells, and are tumoricidal in nature. M2 activated macrophage participate in resolving 
infection, and wound healing, and are known to be pro-tumorigenic. However, in TME, TAMs 
can express markers everywhere on the spectrum of M1 to M2, dependent on the cytokine 
in their environment. 
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At present, macrophages are known to be activated via two pathways, namely 
classical and alternative pathway. Classically activated macrophages are termed M1 
polarised macrophages which are immune stimulatory, are activated by IFN-γ, LPS, 
GM-CSF, TNF-α and TLR engagement (Navegantes et al., 2017). M1 macrophages 
secrete pro-inflammatory factors, such as IL-12, IL-6, IL-1β, TNF-α, and NO species, 
promote local tissue destruction, inflammation, nitrosative stress, and are tumoricidal 
(Mantovani and Sica, 2010, Qian and Pollard, 2010, Mantovani and Locati, 2013, 
Wang et al., 2012, Biswas and Mantovani, 2010). M1 macrophages express cell 
surface markers, such as CD40, CD68, CD80, CD86, MHC II, IL-1R, TLR2, TLR4, 
and SOCS3 in response to the cytokines in their environment (Poh and Ernst, 2018).  
On the other hand, when macrophages are alternatively activated, they’re polarised 
to M2 phenotype, and sub-classified in to M2a (activated by IL-4 & IL-13), M2b 
(activated by immune complexes with IL-1β and LPS), M2c (activated by IL-10, 
glucocorticoids, and TGF-β), and M2d (activated by IL-6, LIF and adenosines) 
(Rőszer, 2015, Poh and Ernst, 2018), play a role in tissue remodelling, angiogenesis, 
and immune-suppression via production of cytokines such IL-10, IL-12, TGF-β and 
52 
 
recruitment of regulatory T cells (Treg) (Kim et al., 2008, Biswas and Mantovani, 
2010). 
In terms of identification, M2 polarised macrophages tend to exhibit a range of 
markers due to existence of various sub-types: M2a – CD163, CD206, MHC II, SR, 
M2b – CD86, MHC II, MerTK, M2c – CD163, TLR1/8, M2d - VEGF; that being said, 
macrophages are very plastic and sit anywhere on the spectrum between M1 and 
M2 with a higher expression of any or combination of these markers depending on 
their location within the tumour and TME (Poh and Ernst, 2018). 
In cancer, role of macrophages still remains unclear, partly due to their plasticity to 
polarise depending on the cytokine environment which varies across the span of a 
tumour. In colorectal cancer study, macrophages have been found to be classically 
activated, expressing M1 marker CD68 upon co-culturing with colorectal tumour 
cells, where the tumour cells showed upregulation of apoptosis associated genes 
and down-regulation of proliferation associated genes, compared to tumour cells 
cultured alone (Ong et al., 2012). The macrophages in the same study also 
expressed T cell co-stimulatory molecules like CD80 and CD86, elaborating further 
on the possibility of recruiting tumoricidal effector T cells to the TME (Ong et al., 
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2012). Migratory inhibitory factor (MIF) is able to induce production of TNF-α and IL-
1β in macrophages producing cytotoxic effects on melanoma cell lines (Pozzi and 
Weiser, 1992). In another in vivo mouse study, IL-18 was found to be secreted from 
macrophages which activated NK cells leading to anti-tumours effects fibrosarcoma 
models; IL-18 also induced the production of other cytokines, IL-1, IL-6, IL-8, and 
TNF-α (Netea et al., 2000, Osaki et al., 1999). 
Having said that, several macrophage depletion studies have reported decreased 
tumour growth and metastasis, suggesting presence of macrophages in and around 
tumours as a double edged sword. Knocking out macrophage colony stimulating 
factor (M-CSF) gene, resulted in delayed mammary tumour growth and metastasis, 
while transgenic expression of M-CSF stimulated tumour progression and metastasis 
to lung (Lin et al., 2001). In another study, presence of CD68+ macrophages 
correlated positively with tumour grade and live metastasis of human pancreatic 
neuroendocrine tumours (PNETs); M-CSF knockdown in mice with PNETs reported 
reduced homing of macrophages to tumour site (Pyonteck et al., 2012). Recently, 
Perrotta, et al found that nitric oxide produced by both human and mice M2 polarised  
(CD206+) TAMs impart chemoresistance towards cisplatin to gliomas (Perrotta et al., 
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2018). Another mouse model of breast cancer, revealed how M2 
CD206+TIE2hiCXCR4hi macrophages assemble around blood vessels in breast 
tumours after chemotherapy, and promote re-vascularisation and relapse via 
secretion of VEGF-A (Hughes et al., 2015b). In the same study, the ligand for 
CXCR4, CXCL12 was found to be upregulated at perivascular sites after 
chemotherapy, promoting migration of TAMs (Hughes et al., 2015b).  Muthana et al 
demonstrated that TAMs can be used as a carrier to deliver oncolytic virus to 
hypoxic tumour sites after chemotherapy or radiation therapy, slowing down tumour 
re-growth and metastasis after treatment (Muthana et al., 2013). 
With such variable roles and potential of TAMs, their recruitment and possible 
polarisation by cancer associated fibroblasts was examined in this thesis. 
1.5 Cancer associated fibroblasts (CAFs) 
Cancer associated fibroblasts, as the name suggests, are present in close proximity 
to cancer cells, fuelling their initiation, progression and metastasis. Lim et al reported 
that fibroblasts from normal oral mucosa, epithelial dysplastic tissue, OSCC 
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(genetically stable and unstable) have different genetic profiles, suggesting 
differential gene regulation in normal environment and TME  (Lim et al., 2011b).  
It has been speculated that cancer associated fibroblasts (CAFs) may be composed 
of heterogeneous populations of which two sub-types identified are myofibroblasts 
and senescent fibroblasts (Routray et al., 2014a, Davalos et al., 2010a). The reason 
for this evident heterogeneity stems from topographical differences, the local 
paracrine milieu and their origins (Fig. 1.5). 
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Figure 1.5: Suggested origins of cancer associated fibroblasts: Numerous studies 
have reported that CAFs express markers from the tissue they originally migrated 
from to transform in to CAFs in response to signalling molecules from the tumour 
cells and their neighbouring cells. So far, evidence suggests resident fibroblasts, 
pericytes, mesenchymal stem cells, adipocytes, endothelial cells, epithelial/cancer 
cells are capable of transforming in to CAFs.  
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1.5.1  Origin of cancer associated fibroblasts: 
1.5.1.1 Resident fibroblast: One of the most convincing sources of CAFs is the 
local tissue resident fibroblasts which are activated in response to 
stimulants secreted by the tumour cells (Augsten, 2014b). TGF-β1 and 
SDF-1 from breast carcinoma cells activate and transdifferentiate 
fibroblasts in to tumour promoting myofibroblasts, forming an autocrine 
loop and maintaining the activated phenotype (Kojima et al., 2010). 
Reactive oxygen species (ROS) from cancer cells lead to an 
accumulation of the transcription factor hypoxia inducible factor (HIF)-1α 
and SDF-1, which again transdifferentiate normal fibroblasts in to CAFs 
(Toullec et al., 2010). Xu et al showed that recombinant extracellular 
matrix metalloproteinase inducer, EMMPRIN/CD147, through both, co-
culture or conditioned medium from breast cancer in vitro, transformed 
quiescent fibroblasts into α-SMA expressing cancer associated 
fibroblasts (Xu et al., 2013). MicroRNAs, an abundant class of small non-
coding RNA, regulate gene expression post transcription, thereby 
influencing the phenotype of cells. A study found CAFs from ovarian 
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cancer had downregulated miRNA-31 and miRNA-214, while miRNA-
155 was upregulated; upon similar manipulation of these miRNAs levels 
in normal fibroblasts led to conversion in to a CAF like phenotype (Mitra 
et al., 2012). Another miRNA, miR-145 has been observed to be up-
regulated in TGF-β1 transdifferentiated myofibroblasts in oral, dermal 
and lung fibroblasts imparting contractility and α-SMA expression 
(Melling, 2015, Yang et al., 2013b). Melling also described how 
excessive over-expression of microRNA-145 could prevent and partially 
reverse myofibroblast transdifferentiation (Melling, 2015). Senescent 
fibroblasts, a sub-type of CAF, have up-regulated microRNA-335, 
modulating an inflammatory secretome supporting tumour progression 
(Kabir et al., 2016). How these microRNAs were deregulated is still 
unclear, however their deregulation was sufficient to transform resident 
fibroblasts to CAFs. Other DNA damaging agents, such as: tobacco, 
areca nut, chemotherapy, radiation therapy, and old age impart CAF like 
phenotype by inducing senescence in resident fibroblasts (Kabir et al., 
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2016, Schmitz et al., 2015, Rehman et al., 2016, Coppe et al., 2008, 
Yang et al., 2013a, Nyunoya et al., 2006). 
1.5.1.2 Bone marrow derived stem cells: Signalling mediators produced and 
secreted by tumour cells can induce effects locally as well as on a 
systemic level resulting in recruiting cells such as bone marrow 
derived mesenchymal stem cells from distant locations to the tumour 
site. This phenomenon has been observed in studies where bone 
marrow from β-galactosidase transgenic mice was transplanted in to 
severe combined immune-deficient mice with a subcutaneous 
xenograft of a pancreatic cell line; analysis of the tumour xenografts 14 
and 28 days post-transplant showed the presence of myofibroblasts in 
and around the tumour which stained positively using X-gal (Ishii et al., 
2003). Another study transplanted green fluorescent protein (GFP) 
positive male mouse-derived bone marrow in to female GFP negative 
mice with pancreatic insulinoma. Tumour sections from female mice 
were then stained for GFP, α-smooth muscle actin, vimentin, and Y 
chromosome which confirmed that the CAFs were derived from the 
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transplanted bone marrow (Direkze et al., 2004).  Recently it was 
discovered that GRP78, otherwise known as endoplasmic reticulum 
chaperone, is over expressed by colon cancer cells and aids 
transformation of murine and human bone marrow MSCs to CAFs by 
inducing expression of α-SMA through TGF-β1 receptor and 
phosphorylation of Smad2/3 (Peng et al., 2013). A study revealed that 
breast cancer cells expressing osteopontin are able to induce 
expression of TGF- β1 in mesenchymal stem cells via myeloid zinc 
finger 1 to form an autocrine loop and adopt a CAF like phenotype. 
The newly acquired CAF phenotype was confirmed by expression of α
-SMA, vimentin, tenascin C and fibroblast specific protein (FSP) 1 
(Weber et al., 2015). 
 
1.5.1.3 Epithelial to mesenchymal transition (EMT): is the process through 
which epithelial cells lose their tight cell-cell junctions to transition in to 
mesenchymal cells with loose cell junctions and stem cells properties. 
TGF-β is one of the factors secreted by the tumour cells responsible 
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for EMT (Routray et al., 2014a, Radisky et al., 2007b, Rhyu et al., 
2005). Furthermore, matrix metalloproteinases (MMPs), especially 
MMP-3, are known to induce EMT in cells via reactive oxygen species 
(ROS) dependent gene alteration and activation of pathways like Snail 
resulting in more CAFs (Radisky et al., 2007b, Radisky et al., 2005). 
Nightingale et al (2004) reported that oncostatin M released from T 
cells and monocytes transdifferentiated epithelial cells in to 
myofibroblasts via JAK/Stat signalling pathway; confirmed by 
upregulation of α-SMA, collagen I, fibronectin EDA and down-
regulation of E-cadherin and cytokeratin 19 (Nightingale et al., 2004). 
However, some studies suggest that CAFs do not arise from cancer 
cells through EMT, such as in the case of when human HEp-2 
laryngeal cancer cell line cells were xenografted into mouse model, 
and the arising CAFs were karotyped and found to be of mouse origin, 
and not human laryngeal origin, suggesting that the CAFs that arose, 
originated from a different source (Wang et al., 2015b). Another similar 
studied transplanted human cancer cells in mice and resulting stroma 
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failed to be recognised by human specific vimentin antibody 
(Dvorankova et al., 2015). Although controversy around the evidence 
for a role for EMT in generating CAF exists, the possibility that EMT is 
one of the many routes to generate CAFs in TME cannot be ignored. 
Perhaps, certain factors facilitate EMT in some cancers, more than 
others. 
1.5.1.4 Endothelial cells of the heart and lung undergo endothelial to 
mesenchymal transition (End-MT) in response to TGF-β1 (Zeisberg et 
al., 2007, Rhyu et al., 2005). Zeisberg et al (Zeisberg et al., 2007) 
treated endothelial cells with TGF-β1 and showed emergence of 
fibroblast specific protein-1 and downregulation of CD31; a marker 
found specifically on endothelial cells (Thiery and Sleeman, 2006, 
Zeisberg et al., 2007, Bierie and Moses, 2006). This suggests 
endothelial cells are also a potential source of CAF. 
1.5.1.5 Adipocyte derived CAFs: There have been suggestions of adipocytes 
contributing to the CAF population, and it was recently described by 
Bochet et al that breast cancer cells coerce mature adipocytes in to 
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becoming CAF like cells in a Wnt dependent manner. These adipocyte 
derived fibroblasts lost their lipid content, expressed FSP-1 but not α-
SMA and generated increased amounts of ECM (Bochet et al., 2013). 
Despite varied origins of CAFs, they still promote tumour progression 
through their unique secretory factors (Fig. 1.6) as described in section 
1.5.2. 
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Figure 1.6: Gamut of factors secreted by CAFs and their effect on malignant cells 
and their environment. This diagram represents the multi-faceted roles that CAFs 
play in tumour proliferation, maintenance of inflammation and immune cell 
recruitment, angiogenesis, invasion and metastasis. 
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1.5.2 Tumour stimulatory effects of CAFs: 
1.5.2.1 Cell proliferation – There is abundance of literature confirming cell 
proliferative effects of CAFs on cancer cells. Secretory factors from 
CD90, vimentin and α-SMA positive CAFs activated PI3k/Akt and 
MAPK/Erk pathways leading to proliferation; confirmed by 
phosophorylation of Akt and Erk, compared to secretory factors from 
normal fibroblasts (Subramaniam et al., 2013). Increased expression 
of TNF-α by CAFs activated EGFR, Akt, and Erk to again promote 
breast cancer cell proliferation (Gao et al., 2013). CAFs are known to 
secrete SDF-1, which was observed to facilitate lung cancer cell line 
proliferation and imparted chemoresistance against cisplatin via 
interaction with CXCR4 mediated activation of NFκB and Bcl-xL (Li et 
al., 2016a). Similarly, hepatocyte growth factor (HGF) secreted by 
CAFs promoted cell proliferation in both hepatocellular carcinoma and 
HNC (Jia et al., 2013, Kumar et al., 2015). CAFs were again seen to 
induce cell proliferation in oral tongue SCC, and HNSCC in pre-clinical 
models (Li et al., 2015, Wheeler et al., 2014). Keratinocyte growth 
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factor (KGF) secreted by CAFs induced proliferation in lingual 
carcinoma cell line (OSCC) (Lin et al., 2011), further providing 
evidence that CAFs promote tumour proliferation . 
1.5.2.2 Migration and invasion – a major difference between benign tumours 
and malignant tumours is the potential to metastasise of the latter, 
which is also what makes them lethal and difficult to treat. CAFs 
produce and secrete a wide array of factors which stimulate 
dissociation of malignant cells from the primary tumour, invasion 
through tumour stroma and basement membrane which is made up of 
modified extracellular matrix (Cai et al., 2012, Matsumoto and 
Nakamura, 2006). Various studies demonstrated the ability of 
individual factors to stimulate tumour cell invasion; Matsumoto and 
Nakamura (Matsumoto and Nakamura, 2006); demonstrated that 
activation of c-Met by HGF leads to dissociation of malignant cells 
from the tumour due to production of metalloproteases and it also 
activates oncogenic pathways namely rat sarcoma, signal transducer 
and activator of transcription 3 (STAT3), and phosphatidylinositide 3-
67 
 
kinase (PI3K) while Cai, et al 2012 (Cai et al., 2012) demonstrated the 
role of HGF in invasion of ovarian cancer cells into the omentum.  
Glycoprotein stanniocalcin-1 (STC1) is a secreted, hypoxia regulated 
protein that was found to activate PDGF receptors expressed on 
CAFs to promote migration and invasion of colorectal cancer in 
matrigel in vitro; while in vivo STC-1 deficient mouse model reported 
reduced intravsation of colorectal cells, and fewer and smaller 
metastasis  (Peña et al., 2013). Bone morphogenic protein 4 (BMP4) 
stimulation of fibroblasts leads to expression of pro-inflammatory 
factors (IL-6, CXCL1, CXCL12, CXCL16, CCL9, VEGF) and 
proteases (MMP2, MMP3), ECM components (versican, collagen, 
fibulin), and increased invasion of breast cancer cells in transwell 
setting by stimulation of both mouse fibroblast and human fibroblasts 
by BMP4, which inhibited using BMP4 receptor antagonist (Owens et 
al., 2013). 
A disintegrin and metalloproteinase with thrombospondin motifs 1 
(ADAMTS1) is known to degrade ECM components such as 
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aggrecan, versican, nidogen – 1 and 2, and decrease cell adheshion, 
promote cell migration and metastasis (Canals et al., 2006, Kuno et 
al., 2000, Rocks et al., 2008, Sandy et al., 2001). When breast cancer 
cells were co-cultured with normal human fibroblasts for 4 days, 
showed an increase in ADAMTS1 secretion, and the same was 
confirmed in patients by finding a correlation between lymph node 
metastasis and ADAMTS1 mRNA expression in patient CAFs (Tyan 
et al., 2012). 
Plenty of evidence exists in HNC confirming the role of CAFs in 
cancer metastasis. Often MMP2/9 are secreted by CAFs in HNC 
which facilitate ECM modulation and promote cell motility and 
invasion (Koontongkaew et al., 2012). IL-33, HGF, FGF8b, SDF-1, 
and Activin secreted by CAFs have been implicated in HNC 
metastasis (Chen et al., 2013, Kumar et al., 2015, Lewis et al., 2004, 
Lui et al., 2011, Li et al., 2016b, Taylor et al., 2015). Endothelin-1 (ET-
1) has shown to activate ADAM-17 mediated release of EGFR ligands 
from mouse embryonic fibroblasts (Blobel, 2005). With this in mind, 
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Hinsley et al confirmed that ET-1 enhanced migration of squamous 
cell carcinoma, SCC4 and H357 (HNC cell lines) in presence of oral 
fibroblasts, which abolished upon blocking ET-1 receptor, ETAR and 
ETBR, as well as by blocking ADAM, or using EGFR antagonist 
(Hinsley et al., 2012). Chemerin, secreted by CAF increased the 
expression and activity of MMP1/2/3 encouraging metastasis of 
squamous oesophageal cancer cells (Kumar et al., 2016). 
1.5.2.3 Epithelial to mesenchymal transtition (EMT) – occurs when the cell 
loses its polarity, ability to adhere to neighbouring cells, and de-
differentiates into a more primitive cell type or becomes multi-
potent/stem cell like. This provides the cell potential to migrate, a 
signature feature of cancer dictating its aggressiveness. Giannoni et al 
(Giannoni et al., 2010) reported CAFs from prostate cancer stroma 
were responsible for EMT in the respective cancer cells due to low-
level secretion of IL-6 and high level secretions of MMP-2 and MMP-9. 
Tsuyada et al, 2012 (Tsuyada et al., 2012a) showed that CCL2 
produced and secreted by CAFs in breast cancer stroma enhanced 
70 
 
cancer stem cell production. Another study showed that CAFs 
increased the migration ability of ovarian cancer cells by increasing 
expression of enhancer of zeste homologue which has been 
implicated in promoting tumorigenesis (Xu, 2014). In one particular 
study, co-culture of CAFs and SCC9 cells (HNC cancer cell line) 
upregulated EMT markers like vimentin and fibronectin, while down-
regulating E-cadherin (Zhou et al., 2014). It was observed that oral 
tongue squamous cell carcinoma cells in close proximity of CAFs have 
down-regulated E-cadherin, and the ECM around contained Cadherin-
11, syndecan-1, SPARC, and FSP-1, further supporting EMT (Vered 
et al., 2010). Fibroblast growth factor 1 (FGF1) secreted by CAFs 
induced EMT in tongue squamous cell carcinoma via the FGFR with 
reduction in E-cadherin and increase in expression of vimentin (Jiao et 
al., 2015). Exposure to conditioned medium from irradiated fibroblasts 
induced expression of vimentin and loss of E-cadherin in esophageal 
squamous cell carcinoma (ESCC) suggesting ESCC cells having 
undergone EMT (Bao et al., 2015). 
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1.6 Types of cancer associated fibroblasts 
As mentioned previously, the sources of CAFs vary, also depending on the type of 
tumour; different sub-populations of CAFs must exist within the tumour milieu. 
However, due to lack of CAF specific markers it has so far been a challenge to 
distinguish between the heterogeneous populations. Although CAFs can be 
distinguished from their normal counterparts based on markers such as: α-smooth 
muscle actin (α-SMA), FSP-1, fibroblast-activated protein (FAP), NG2 chondroitin 
sulphate proteoglycan (NG2), platelet-derived growth factor receptor α (PDGFR α), 
or podoplanin (Calon et al., 2014), there remains much to learn about different CAF 
phenotypes present in tumours. 
1.6.1 Myofibroblasts 
The most common type of activated fibroblast found is the myofibroblast 
expressing α-SMA as a significant and primary marker. Cancer associated 
myofibroblasts are similar to the activated fibroblasts/myofibroblasts 
associated with wound healing and fibrosis (Zigrino et al., 2005). The most 
common and prominent factor facilitating fibroblast activation is TGF-β, which 
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is found abundantly in the tumour stroma; produced by tumour cells 
themselves, and by other immune like macrophages and dendritic cells 
(Kellermann et al., 2008, Calon et al., 2014, Evans et al., 2003a).  
Another type of CAF was reported by Gionnani et al in 2010, which was 
activated by IL-6, without expression of α-SMA but identified by expression of 
FAP and secretion of extra-cellular matrix. These CAFs, through secreted 
factors induced EMT markers confirmed by up-regulation of Snail, Twist, 
vimentin, and Met, while down-regulating E-cadherin, and up-regulated 
invasiveness by secreting MMP2 and MMP9 (Giannoni et al., 2010). 
1.6.2 Senescent fibroblasts 
Cellular senescence presents itself in response to DNA damage due to 
physical or chemical insults acquired during therapeutic interventions 
(chemotherapy or radiation therapy), or endogenous processes like mitogenic 
signals or oxidative stress and prevent the damage from being passed onto 
the next generation of cells and arrest malignant transformation. Some cells, 
however, especially fibroblasts, develop a senescence associated secretory 
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phenotype or SASP which allows them to secrete a wide range of proteases, 
growth factors, cytokines and chemokines, and insoluble ECM components 
(Freund et al., 2010, Hassona et al., 2013b). Since these cells are 
metabolically active; they persistently secrete molecules able to alter their 
surrounding microenvironment to one that is beneficial to tumours and allows 
them to progress and metastasise (Parkinson et al., 2016).  
Senescent fibroblasts have been observed in several carcinomas; often 
recognised by the expression of α-SMA and staining positively in senescence 
associate β-galactosidase assay, along with an upregulation of p16 and p21 
(Kabir et al., 2016, Mellone et al., 2017). They promote increased cancer cell 
proliferation in melanoma, breast cancer, prostate cancer with secretions of 
connective tissue growth factor (CTGF), SDF-1α, GRO-α, and IL-8 (Coppé et 
al., 2010a). The SASP of fibroblasts also enhances angiogenesis and 
immune-suppression by secreting VEGF, and granulocyte macrophage – 
colony stimulating factor (GM-CSF), IL-6 stimulating endothelial cells and 
myeloid suppressor cells respectively (Coppé et al., 2010a, Kabir et al., 2016).  
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SASP of the fibroblasts also stimulates cell migration and invasion through 
HGF, and MMP-2 (Hassona et al., 2014, Coppé et al., 2010b). 
Senescent fibroblasts are also known to secrete high levels of chemokines 
and cytokines to attract and activate various immune cells to the tumour 
microenvironment: CCL-2, 8, 13 attracting primarily monocytes, NK cells, 
dendritic cells, T cells, stem cells, and macrophage inflammatory protein (MIP) 
– 3α and 1α recruiting lymphocytes, while attracting granulocytes causing 
neutrophilic inflammation and inducing fibroblasts to further secrete IL-1, IL-6 
and TNF- α (Baba et al., 1997, Davalos et al., 2010a, Irving et al., 1990, Ohgo 
et al., 2015). Sica, et al 2006 (Sica et al., 2006b) described that tumour 
associated macrophages are recruited, activated and polarised (distinctly 
towards M2 phenotype) in the tumour site where the chemokines (CCL2) and 
other factors such as M-CSF, IL-4, are found to be secreted by senescent 
fibroblasts, giving rise to the possibility of senescent fibroblasts recruiting and 
polarising macrophages (Davalos et al., 2010a, Irving et al., 1990). This 
gamut of immune and stromal cells maintain inflammation, help in immune 
75 
 
evasion, and down-regulate the immune reaction allowing tumour cells to 
thrive. Senescent fibroblasts undergo catabolic metabolism due oxidative 
stress and coupled with anabolic cancer cells providing a nutrient rich 
environment for them via secretions of ketone bodies, lactate, glutamine, fatty 
acids, and other amino acids (Martinez-Outschoorn et al., 2014). 
A notable observation made by Hassona et al is that senescent fibroblasts 
were genetically stable in the stroma of genetically unstable oral squamous 
cell carcinoma, which makes them a better and more reliable target for 
prognostic and therapeutic purpose as they lack the potential to develop 
resistance towards therapies through genetic mutations (Hassona et al., 
2013b). They also observed that senescent fibroblasts are first activated to a 
myofibroblastic phenotype before reaching senescence (Hassona et al., 
2013b). Another study observed similar phenomenon where activated 
fibroblasts or myofibroblasts from oral submucous fibrosis senesced due to 
oxidative damage to the DNA caused by ROS, possibly resulting from 
damaged mitochondria in presence of areca nut or tobacco chewing (Pitiyage 
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et al., 2011). Krizhanovsky et al revealed that hepatic stellate cells 
(myofibroblasts) senesce to resolve fibrosis in the liver by NK cells, however 
the mechanism causing senescence is yet to be determined; mice were 
treated with fibrosis inducing chemical, CCl4, confirmed by positive 
immunochistochemistry (IHC) staining of fibrotic tissue with desmin and α-
SMA, and senescence confirmed by positive IHC staining for senescence 
associated β-galactosidase assay, p16, p21 and p53  (Krizhanovsky et al., 
2008a). In the same study, senescent hepatic stellate cells also showed up-
regulated MICA, and ULBP2, which are activation ligands for NK cell receptor 
NKGD2 (Krizhanovsky et al., 2008b, Sagiv et al., 2016). Similarly, a study 
showed cysteine-rich angiogenic protein 61; a matricellular protein induced 
senescence in wound healing fibroblasts limiting fibrosis in cutaneous wound 
healing (Jun and Lau, 2010). All of these studies suggest that myofibroblasts 
could be senesced and this phenomenon could be targeted to gain control 
over the cross talk occurring between these fibroblasts and immune cells 
preventing the recruitment of the latter and checking inflammation, tumour 
progression and metastasis. 
77 
 
With review of literature providing evidence that CAFs, produce pro-
inflammatory factors including chemoattractants, and that the presence of 
macrophages in tumours impacts prognosis of HNC, the following study was 
conducted to examine recruitment of macrophages by CAFs. 
1.7 Main hypothesis and aims 
With evidence present in literature that different sub-populations of CAFs 
(myofibroblasts and senescent fibroblasts) exist, and produce pro-inflammatory 
factors capable of recruiting macrophages, presence of which leads to poor 
prognosis in HNC, it was hypothesised that the two sub-populations of CAFs, namely 
myofibroblasts and senescent fibroblasts possess different capacities to recruit 
macrophages in HNC. 
The aims of the study are: 
 To establish previously described phenotypical characteristics of 
myofibroblasts and senescent fibroblasts in normal oral fibroblasts.  
 Examine differential macrophage recruitment capabilities by both phenotypes 
and by patient derived CAFs.  
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 To confirm that the primary chemokine/receptor used by monocytes for 
migration is the CCL2/CCR2 axis.  
 To characterise and differentiate between the secretomes of myofibroblasts, 
senescent fibroblasts, and a patient CAF.  
 Investigate the effects of factors secreted by these phenotypes on 
macrophage polarisation. 
 To examine correlation between presence of CAFs and macrophages in 
tumour sections. 
 To study the effect of macrophage polarisation on fibroblast activation via 
secretory factors. 
 
 
 
 
 
 
Chapter 2.   
2. Materials and methods 
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2.1. Equipments: 
All the laboratory equipment used in the project is listed in appendix 1. 
2.2. Buffers and solutions: 
Buffers and solutions prepared in-house are listed with their ingredients in 
appendix 2.  
2.3. Primers: 
Both SYBR green primers (table 1) used with SYBR green master mix 
(Thermo Fisher, UK) and Taqman primers/probes (table 2) used with Taqman 
Universal master mix II (Thermo Fisher, UK) were used in this research 
project.  
 
 
 
Table 1: SYBR green primers: 
Gene Forward primer Reverse primer 
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U6 5’CTCGCTTCGGCAGCACA3’ 5′ AACGCTTCACGAATTTGCGT 3’ 
CCL2 5’AATAACGCGAGCTATAGAAGAA3’ 5’TTATTGTCAGCACAGATCTCCTT3’ 
IL-6 5’AATAAAACAACCTGAACCTTCCA3’ 5’TTATTGATTTTCACCAGGCAAGT3’ 
α-SMA 5’GAAGAAGAGGACAGCACTG3’ 5’TCCCATTCCCACCATCAA3’ 
CD86 5’CCTTTCTCTATAGGAACCAAC3’ 5’GGCTTCATCAGATCTTTCAG3’ 
CD206 5’AAATTTGAGGGCAGTGAAAG3’ 5’GGATTTGGAGTTTATCTGGTAG3’ 
 
Table 2: Taqman primers/probes: 
Gene  Refseq Assay ID 
CD80 NM_005191.3 Hs00175478_m1 
CD163 NM_004244.5, NM_203416.3 Hs00174705_m1 
β2-Microglobulin NM_004048.2 Hs00187842_m1 
 
 
2.4. Antibodies, small molecule antagonist, and recombinant proteins:  
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Mouse monoclonal anti α-smooth muscle actin antibody (A2547), horseradish 
peroxidase-conjugated rabbit anti-mouse IgG (whole molecule)(A9044), and FITC-
conjugated mouse anti-α-smooth muscle actin monoclonal antibody (F3777) were 
obtained from Sigma, UK. Recombinant TGF-β1 (240-B), CCL2 (279-MC), and 
mouse anti-CCR2 monoclonal PE conjugated antibody (FAB151P) and mouse IgG2B 
PE isotype control (IC0041P) antibody were from R & D Systems, UK. Mouse 
monoclonal anti-CD68 antibody (M0814, clone KP1) was from Dako, UK. CCR2 
antagonist RS 504393 (ab120813) was from Abcam, UK.  
2.5. Isolation of primary normal oral fibroblasts: 
Buccal or gingival tissue was obtained from subjects during routine (not malignancy 
excisions) dental procedures with written, informed consent (ethical approval number 
Ref: 07/H1309/105). Biopsies of 5-10 mm3 were collected in sterile tubes of DMEM 
(Sigma, UK) supplemented with 0.625 µg/ml of amphotericin B, 100 µg/ml of 
streptomycin, 100 IU/ml of penicillin (all from Sigma, UK) and stored a 4°C. 
Primary normal oral fibroblasts (NOF) were then isolated from the connective tissue 
of the biopsy by mincing it using a surgical scalpel and incubating the tissue in 10 ml 
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of 0.25% (w/v) collagenase 1A (Thermo Fisher, UK) dissolved in DMEM at 37°C with 
5% CO2 in a humidified incubator for a minimum of 3 h. The tissue was then 
centrifuged at 384 g for 10 min and the cellular pellet was re-suspended in DMEM 
and supplemented with 10% foetal calf serum (FCS) (Thermo Fisher, UK), 1% 
amphotericin B and 1% penicillin and streptomycin and seeded in T25 flasks with a 
vented lids in the same medium, usually reaching confluence at 1.2 x 106 cells. 
2.6. Cell culture: 
Primary NOFs, cancer associated fibroblasts (CAF002, BICR18, BICR69, BICR73, 
BICR78) and H357 cells - human oral squamous cell carcinoma-derived cell line 
derived from the tongue (ECACC 06092004) (Sigma, UK) - were cultured in DMEM 
with 10% (v/v) FCS and 2 mM L-glutamine.  
The monocytic cell line; THP-1 derived from peripheral blood of a patient with acute 
monocytic leukaemia (ECACC 88081201) (Sigma, UK) was cultured in RPMI 1640 
(Sigma, UK) supplemented with 5% 100 IU/ml penicillin-streptomycin and 10% (v/v) 
FCS. The tongue-derived squamous cell carcinoma cell line SCC4 (ECACC 
89062002) (Sigma, uk) was cultured in F12 nutrient medium and DMEM (1:1 v/v) 
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with 10% FCS and 2mM L-glutamine (Sigma, UK). Human monocyte-derived 
macrophages (refer to section 2.8) were cultured in IMDM (Thermo Fisher, UK) with 
2% (v/v) human serum (Thermo Fisher, UK), and 5% (v/v) 100 IU/ml penicillin-
streptomycin. 
All cell cultures were incubated at 37°C, 100% humidity and 5% CO2, and routinely 
tested for mycoplasma infection every 3-4 months. 
Table 3: Details of cell type used: 
Cell type: Details: 
NOF  Normal oral fibroblast from patients 316, 320, and 343 
H357 Squamous cell carcinoma cell line derived from the tongue of 
a 74 year old male patient, stage I, node negative, with mutant 
p53, produces high levels of TGF-β1, and undergoes EMT in 
response to it TGF-β1.  
SCC4 Squamous cell carcinoma derived cell line from the tongue of 
a 55 year old male patient. SCC4 forms colonies in semi-solid 
medium. 
THP-1 Derived from peripheral blood of 1 year old acute monocytic 
leukaemia patient. THP-1 cells have C3b and Fc receptors but 
lack surface and cytoplasmic immunoglobulins, produce 
lysosomes and are phagocytic. They can be differentiated in 
to macrophage like cells using DMSO.  
PBM Peripheral blood monocytes isolated from buffy coats using 
Ficoll density gradient method, purified further using monocyte 
isolation kit (Miltenyibiotec). 
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CAF002 Cancer associated fibroblasts from oral squamous cell 
(OSCC) carcinoma patient 002. 
BICR18 Cancer associated fibroblasts from genetically unstable OSCC 
BICR69 Cancer associated fibroblasts from genetically stable OSCC 
BICR73 Cancer associated fibroblasts from genetically stable OSCC 
BICR78 Cancer associated fibroblasts from genetically unstable OSCC 
 
2.7. Cell harvesting and passaging: 
All fibroblasts, H357 cells, and SCC4 cells were treated with trypsin/EDTA (Sigma, 
UK) at 80% confluency (5 min for fibroblasts, 15 min for cell lines) at 37°C. The sides 
of the flask were then struck firmly to physically dislodge cells from the plastic 
surface. Trypsin was neutralised using DMEM with 10% (v/v) FCS in a 1:3 ratio and 
centrifuged at 192 g for 5 min to form a cell pellet. The supernatant was discarded, 
the cell pellet re-suspended in appropriate medium for each cell line and seeded at 3 
x 105 cells in T75 or 5 x 105 in T175 tissue culture flasks. Primary oral fibroblasts 
were not used beyond passage 8, BICRs and CAF002 were not used beyond 
passage 5, monocytes were used the same day of purification, while macrophages 
were always used at passage 1. 
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THP-1 cells were centrifuged at 192 g for 5 min and seeded at 1:5 ratio in RPMI 
medium with 100 IU/ml penicillin-streptomycin and 10% FCS.  
2.8. Monocyte isolation and macrophage culture: 
Monocytes were isolated from buffy coats from the NHS Blood and Transplant 
Service (ethical approval reference SMBRER139) using a Ficoll-density 
gradient in which Hank’s buffered salt solution (HBSS) (Thermo Fisher, UK) 
and blood was mixed (1:1; 30 ml), layered carefully onto 20 ml Ficoll (GE 
healthcare, UK), and centrifuged at 270 g for 40 min with brakes off.  The 
mononuclear cell layer containing monocytes and lymphocytes was visible as a 
distinct white layer between the upper serum layer and lower Ficoll layer, which 
was removed using a sterile Pasteur pipette and transferred to a fresh tube. 
The mononuclear cells were washed by making up to 50 ml with HBSS and 
centrifuged again for 15 min at 270 g with rotor braking on. The supernatant 
was discarded, the pellet was re-suspended in 50 ml of HBSS, and centrifuged 
again for 10 min. Cells were re-suspended in HBSS, counted, and washed 
again for a further 10 min (Eligini et al., 2013, Martinez et al., 2006, Chitra et al., 
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2014). Supernatant was discarded, and the cell pellet was used to purify 
monocytes further for migration assays (section 2.8.1) or re-suspended in 
IMDM medium with 2% (v/v) human serum, and 5% (v/v) 100 IU/ml penicillin-
streptomycin, and either cultured in T75 flasks at 3x107 in 10 ml seeding 
density for monocyte to macrophage differentiation. Cells were washed twice 
with PBS following 3 h incubation to remove non-adherent lymphocytes, and 
fresh medium was added, followed by washes and medium changes every 3 
days for a week in total. 
2.8.1.  Monocyte purification: 
Monocytes were purified from lymphocytes using a Pan Monocyte Isolation kit 
(Miltenyi Biotech, USA) containing antibodies specific for lymphocyte 
populations to negatively select monocytes; allowing them to pass through a 
MACs magnetic separation column.  Mononuclear cell number was determined, 
and the reagents from Pan Monocyte Isolation kit were added per 107 total 
cells. Cell pellet from section 2.8 was re-suspended in 30 μl of MACs buffer 
(appendix 2) followed by addition of 10 μl each of FcR blocking reagent and 
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Biotin-Antibody cocktail from the kit. The contents of the tube were mixed and 
incubated at 2-8°C for 5 min. Another 30 μl of MACs buffer was added, 
followed by 20 μl of anti-biotin Microbeads (included in the kit) which are 
magnetic, the contents were mixed again and incubated at 2-8°C for 10 min.  
Subsequently, a MACs separation column (LS column, Miltenyi Biotech, USA) 
was placed in a magnetic separator (VarioMACS Separator, Miltenyi Biotech, 
USA), rinsed with 3 ml MACs buffer, and the cell suspension prepared 
previously was allowed to run through the column and cells collected after 
separation. The flow through contained negatively selected monocytes while 
the lymphocytes were magnetically attached to the column. The column was 
then washed 3 times with 3 ml MACs buffer to collect any further monocytes 
sticking within the column, and the resulting purified monocytes were then used 
for migration assays only. The purity of resulting monocyte culture, tested by 
flow cytometry for CD14 reported 91.9% pure (fig. 4.4 in section 4.5). 
2.8.2. Macrophage polarisation: 
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From M0 macrophage culture described in section 2.8, the cells were polarised 
towards 2 states – M1, or M2 using the following methods (Mia et al., 2014, 
Zhang et al., 2013): 
M1 polarisation: Mononuclear cells were seeded and washed as described for 
M0 macrophages in section 2.8 but with addition of 10 ng/ml granulocyte 
macrophage colony stimulating factor (GM-CSF) (Peprotech, UK) in the 
medium. On the 6th day 100 ng/ml lipopolysaccharide ((LPS) Escherichia coli 
O55:B5) (Peprotech, UK), and 20 ng/ml interferon γ (IFNγ) (Peprotech, UK) 
were added to the medium in addition to 10 ng/ml GM-CSF for 24 h (Zhang et 
al., 2013). 
M2 polarisation: Mononuclear cells were seeded and washed as described for 
M0 macrophages in section 2.8 but with addition of macrophage colony 
stimulating factor (M-CSF – 25 ng/ml) (Peprotech, UK) in the medium. On the 
6th day 20 ng/ml interleukin 10 (IL-10) (Peprotech, UK) was added to the 
medium in addition to 25 ng/ml M-CSF for 24 h (Mia et al., 2014). 
2.9. Myofibroblast transdifferentiation: 
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Normal oral fibroblasts from 3 different patients (anonymously coded NOF343, 
NOF316, NOF320) were cultured in DMEM supplemented with 2mM L-glutamine 
and 10% (v/v) FCS. At 80-90% confluency cells were trypsinised and 2.5 x 105 cells 
were seeded in 6 well plates in triplicates or 106 cells in T75 flask overnight. Cells 
were serum starved for 24 h prior to treatment with TGF-β1 (R & D Systems, UK).  
TGF-β1 (5 ng/ml) made up in serum-free DMEM was added to the wells/flasks and 
serum-free DMEM was added to the control wells/flasks (Melling, 2015). Cells were 
exposed to TGF-β1 for 24, 48 and 96 h. After each time point, medium containing 
TGF-β1 was removed and cells were washed with PBS before 1 ml of serum-free 
DMEM was added to the culture wells or 5 ml to T75 flask, and collected 24 h later 
as conditioned medium. Cells were then trypsinised using trypsin/EDTA and 
harvested in 0.1% (w/v) bovine serum albumin (BSA) (Sigma, UK) in DMEM and 
used for protein or RNA analyses, as described in sections 2.13 and 2.17. 
 
 
2.10. Induction of senescence: 
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Senescence was induced in NOF by treating with cisplatin at a concentration of 10 
µM in DMEM for 24 h, followed by culturing in normal DMEM for 14 days (Kabir et 
al., 2016). Senescence was detected by β-galactosidase detection kit (Abcam, UK) 
which detects activity of lysosomal β-galactosidase by cleaving X-gal at pH 6, 
resulting in generation of a blue precipitate, visible by light microscopy. For this 
assay, cells were trypsinised and re-seeded in a 12 well plate at a concentration of 
10,000 cells per well for 24 h. After one wash with PBS, 500 µl of ‘Fixative solution’ 
from the kit was added and incubated at room temperature for 20 min. Cells were 
then washed with PBS twice and 500 µl of staining solution was added to each well. 
The staining solution was made by adding 25 µl of X-gal (20 mg/ml in dimethyl 
formamide) to 470 µl of ‘Staining solution’ and 5 µl of ‘Staining supplement’, all of 
which were provided in the kit. The plate was covered in aluminium foil and 
incubated overnight at 37°C. Photographs were taken at 10 x and 20 x magnification 
using Nikon Eclipse TS100 microscope. Positively stained cells were counted 
manually to calculate percentage of positive cells from total number present. 
2.11. Preparation of conditioned medium: 
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Fibroblasts, H357 and SCC4 cells (both OSCC-derived cancer cell lines), and 
macrophages were washed twice with PBS after the respective treatment and 
incubated with serum-free DMEM or F12 with DMEM or IMDM for 24 h at 37°C, and 
5% CO2. The conditioned media was collected, passed through 0.22 micron filter 
(Milipore, UK) and stored at -80°C to be used in migration assays (section 2.12), 
ELISAs (section 2.20), concentrated for Mass Spectrometry (section 2.22). 
2.12. Migration assay: 
Monocytic cell line, THP-1 cells were cultured in RPMI with 10% (v/v) FCS and 
penicillin-streptomycin and allowed to reach 80-90% confluency in preparation for 
the assay. Cells were then serum starved for 24 h prior to experimentation. Cells 
were re-suspended in RPMI with 0.1% BSA, and centrifuged at 192 g for 5 min to 
form a pellet. Both THP1 cells and peripheral blood monocytes (after purification 
described in section 2.81) were counted to obtain 100,000 cells and re-suspended in 
200 µl serum-free RPMI, and added to the top chamber of a transwell (Corning, 
USA) with pore size of 5 µm in a 24 well plate. Conditioned medium (500 µl) was 
added to the bottom chamber/well of the plate. Serum-free RPMI was used as 
92 
 
negative control and CCL2 (10 ng/ml) (R&D Systems, UK) in RPMI was used as 
positive control (figure 4.1, section 4.3). 
The cells were allowed to migrate at 37 ͘°C and 5% CO2 for 4 h. After incubation, the 
transwells were moved to a new plate while the conditioned media was gently 
pipetted to disperse cells evenly in the conditioned media. Cells were counted from 3 
randomly selected fields at 20 x magnification using light microscopy.  
Remaining cell suspension was removed from the transwells and the upper side of 
the porous membrane was swabbed with a cotton bud to remove non-migrated cells. 
PBS (500 µl) was added to upper and lower chamber of the transwell to wash the 
membrane, followed by addition of cold methanol (Sigma, UK) to fix cells on the 
lower face of transwell membrane overnight in the fridge. 
Methanol was removed and the transwell membrane was washed with PBS, followed 
by staining of cells using Differential Quik Staining kit according to manufacturer’s 
protocol (Polysciences, UK) and photographs were taken of 3 randomly selected 
fields at 20 x magnification using Nikon Eclipse TS100 microscope. The cells were 
counted manually using ImageJ. Relative number of cells migrated was calculated 
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by averaging counts from 3 random fields of the same well, while absolute number 
was calculated by normalising to fibroblast  
2.12.1. CCR2 inhibition:  
To inhibit the CCR2 receptor before migration, peripheral blood monocytes 
were incubated with 10 µM CCR2 inhibitor in serum free RPMI for 1 h (Carmo 
et al., 2014). The cells were then centrifuged to form a pellet and re-
suspended in fresh serum-free RPMI for migration assay. 
2.12.2. Pertussis toxin treatment: 
Peripheral blood monocytes were treated with Pertussis toxin (1 µg/ml in 
serum free RPMI) to inhibit G-protein coupled receptors, which include 
chemokine receptors, for 30 min prior to migration (Malik et al., 2009).  
2.13. Protein extraction: 
Cell lysis buffer (radioimmunoprecipitation assay (RIPA) buffer) (Sigma, UK) with 
Halt Protease and Phosphatase Inhibitor cocktail (1:100) (Thermo Fisher) was added 
to each well (60 µl) in a 6 well plate to lyse the cells. Cell extracts were kept on ice 
for 15 min to allow complete cell lysis with minimum effect of proteases. Cells were 
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scraped and the extract was then centrifuged at 4°C at 8000 g for 15 min to separate 
protein from cell debris, followed by transfer of supernatant containing protein into a 
new 1.5 ml Eppendorf and stored at -20°C for a maximum of one week before use in 
western blot (section 2.15). 
2.14. Protein concentration: 
Protein concentrations were determined by Pierce bicinchoninic acid (BCA) assay 
(Thermo Fisher, UK) and BSA of known concentrations were used as standards. 
BCA assay involves reduction of cupric ion (Cu2+) to cuprous ion (Cu+) in an alkaline 
medium, followed by chelation of 2 molecules of bicinchoninic acid with one cuprous 
ion; resulting in a purple reaction complex which exhibits strong absorbance at 562 
nm wavelength, almost linear with increasing protein concentration in the range of 
20-2000 µg/ml. The absorbance was read using BMG POLARstar Galaxy microplate 
reader at 562 nm, and concentration of protein was determined by interpolating a 
known standard curve. 
 
2.15. Western blot: 
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Protein samples (5 µg; from fibroblast lysate) were denatured by addition of 5x 
Laemmli buffer (appendix 2), vortexed, and heated at 95°C for 5 min. SDS denatures 
proteins and gives them a negative charge so that they can be separated based on 
molecular weight rather than charge, while β-mercaptoenthanol reduces disulphide 
bonds within the protein structure. Glycerol increases the density of the samples so 
that they settle to the bottom of wells, while bromophenol blue acts as a colouring 
agent to track movement of samples through the gel. The samples were vortexed 
again after heating, and a protein ladder (5 µl) (EZ-Run, Fisher) and the samples 
were loaded into 1.5 mm wells of NuPAGE 3-8% Tris-Acetate gel submerged in 
running buffer and electrophoresed at 150 V for 1 h followed by 100 V until the dye 
front reached the end of the gel. 
iBlot Dry Blotting System (Invitrogen) was used to transfer proteins from the gel to 
polyvinylidene fluoride (PVDF) membrane. Success of transfer was observed by 
soaking the PVDF membrane in Ponceau Red (Sigma, UK) diluted 1:10 in TBS-
Tween for 5 min on a rocker and protein bands were observed. 
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To prevent non-specific binding, the membrane was blocked in 5% (w/v) skimmed 
milk and 3% (w/v) BSA in TBS (appendix 2) for an hour prior to incubation with 
primary α-SMA antibody (diluted 1:1000 in 5% skimmed milk and 3% BSA in TBS) 
for 1 h on a rocker at room temperature. The membrane was washed thrice with 
TBS-tween and incubated with secondary anti-mouse IgG horseradish peroxidase 
linked antibody, diluted 1:4000 in 5% skimmed milk and 3% BSA and TBS, for 30 
min at room temperature on a rocker. Following two washes with TBS-tween and 
once with TBS, antibody binding was visualised using the Pierce ECL substrate and 
autoradiography film (GE Healthcare, UK) developed in a Compact X4 (Xograph 
healthcare, UK). α-SMA expression was quantified relative to GAPDH (primary 
antibody – 1:7500, secondary antibody – 1:5000) after stripping the blot with stripping 
reagent for 1 h on the rocker and reprobing with the anti-GAPDH antibody using the 
same protocol as described for α-SMA. 
Densitometry was carried out using Image J software and band density normalised 
to GAPDH signals from the same sample. 
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2.16. Immunocytochemistry: 
Normal oral fibroblasts were seeded on coverslips in a 6 well plate for attachment 
overnight at 37°C and 5% CO2 in an incubator. The cells were serum starved the 
next day for 24 h, followed by treatment with 5 ng/ml TGF-β1 for 24 h, 48 h, and 96 h 
time points with their respective controls cultured in serum-free DMEM. 
Upon completion of treatment, the cells were washed twice with PBS for 5 min, and 
fixed in 100% methanol for 20 min at room temperature. The fixative was removed, 
and the cells were washed again with PBS for 5 min.  The cells were then incubated 
with 0.5 ml of 4 mM sodium deoxycholate (Sigma, UK) for 10 min. After washing with 
PBS for 5 min, the non-specific binding sites were blocked with 2.5% BSA in PBS for 
30 min. Followed by incubation with 100 µl FITC labelled α-SMA antibody diluted 
1:100 in the blocking medium for 1 h at room temperature protected from light. The 
primary antibody was aspirated, cells were washed twice with PBS for 10 min, and 
the coverslips were mounted on glass slides using mounting medium containing 
Dapi (Vector Labs, UK). Images were taken at 20 x magnification using Zeiss 
Axioplan 2 Imaging microscope. 
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To quantify fluorescence, ImageJ software was used where the image was 
converted to grey scale, and corrected total cell fluorescence (CTCF) was calculated 
using the following formula: 
CTCF=Integrated density-(Area of selected cell x mean fluorescence of background readings) 
2.17. RNA extraction:  
Total RNA was extracted from cell pellets (centrifuged at 438 g for 3 min in 0.1% 
(w/v) BSA) using ISOLATE II RNA mini kit (Bioline, UK) according to manufacturer’s 
protocol, and all buffers are provided in the kit. In brief, for every 5 x 106 cells 3.5 µl 
of β-mercaptoethanol and 350 µl of lysis buffer was added and vortexed vigorously 
to lyse and homogenise cells. The lysis buffer contains guanidinium thiocynate that 
immediately deactivates endogenous RNase ensuring purification of intact RNA. The 
lysate was loaded on to ISOLATE II filter (violet) with their collection tubes, and 
centrifuged for 1 min at 11,000 g to reduce viscosity and clear the lysate. The filters 
were discarded and 350 µl of 70% ethanol was added to the homogenised lysate, 
mixed, and loaded on to ISOLATE II RNA mini column (blue). The columns were 
centrifuged for 30 s at 11,000 g and placed in new collection tubes. The silica 
membrane in the column was desalted by adding 350 µl Membrane Desalting Buffer 
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and centrifuged for 1 min at 11,000 g to enhance DNase I activity. DNase I was 
diluted 1:10 in Reaction buffer for DNase, and 95 µl of the reaction mixture was 
applied directly on to the centre of the silica membrane, and incubated for 15 min at 
room temperature. The silica membrane was then washed with 200 µl of Wash 
buffer 1 by centrifuging at 11,000 g for 30 s. The silica membrane was then washed 
with 600 µl of Wash buffer 2 at 11,000 g for 30 s. Flow through was discarded and 
the third wash was done by adding 250 µl of Wash buffer 2 to the column and 
centrifuged at 11,000 g for 2 min, ensuring complete drying of the membrane. Elution 
of RNA was achieved by placing the columns in nuclease free tubes, adding 20 µl of 
RNase free water and centrifuging at 11,000 g for 1 min.  
The concentration of extracted RNA was evaluated using a NanoDrop 
spectrophotometer. 
2.18. Complementary DNA preparation: 
RNA extracted as described in section 3.19 was used to prepare complimentary 
DNA (cDNA) for qPCR analysis using High Capacity cDNA Reverse Transcription kit 
(Thermo Fisher, UK). The following reagents were used for each 20 μl reaction: 
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Table 4: cDNA preparation reaction: 
Component Volume (μl) per reaction 
10X RT Buffer 2.0 
25X dNTP Mix (100mM) 0.8 
10X RT Random Primers 2.0 
MultiScribe Reverse 
Transcriptase 
1.0 
Nuclease free water 4.2 
RNA 10.0 
Total per reaction 20.0  
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The mix was then subjected to different temperatures in a thermal cycler with the 
following temperature and duration settings: 
Table 5: cDNA thermal cycle settings: 
Temperature (°C) Duration (min) 
25 10 
37 120 
85 5 
4 ∞ 
 
The resulting cDNA products were then stored at -20°C for no more than a week 
before being used for qPCR. 
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2.19. Quantitative PCR:  
SYBR green dye incorporates into double stranded DNA, the resulting complex 
absorbs blue light (λmax = 497 nm) and emits green light (λmax = 520 nm). As PCR 
progresses new DNA amplicons are produced and SYBR green dye binds to them 
increasing fluorescence intensity proportional to the PCR products produced giving 
an estimate of expression of target gene.  
RNU6-1 or U6 was chosen as the endogenous housekeeping gene for SYBR 
primers. U6 is a highly conserved small nuclear RNA which codes for a component 
of the spliceosome, and showed least CT cycle deviations (Kabir, 2015). 
Taqman probes are composed of a fluorophore attached to the 5’ end of an 
oligonucleotide probe, and a quencher (to quench fluorescence) at the 3’ end. These 
probes anneal to a region of the cDNA, and as long as the probe is intact 
fluorescence from the excited fluorophore is quenched. However, as Taq 
polymerase extends the primers of interest, its exonuclease activity degrades the 
probe, allowing the fluorophore to fluoresce freely. This fluorescence passes through 
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the detection filters to give an estimate of amount RNA derived from the gene of 
interest. 
Two qPCR systems (ABI 7900HT Fast Real-Time PCR system and Rotor Gene Q) 
were used to quantitatively detect IL-6, CCL2, α-SMA, CD80, CD86, CD163, and 
CD206 in the cDNA samples prepared as described in 3.19 with pre-designed SYBR 
Green and Taqman primers (table 1 & 2). 
The reaction mix was prepared according to the manufacturer’s instructions: 
Table 6: qPCR preparation using SYBR green mix: 
Ingredients Volume (µl) 
SYBR Green master mix 5 
Forward primer 0.5 
Reverse primer 0.5 
cDNA 0.5 
Nuclease free water 3.5 
Total 10 
104 
 
Table 7: qPCR preparation using Taqman mix: 
Ingredients Volume (µl) 
Taqman Universal PCR master mix 5 
FAM-labelled Primer 0.5 
VIC-labelled B2M 0.5 
cDNA 0.5 
Nuclease free water 3.5 
Total 10 
 
For ABI 7900HT Fast Real-Time PCR system, the reaction mix was prepared for 
triplicates of the endogenous control and target sample in a 96-well plate, which was 
then centrifuged for a minute at 1000 g and loaded onto the thermocycler. SDS 2.4 
software was used to set up and run the thermal cycles necessary for qPCR.  
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For Rotor Gene Q, the reaction mix was prepared in triplicates in PCR tubes. The 
tubes were then loaded on to the system and following parameters were used for 
qPCR: 
Table 8: qPCR thermal parameters 
Temperature (°C) Duration (s) Cycle Purpose 
95 20 Hold AmpliTaq® Fast DNA polymerase, UP 
activation 
95 1 40 Denature 
60 20 40 Anneal/Extend 
 
Once the run was complete, RQ manager 1.2.1 software in ABI 7900HT Fast Real-
Time PCR system, and Rotor-Gene Q software in the same system were used to 
extract and analyse raw qPCR data, which measured the cycle number when 
fluorescence crossed the detection threshold (CT).  
Triplicate CT values were obtained and accepted only if there was a difference of <1 
cycle within each other to ensure a small standard deviation. Target gene values 
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(∆CT) were normalized by calculating the difference between average target gene 
value and endogenous control gene value as follows:     
∆CT = CT endogenous - CT target 
Relative expression of target gene to endogenous control was determined by the 
following expression and represented in a bar graph: 
Relative expression = 2-∆∆CT 
Data are represented as relative to 24 h control as the data set contains a second 15 
d control (untreated equivalent for 15 d cisplatin treatment), which when compared to 
24 h control highlights changes occurring due to time in culture. Therefore, 24 h 
control is the least impacted control used for comparison. 
2.20. ELISA: 
Sandwich Enzyme Linked Immunosorbent Assay was used to detect levels of IL-6, 
and CCL2 (BD Biosciences, UK) in conditioned media. According to the 
manufacturer’s protocol, the 96-well plate was first coated with 100 µl capture 
antibody (capture antibodies for both IL-6 and CCL2 diluted 1:250 in 0.1 M sodium 
carbonate, pH 9.5) and incubated at 4°C overnight; followed by washing three times 
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with wash buffer (0.05% (v/v) Tween-20 in PBS). Next, the wells were blocked with 
≥200 µl assay diluent (PBS with 10% (v/v) FCS) for 1 h at room temperature. The 
diluent was aspirated and wells were washed as mentioned previously; followed by 
addition of 100 µl of each standard (from 300 pg/ml to 4.7 pg/ml diluted in assay 
diluent) and samples (diluted 1:20 in assay diluent) and sealed before incubation at 
room temperature for 2 h. Samples were aspirated and the wells were washed 5 
times. Working detector solution (detection antibody diluted at 1:250 for IL-6, and 
1:1000 for CCL2 in assay diluent, while streptavidin-HRP diluted at 1:250 for both in 
the same working detector solution) was added in volume of 100 µl per well, sealed 
and incubated at room temperature for 1 h. Working detector was aspirated and the 
wells washed 7 times, allowing the wells to soak in wash buffer for at least 30-60 s. 
Substrate solution (BD biosciences, UK) equal volumes of tetramethylbenzidine and 
hydrogen peroxide from the kit were mixed to make up the substrate solution) was 
added to each well (100 µl) and incubated in the dark at room temperature without 
sealing for 30 min. Stop solution (2 N H2SO4; 50 µl) was added to each well and the 
absorbance read at 450 nm and corrected at 570 nm. 
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2.21. Immunohistochemistry: 
Immunohistochemical staining was performed on formalin fixed paraffin embedded 
tissue sections derived from OSCC patients (10) from Unit of Oral and Maxillofacial 
Pathology, School of Clinical Dentistry, University of Sheffield archive (year 2000) 
(ethical approval number: 07/H1309/150). Tissue sections were deparaffinised by 
immersing sections in xylene (Sigma, UK) twice for 5 min each, followed by 
immersion in 100% ethanol twice for 5 min each. To quench endogenous 
peroxidases, the sections were immersed in 3% (v/v) hydrogen peroxide (Thermo 
Fisher, UK) in methanol for 20 min to reduce background.  
For antigen retrieval, the sections were microwaved for 8 min in 0.01 M sodium 
citrate pH 6, followed by cooling in the same buffer for 30 min. The sections were 
then blocked with horse serum for 30 min for α-SMA antibody, and 1 h for CD68 
antibodies (Dako, UK). 
The sections were incubated with primary antibodies diluted in the same serum (α-
SMA – 1:200, CD68 – 1:400) overnight at 4°C, and were then washed twice with 
PBS for 5 min each the following day. Secondary antibody was prepared as 1 drop in 
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10 ml PBS with 3 drops of horse serum from Vectastain ABC kit (Vector Labs, UK) 
and incubated with sections for 30 min. ABC reagent from Vectastain kit was 
prepared 30 min before use as 2 drops of reagent A and B each in 5 ml PBS. The 
sections were washed twice in PBS before being incubated with ABC reagent for 30 
min. Finally, for colour development, NovaRed kit (Vector Labs, UK) was used for α-
SMA, and DAB (Vector Labs, UK) for CD68 for 5 mins, followed by a wash in double 
distilled water. Finally, the sections were counter-stained with haematoxylin and 
analysed using HistoQuest software. 
Positive control for α-SMA (blood vessels in normal tissue) and CD68 (lymph node 
tissue infiltrated with macrophages confirmed by oral pathologist) stained tissue 
sections were used to set the threshold for presence or absence of cellular staining 
for each marker in Histoquest software. This threshold was then used by the 
software to detect presence or absence of stain in adjacent tumour sections (stained 
separately for either marker), and calculate a percentage of positively stained cells in 
region of interest (tumour mass, stroma, tumour invasive front).   
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2.22. Cytokine array 
Human cytokine array C6 (Raybiotech) was used to detect the presence of other 
cytokines in conditioned media (CM) from 24 h TGF-β1 treated fibroblast, 15 d 
cisplatin treated fibroblast, and their controls. The membranes were blocked with 
Blocking Buffer (supplied with the kit) for 30 min at RT. After aspiration, the 
membranes were incubated with 1 ml CM overnight at 4°C. The CM was aspirated, 
and membranes were washed thrice with 2 ml of 1X Wash Buffer I (supplied with the 
kit) for 5 min each, and twice with 2 ml of 1X Wash Buffer II (kit) for 5 min each. The 
membranes were then incubated with 1 ml of prepared Biotinylated Antibody 
Cocktail for 2 h at RT. Membranes were washed again as described before. HRP-
Streptavidin (1X) in 2 ml volume was added to the membranes, and incubated for 2 h 
at RT. After aspiration, the membranes were washed again. Detection Buffer C and 
D (kit) were mixed in 1:1 volumes, and 500 µl was pipetted onto each membrane for 
2 min at RT. Autoradiography films were then exposed to the membranes for 
chemiluminescence and developed as described in section 2.15. 
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2.23. Concentration and purification of conditioned media: 
Conditioned media from NOF, myofibroblasts, senescent fibroblasts, and patient 
CAF were concentrated, digested, and purified prior to mass spectrometry using the 
following method: 
Protein concentration in the conditioned media was determined using BCA protein 
assay, following which conditioned media containing 100 µg protein was added to a 
LoBind microfuge tube containing 10 µl StrataClean resin beads (Agilent 
Technologies Ltd, UK) (B1). Samples were vortexed for 1 min, centrifuged at 2000 g 
for 2 min, and the supernatant was aspirated and transferred to a second tube (B2) 
containing 10 µl of resin beads. 
The samples and resin in B2 were vortexed for 1 min, and transferred back to B1 
with the resin from B2, before centrifuging and discarding the supernatant.  
The beads were washed twice with 1 ml of 25 mM ammonium bicarbonate (here 
after termed as ambic). For on-bead digestion, the beads were re-suspended in 80 µl 
of 25 mM ambic and 5 µl of 1% (w/v) Rapigest (Waters Limited, UK) in 100 mM 
ambic. The samples were then heated at 80°C for 10 mins, and reduced by addition 
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of 5 µl of dithiothreitol (DTT; 9.2 mg/ml in 25 mM ambic), and heated at 60°C for 10 
mins. Following cooling, 5 µl of iodoacetamide (33 mg/ml in 25 mM ambic) was 
added and the samples incubated at RT for 30 mins in the dark. Trypsin (Porcine 
trypsin, sequencing grade) (1µg) was added and the sample was incubated at 37°C 
overnight on a rotary mixer. The digests were acidified by the addition of 1 µl of 
trifluoracetic acid (TFA) and incubated at 37°C for 45 mins. Samples were then 
centrifuged at 17,000 g for 30 mins, and supernatants transferred to 0.5 ml LoBind 
tubes. The pre and post-acidification digest were analysed by SDS-PAGE to check 
for the absence of protein and hence complete digestion. 
The digested peptides were purified to remove any impurities, and inorganic salts. 
The filtration column (SUM SS18V, Nest Group Inc., USA) was first conditioned with 
200 µl of acetonitrile (ACN) (Sigma, UK), centrifuged at 100 g for 30 sec, and 
discarded. The columns were washed twice with 200 µl HPLC grade water (Sigma, 
UK). The samples were then added to the loading buffer (3% ACN, 97% H2O, 0.1% 
TFA), and loaded on to the columns and centrifuged at 100 g for 1 min. The flow 
through was loaded again, centrifuged, and finally discarded.  
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The columns were then washed with salt removal buffer (3% ACN, 97% H2O, 0.1% 
fluoric acid (FA)) 4 times. The bound protein was eluted in to LoBind microfuge tubes 
(Sigma, UK) using 200 µl of buffer (3% H2O, 97% ACN, 0.1% FA) at 100 g for 2 min. 
The filtered samples were then run for QC before being processed for Label-free 
quantification in Q Exactive HF Orbitrap. Data generated was then analysed using 
MaxQuant and Perseus softwares. 
2.24. Mass Spectrometry 
Mass spectrometry procedure was carried out by Dr. Caroline Evans in Chemical 
and Bioengineering department of University of Sheffield. Mass spectrometry with 
label-free quantification method was used with the following settings: A 105 minute 
data dependent acquisition (DDA) method was set up on the QExactive HF. The full 
MS scan was from 375-1500 m/z was acquired in the Orbitrap at a resolution of 
120,000 in profile mode. Subsequent fragmentation was Top 10 in the HCD cell, with 
detection of ions in the Orbitrap using centroid mode, resolution 30,000. The 
following MS method parameters were used: MS1, Automatic Gain Control (AGC) 
target 1e6 with a maximum injection time (IT) of 60 ms. MS2, Automatic Gain Control 
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(AGC) target 1e5, maximum injection time (IT) of 60 ms and isolation window 2 Da. 
The intensity threshold was 3.3e4, normalized collision energy 27, charge exclusion 
was set to unassigned, 1, exclude istopes was on, apex trigger deactivated. The 
peptide match setting was preferred with dynamic exclusion of 20 seconds. 
Raw data obtained was analysed back in Dental School of University of Sheffield 
using softwares Maxquant and Perseus to generate a list of significantly expressed 
proteins in the CM analysed. Fold changes were calculated by comparing to 
secretion by 24 h. 
2.25. Statistical analyses: 
Graphpad Prism 7 software was used to generate plots and perform statistical 
analyses. Multiple ANOVAs were used to asses any significant differences between 
more than 2 conditions, i.e. different time points in TGF-β1 treated, and cisplatin 
treated, along with their respective controls. When only 2 conditions from the same 
cells were tested for significance, paired T test was used. 
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Chapter 3 
3. Characterisation of myofibroblast and senescent fibroblast phenotypes in primary 
normal oral fibroblast 
Myofibroblasts are the most studied form of ‘activated’ fibroblast; normally found at 
sites of tissue injury, contracting the wound bed and secreting ECM components to 
repair damaged or lost ECM. This amplified accumulation of collagenous ECM leads 
to contraction and, sometimes, scarring of the injured tissue (Hinz, 2016). When the 
repair process is successful and sufficient, myofibroblasts are eliminated via 
apoptosis, or possibly de-activated (Desmoulière et al., 2005, Yang et al., 2014). 
Fibroblasts undergo a two-step activation to achieve a myofibroblastic phenotype:  
(a) the fibroblasts first attain a migratory phenotype by developing contractile fibre 
bundles made of cytoplasmic actin, but produce smaller traction forces compared to 
fully activated and contractile myofibroblasts; this early differentiation is known as 
proto-myofibroblast (Hinz, 2007). b) With continuous remodelling activity in response 
to mechanical and chemical autocrine and paracrine signals they undergo further 
differentiation into fully activated myofibroblasts with de novo expression of α-smooth 
muscle actin (αSMA). This is mainly regulated by the actions of the growth factor 
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TGF-β1, the ECM protein fibronectin-EDA, and the surrounding mechanical 
microenvironment (Tomasek et al., 2002). Upon activation myofibroblasts exhibit 
increased proliferation, migratory ability, production of ECM components and 
cytokines (Powell, 2000). Myofibroblasts are implicated in most cancers like gastric 
cancer, colon cancer, colorectal cancer, pancreatic cancer, liver cancer, bladder 
cancer, and head and neck cancer to promote cancer progression and metastasis 
via cell proliferation and survival, angiogenesis, immune cell recruitment, ECM re-
modelling and cell invasion (Mehner and Radisky, 2013, Serini et al., 1998, Radisky 
et al., 2007a, Hinz, 2007, Darby et al., 2016, Tomasek et al., 2002, Toullec et al., 
2010, Otranto et al., 2012, Evans et al., 2003b, Desmoulière et al., 2005).  However, 
it is becoming increasingly clear that these cancer-associated fibroblasts are not 
simply myofibroblasts, despite sharing phenotypic similarities, but instead represent 
a heterogeneous range of fibroblast phenotypes, such as senescence. 
Senescence, a state of permanent growth arrest, is induced in cells in response to 
persistent DNA damage due to smoking/chewing tobacco, anti-cancer treatment 
such as chemotherapy, and irradiation, as well as oxidative stress from mitochondrial 
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disorders, overexpression of oncogenes, or shortening of telomeres every replication 
to a critical length (Di Micco et al., 2006, Crabbe et al., 2004).  
Consequent to persistent DNA damage, ataxia-telangiectasia mutated (ATM) gene 
upregulates p53 which subsequently promotes accumulation of the cyclin dependent 
kinase inhibitor (CDKi), p21, which inhibits activity of CDK2, a cyclin dependent 
kinase required for progression from G1 phase to S phase in cell cycle, leading to 
cell cycle arrest (Herbig et al., 2004). Long-term activation of p21 also leads to 
mitochondrial dysfunction and elevated ROS, which in turn causes DNA damage, 
completing the self-inducing loop and maintaining cell cycle arrest (Passos et al., 
2010). Unrepairable DNA damage also leads to upregulation of p16INK4A, which has 
a role in maintenance of cell cycle arrest (Robles and Adami, 1998). MicroRNAs 
such as 26b, 181a, 220 and 424 were found to activate p16INK4A to induce 
senescence in cells, where microRNA signatures in actively proliferating human 
mammary epithelial cells (HMECs) and replicative senescent HMECs were 
established using microRNA array; quenching expression of these microRNAs led to 
active proliferation of HMECs (Overhoff et al., 2014). As a result of repeated DNA 
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damage and senescence, fibroblasts stop proliferating but remain metabolically 
active and develop a senescent associated secretory phenotype (SASP) which up-
regulates secretion of many cytokines, one of them being IL-6 (Coppé et al., 2010b).  
In cancer, senescent fibroblasts are often overlooked and not differentiated from 
myofibroblasts as the most common CAF marker used in research is α-SMA, which 
was recently shown to be expressed by both myofibroblasts and senescent 
fibroblasts (Mellone et al, 2016). There is evidence of senescent fibroblasts 
promoting cancer-associated inflammation, cell proliferation, survival, ECM re-
modelling and angiogenesis (James et al., 2015, Ohgo et al., 2015, Davalos et al., 
2010b, Parkinson et al., 2016, Coppé et al., 2010b, Alspach et al., 2013, Freund et 
al., 2010, Mellone et al., 2016, Prime et al., 2017, Passos et al., 2010, Burton and 
Faragher, 2015, Overhoff et al., 2014), but the relative contributions of these different 
phenotypes to cancer progression is unclear, and their effects on immune cell 
recruitment and phenotype poorly understood. 
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Delineating the mechanisms of by which myofibroblasts and senescent fibroblasts 
influence cancer progression and immune responses will be helpful in devising new 
therapeutic targets and prognostic biomarkers in the tumour microenvironment. 
Based on the literature above and in chapter 1, this chapter sets out to characterise 
myofibroblastic phenotype and senescent phenotype in normal oral fibroblasts. 
3.1. Hypothesis:  
Normal fibroblasts transdifferentiate into myofibroblast in response to TGF-β1, while 
cisplatin – a chemotherapeutic drug - induces senescence in fibroblasts; both 
myofibroblast and senescent fibroblasts develop a secretory phenotype. 
3.2.  Aims:  
 To determine the optimum duration of TGF-β1 treatment required to 
transdifferentiate normal oral fibroblast into myofibroblasts; confirm 
transdifferentiation by validating the expression of the most commonly used 
myofibroblast marker, α-SMA, over the course of TGF-β1 treatment at mRNA 
and protein level by qPCR and western blot. 
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 To induce senescence in normal fibroblasts using cisplatin, and confirm 
senescence by validating markers p16INK4A and p21 using qPCR, and by 
senescence associated β-galactosidase assay. 
 To compare expression and secretion of the SASP marker, IL-6, between 
myofibroblasts and senescent fibroblasts using qPCR and ELISA. 
 To examine expression levels of ECM components, FNEDA and COL1A1, in 
myofibroblast and senescent fibroblast. 
3.3. Transdifferentiation of normal fibroblast to myofibroblast through TGF-β1 treatment 
Normal oral fibroblasts (NOF320, NOF316, NOF343), derived from biopsies taken 
during routine dental procedures from healthy volunteers, were isolated and treated 
with 5 ng/ml TGF-β1 for 24, 48, and 96 h (Tamm et al., 1996). Although the optimum 
time point for TGF-β1 treatment to induce myofibroblast transdifferentiation was 
previously found in the lab to be 48 h (Melling, 2015), here shorter and longer time 
points were selected to examine the dynamics of any secretory phenotype detected, 
and to assess possible desensitisation to TGF-β1 due to long exposure (Baugé et 
al., 2011, Yamane et al., 2003, Hasan et al., 1997). To determine expression of α-
SMA mRNA transcripts in the NOFs, RNA was extracted from these cells, reverse 
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transcribed and subjected to quantitative PCR normalised to RNU6-1 (U6) as the 
housekeeping gene. Both NOF316 and NOF320 showed the highest increase in 
transcription of α-SMA after 24 h TGF-β1 treatment of 11 and 13.5 folds from their 24 
h untreated controls, respectively (Fig. 3.1 A and B). The increase was smaller at 48 
h (0.5 and 1.3 fold for NOF316 and NOF320, respectively); followed by even smaller 
increase of 0.14 and 0.1 fold at 97 h in NOF316 and NOF320, respectively. At 24 h, 
NOF343 showed an increase of 4.5 folds in α-SMA transcripts compared to 
untreated controls, while the highest increase in transcription was observed after 48 
h of TGF-β1 treatment with a fold increase of 14, and dropping down to 4.4 folds at 
96 h timepoint (Fig. 3.1 C). 
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Figure 3.1: Relative mRNA expression of α-SMA in TGF-β1 treated and untreated 
fibroblasts to 24 h ctrl. Normal oral fibroblasts from 3 patients were treated with 5 
ng/ml TGF-β1 for 24, 48, and 96 h duration, with untreated controls cultured in 
serum-free DMEM. Subsequently, RNA was collected and reverse transcribed from 
both treated and untreated controls, and α-SMA was validated at mRNA level 
against RNU6-1 as housekeeping gene through qPCR. A) NOF316 showed a 
relative increase in α-SMA mRNA transcripts of 11, 0.5, and 0.14 at 24 h, 48 h, and 
96 h, respectively. B) NOF320 showed a relative increase of 13.5, 1.3, and 0.1 at 24 
h, 48 h, and 96 h, respectively. C) NOF343 showed a relative increase of 4.5, 14, 
and 4.4 at 24 h, 48 h, and 96 h, respectively. Data +/- SEM, n = 3 biological repeats. 
 
 
 
 
123 
 
Having identified a trend towards an increase in α-SMA transcript level, albeit of 
variable magnitude, western blot analysis was carried out next to determine protein 
expression of α-SMA in the TGF-β1 treated and untreated NOF316, NOF320, 
NOF343 as shown in fig. 3.2. It was observed that α-SMA mRNA levels decreased 
with increasing duration of TGF- β1 treatment (fig 3.1 A), yet, NOF316 showed 
increases in relative expression of α-SMA protein with increasing duration of TGF-β1 
treatment; at 24 h, 48 h, and 96 h, the increase in relative expression was 3, 88, and 
121-fold, respectively (Fig 3.2 A). Melling made similar observation in the same lab  
where targeting levels of α-SMA mRNA did not impact translation into α-SMA protein 
(Melling, 2015). NOF343, following more closely the pattern of mRNA expression 
(fig. 3.1 C) changes observed, displayed relative increases of 1.9, 3, and 2.3-fold at 
24 h, 48 h and 96 h, respectively (Fig. 3.2 C). However, in fig. 3.1. B, NOF320 TGF-
β1 treated and untreated cells expressed similar levels of α-SMA (relative expression 
of 1.2, 1 and 1-fold at 24 h, 48 h, and 96 h, respectively) as seen in Fig. 3.2 B.  
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Figure 3.2: Western blot analysis protein expression of α-SMA in TGF-β1 transdifferentiated 
myofibroblasts. Normal oral fibroblasts were treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 
96 h duration; lysates were collected from treated and untreated fibroblasts and α-SMA and 
GAPDH proteins were identified using antibodies raised against the same through western 
blotting. Densitometry was used to quantify expression of α-SMA protein, normalised to 
GAPDH. A) and C) NOF316 and NOF343 both showed an increase in absolute expression 
of α-SMA with increasing duration of TGF-β1 treatment B) NOF320 failed show a prominent 
difference between treated and untreated cells. N = 1 biological repeat. 
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Out of the three patient samples, NOF343 was selected to continue on with the 
project due to its robust response to TGF-β1, and availability of low passage 
cultures.  
Having established that TGF-β1 treatment provoked an increase in cellular levels of 
α-SMA in NOF343 cells, immunofluorescence was next employed whereby a FITC 
conjugated antibody specific to α-SMA was used to validate and extend the western 
blot results by allowing visualisation of α-SMA stress fibres following TGF-β1 
treatment of fibroblasts using fluorescence microscopy as described in section 2.16 
and depicted in Fig 3.3 A. As seen in fig. 3.3 B, the increase in fluorescence of α-
SMA stress fibres in TGF-β1 treated NOF343 is significant with respect to their timed 
untreated controls, with p<0.0001 at 24 h and 96 h, and p<0.007 at 48 h time points. 
 
 
 
126 
 
 
127 
 
 
Figure 3.3: Immunofluorescence analysis of α-SMA stress fibres. NOF343 was 
cultured on coverslips and treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 96 h, with 
untreated cells cultured in serum-free DMEM. A) TGF-β1 treated fibroblasts show α-
SMA stress fibres clearly at all time points while untreated fibroblasts displayed 
minimal expression of α-SMA stress fibres. B) Quantification of immunofluorescence 
shows significantly higher expression of α-SMA with p<0.0001 at 24 h and 96 h time 
point, and p<0.007 at 48 h. Statistical analysis – ANOVA, data +/- SEM, n = 3 wells. 
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3.4.  Cisplatin-induced senescence in normal oral fibroblasts 
Normal oral fibroblasts NOF343 were treated with a chemotherapeutic drug 
commonly used in head and neck cancer patients,  cisplatin (10 µM) for 24 days, 
then allowed to senesce over 14 days. These conditions were chosen on the basis of 
characterisation previously carried out in the lab (Kabir et al., 2016). The acquisition 
of senescence was indicated by increases in the expression of p16INK4A and p21; 
cyclin dependent kinase inhibitors regulating cell cycle progression commonly used 
as indicators of senescence acquisition, as assessed by qPCR. The cisplatin treated 
fibroblasts exhibited elevated levels of both p16INK4a (1.71 fold increase) and p21 (3.4 
fold increase) compared to their untreated counterparts (fig. 3.4), although this did 
not reach statistical significance due to variation between experiments. 
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Figure 3.4: Expression of senescence marker transcripts in cisplatin treated and 
untreated fibroblasts. NOF343 were treated with 10 µM cisplatin for 24 h, then 
cultured in DMEM over 14 days. RNA was isolated from control and treated NOFs, 
used to generate cDNA for qPCR using primers for p16INK4A, p21, and RNU6-1 (U6) 
as endogenous control. A) and B) Cisplatin treated senescent fibroblasts expressed 
elevated levels of both p16INK4a and p21 transcripts, as assessed by qPCR 
normalised to RNU6-1, compared to untreated control fibroblasts. Statistical analysis 
– Student paired T test, data are mean +/- SEM, and not significant, n=3 biological 
repeats. 
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Senescence associated β-galactosidase assay employs cleavage of a chromogenic 
substance, X-gal, which upon hydrolysis by β-galactosidase at pH 6 in aged cells 
forms a blue precipitate, hence it is used as a method of confirming senescence 
(Dimri et al., 1995) along with elevated p16INK4a and p21 (Ohgo et al., 2015). 
Cisplatin (10 µM) treated normal oral fibroblasts NOF343 exhibited a blue stain in 
more than 90% of the cells due to cleavage of X-gal upon accumulation of lysosomal 
β-galactosidase (p<0.0009), while the untreated control was devoid of the blue stain 
(fig. 3.5 A and B). Senescent fibroblasts were also more flattened and bigger in 
appearance compared to control fibroblasts (fig. 3.5 A). 
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Figure 3.5: Senescence associated β-galactosidase assay (SA β-gal) confirming 
senescence. Normal oral fibroblast NOF343 were treated with 10 µM cisplatin for 24 
h before allowing to senesce for 14 d in DMEM. A) In senescence associated β-
galactosidase assay cisplatin treated fibroblasts (>90%) developed a blue precipitate 
due to cleavage of X-gal at pH 6 because of higher activity of lysosomal β-
galactosidase while the control fibroblasts remained free of any precipitate 
development when subjected to SA β-gal assay. B) The positive precipitate 
development in cisplatin treated fibroblasts was significant with p<0.0009. Statisticaly 
analysis – Student T test, data +/- SEM, n=3 biological repeats. 
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IL-6 is a prominent cytokine in the inflammatory environment with evidence in the 
literature of it being up-regulated in both myofibroblasts and senescent fibroblasts 
(Zhu et al., 2014, Hendrayani et al., 2016, Ara and Declerck, 2010, Kojima et al., 
2013, Rose-John, 2012). In myofibroblasts, IL-6 aids secretion of ECM components 
during wound healing, promoting angiogenesis, and causing inflammation in the area 
via recruitment and differentiation of immune cells (Zhu et al., 2014, Rose-John, 
2012, Ara and Declerck, 2010, Mueller et al., 2010, Zhu et al., 2016). In senescent 
fibroblasts, IL-6 helps maintain senescence in an autocrine loop, while promoting 
senescence in neighbouring fibroblasts by up-regulating production of ROS (Tanaka 
et al., 2014, Kojima et al., 2013, Burton and Faragher, 2015, Passos et al., 2010, 
Mellone et al., 2016, Davalos et al., 2010b). Therefore expression and secretion of 
IL-6 by myofibroblasts and senescent fibroblasts was quantified at mRNA and 
protein level using qPCR and ELISA, respectively. Surprisingly, at the mRNA level in 
myofibroblasts at 24 h, 48 h, and 96 h, IL-6 was marginally down-regulated 
compared to untreated controls (fig. 3.6 A). At the secreted protein level, however, 
there was a significant increase (p=0.0123) in IL-6 secretion after 24 h of treatment 
with TGF-β1, an increase which declined with increasing duration of TGF-β1 
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exposure (Fig. 3.6 B). On the other hand, cisplatin induced senescent fibroblasts 
showed an upregulation in both IL-6 mRNA but not significant (fig. 3.6 A), while there 
was an upregulation observed at secretory level and significant (p=0.0125), 
compared to proliferating controls (Fig. 3.6 B).  
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Figure 3.6: IL-6 expression in myofibroblasts and senescent fibroblasts: Normal oral 
fibroblasts NOF343 were treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 96 h to 
induce myofibroblast transdifferentiation. To induce senescence, normal oral 
fibroblasts NOF343 were treated with cisplatin (10 µM) for 24 h and senesced over 
14 d. RNA was extracted from these NOFs to generate cDNA, used in qPCR with IL-
6 and RNU6-1 (U6) primers. All bars are relative to 24 h control. A) IL-6 transcripts 
were down regulated in TGF-β1 treated fibroblasts, and reduced further with 
increasing duration of treatment. However, IL-6 transcripts were up-regulated in 
cisplatin induced senescent fibroblasts and significant to control and TGF-β1 treated 
fibroblast at 24, 48 and 96 h with * = p<0.002. B) Secretion of IL-6 was significantly 
up-regulated at 24 h time point of TGF-β1 treatment (mean 1214 pg/ml) compared to 
its 24 h control (mean 125.3 pg/ml) with p=0.0123. IL-6 secretion down-regulated 
with increase in duration of TGF-β1 exposure. Cisplatin induced senescent fibroblast 
showed a significant increase (mean 1824 pg/ml) compared to its control (mean 
407.6) with p=0.0125. Statistical analysis – ANOVA with Tukey’s multiple 
comparison, data +/- SEM, n=3. 
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In addition to augmented cytokine and growth factor secretions, CAFs also secrete 
ECM components, such as fibronectin-EDA (FNEDA), collagen, fibrin, elastin, MMPs 
and proteoglycans (Tomasek et al., 2002, Ohlund et al., 2014, Erdogan and Webb, 
2017).  
Levels of transcripts corresponding to the ECM genes fibronectin extradomain A 
(FNEDA) and collagen α-1 (I) chain (COL1A1) were determined in both 
myofibroblast and senescent fibroblast phenotypes of NOF343 (Fig. 3.7 A and B), 
generated as described in sections 3.4 & 3.5. Transcripts of both FNEDA and 
COL1A1 were found to be up-regulated in TGF-β1 treated fibroblasts 
(myofibroblasts) (Fig. 3.7 A and B), with FNEDA transcripts significantly elevated at 
24 h TGF-β1 treatment time point with p=0.0169 (Fig. 3.7 A). In contrast, cisplatin 
induced senescent fibroblasts showed relatively equal levels of FNEDA (Fig. 3.7 A), 
and down regulation of COL1A1 (Fig. 3.7 B) compared to their untreated controls. 
Increase in FNEDA and COL1A1 transcripts in TGF-β1 transdifferentiated 
myofibroblasts has been observed before in several studies (Melling, 2015, Zeisberg 
et al., 2007, Torr et al., 2015, Mellone et al., 2017). 
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Figure 3.7: Expression of FN-EDA and COL1A1 mRNA transcripts in 
myofibroblast and senescent fibroblast: Normal oral fibroblast NOF343 was 
treated with 5 ng/ml TGF-β1 for 24 h, 48 h, and 96 h to transdifferentiate into 
myofibroblast, while cisplatin (10 µM) was used for 24 h, and 14 d of normal 
culture to induce senescence. RNA was isolated from control and treated NOFs, 
used to generate cDNA for qPCR using primers FNEDA, COL1A1, and 
endogenous control RNU6-1 (U6). All bars are relative to 24 h control. A) 
Myofibroblast expressed higher mRNA transcripts of FN-EDA compared to their 
controls, with significance (p=0.0169) after 24 h TGF-β1 treatment. Senescent 
fibroblast and its untreated control expressed similar level of FN-EDA mRNA 
transcripts with no significance. B) Col1A1 mRNA was upregulated only in 
senescent fibroblast and its untreated control, while TGF-β1 treated fibroblasts 
showed a small increase in expression compared to their controls. Statistical 
analysis – ANOVA with Tukey’s multiple comparison, data are +/- SEM, n=3 
biological repeats. 
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3.5.  Summary 
This chapter describes characterisation of fibroblast to myofibroblast and senescent 
fibroblast phenotypes. Normal oral fibroblasts were treated with 5 ng/ml TGF-β1 for 
three time points – 24 h, 48 h, and 96 h to study the effects of TGF-β1 during both 
short and long exposures. Senescence was induced in normal oral fibroblasts using 
cisplatin; treating cells for 24 h and allowing the fibroblasts to senesce over the 
course of 2 weeks in normal culture. 
It was found that upon TGF-β1 treatment, normal oral fibroblasts (NOFs) exhibited 
increased expression of α-SMA at protein level with appearance of stress fibres, 
which is also a commonly used identifying marker for myofibroblastic phenotype. The 
expression of α-SMA increased with increasing duration of TGF-β1 treatment, even 
though expression at mRNA level differed from protein expression. One of the NOFs, 
NOF320, used in the study displayed very limited changes in response to TGF-β1 
treatment, suggesting desensitisation to TGF-β1.  This desensitisation to TGFβ1 and 
relatively high levels of basal α-SMA expression could be due to possible extraction 
of these fibroblasts from an already inflamed site; (Hasan et al., 1997, Yamane et al., 
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2003) unfortunately this clinical information was not available. A further dose-
dependent TGF-β1 treatment compared to untreated control showing no changes in 
expression of α-SMA would confirm desensitisation but was not completed for this 
thesis due to time constraints.  
Cisplatin induced senescence in NOF343, as indicated by positive staining in SA β-
gal assay, broad and flattened cell morphology, and increased expression of 
p16INK4A and p21 mRNA. 
Expression of IL-6 known to be secreted by senescent cells (Kojima et al., 2013). 
This was confirmed in this study as well, and compared with expression by 
myofibroblasts where both senescent fibroblasts and myofibroblasts showed 
significant increases in secretion of IL-6 compared to their respective time controls, 
with myofibroblasts showing highest secretion at 24 h post TGF-β1 treatment, and 
declining with increasing duration of treatment. 
ECM components FNEDA and COL1A1 are markers of myofibroblast 
transdifferentiation (Melling, 2015, Zeisberg et al., 2007, Torr et al., 2015, Mellone et 
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al., 2017). This was then compared with expression by senescent fibroblasts which 
didn’t show an increase in expression of both FNEDA and COL1A1 mRNA. 
With the confirmation of change in phenotype of both TGF-β1 treated fibroblasts and 
cisplatin treated fibroblasts, capability to recruit monocytes was examined in the next 
chapter to observe possible differences in the same. 
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Chapter 4 
4. Comparing monocyte recruitment capability of myofibroblast and senescent 
fibroblastic phenotypes 
Monocytes originate in the bone marrow before being released into to bloodstream, 
where they constitute 3-8% of total circulating leukocytes. Monocytes are further 
divided in to subsets based on the expression of CD14 and CD16. The most 
prevalent subset in circulation, the classical monocyte, expresses CD14++CD16- with 
CCR2hiCX3CR1low expression and participates in pro-inflammatory and anti-microbial 
roles (Shi and Pamer, 2011). Other subsets include intermediate and non-classical 
with CD14++CD16+, and CD14-CD16++ expression, respectively with roles in 
inflammation and patrolling (Shi and Pamer, 2011).  
Sub-populations of CAFs with varying phenotype present in the TME secrete an 
array of growth factors, angiogenic factors and numerous cytokines/chemokines 
(detailed description in chapter 5) which present the capability to recruit these 
monocytes through promiscuous receptor/ligand axes such as CCR2/CCL2 (Ohgo et 
al., 2015, Mueller et al., 2010, Wu et al., 2011, Loberg et al., 2007, Min et al., 2015, 
Li et al., 2014b, Tsuyada et al., 2012b). These monocytes are recruited to the TME 
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and the tumour mass itself to differentiate and polarise into M1 and M2 macrophages 
depending on the cytokine environment encountered (Bingle et al., 2002, Mantovani 
and Sica, 2010, Sica et al., 2006a). The presence of macrophages in most solid 
tumours, including those of the head and neck, lead to poor prognosis (Li et al., 
2002, Marcus et al., 2004, Liu et al., 2008).  
The data described in this chapter uses in vitro approaches to explore the potentially 
differential monocyte recruitment capabilities of two recognised subsets of cancer-
associated fibroblast phenotypes; myofibroblastic and senescent fibroblasts, and 
compare this to the recruitment capabilities of tumour-derived CAF. This might 
provide the mechanistic information required to begin to target subpopulations of 
CAF more effectively to prevent specific recruitment of immune cells, especially 
macrophages, to improve prognosis.  
4.1  Hypothesis:  
Myofibroblasts, senescent fibroblasts and CAFs have distinct secretory phenotypes 
and have different abilities to recruit monocytes. 
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4.2  Aims: 
 To examine the capability of myofibroblasts, senescent fibroblasts and patient 
CAFs to recruit THP1 cells and PBMs via secreted factors. 
 To measure levels of monocyte chemokine – CCL2 secreted by 
myofibroblasts, senescent fibroblasts, and patient CAFs. 
 To determine expression of CCR2 – receptor for CCL2 on THP1 cells and 
PBMs. 
 To inhibit CCR2 using a small molecule inhibitor or pertussis toxin and study 
monocyte migration. 
 To investigate macrophage polarisation in response to secreted factors from 
myofibroblasts, and senescent fibroblasts. 
 To investigate possible correlation between presence of TAMs and CAFs in 
tumour sections. 
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4.3  THP1 cell migration in response to factors secreted by myofibroblast and senescent 
fibroblast 
THP1 cells, a monocytic cell line isolated from the peripheral blood of a patient with 
acute leukaemia (Tsuchiya et al., 1980), were replicated from the pilot study (Kabir, 
2015) to test for suitability for this study. THP-1 were used in a modified Boyden 
chamber/transwell assay, in which conditioned medium (CM) from myofibroblasts 
(NOF343 treated with 5 ng/ml TGF-β1), senescent fibroblasts (NOF343 pulsed with 
10 µM cisplatin), and their respective untreated controls were placed in the bottom 
chamber, and the THP1 cells in the upper chamber (Fig. 4.1).  
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Figure 4.1: Boyden chamber (transwell) setup used for migration assay:  THP-1/monocytes 
were placed in the upper chamber of the transwell in serum free medium, and allowed to 
migrate through a porous membrane in the transwell to the lower chamber containing 
conditioned medium (CM) from fibroblasts over 4 h. The number of monocytes in lower 
chamber and underside of the transwell were counted as migrated and used for statistical 
analysis comparing migration towards CM from different phenotypes of fibroblasts. 
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Migrated cells on the underside of the porous membrane were methanol fixed, and 
stained with DiffQuik (as described in chapter 2, section 2.12), and cells migrated all 
the way in to the CM were gently agitated; at least three images taken by light 
microscopy at 20 X magnification. The cells were then counted using ImageJ as 
described in chapter 2, section 2.12.  
At 24 h THP-1 migrated less towards myofibroblast CM compared to 24 h control CM 
with a fold decrease of 0.14, but at 48 h myofibroblast CM recruited more THP-1 
than 48 h control CM with a 2.18 fold increase, although it was not statistically 
significant (Fig. 4.2). However, at 96 h, both myofibroblast CM and control CM 
recruited the same number (+/- 1) of THP-1 cells. THP-1 recruitment by senescent 
fibroblasts showed a 1.6 fold increase from its 15 d control CM. Statistically, 
recruitment by senescent fibroblast CM was significant compared to recruitment by 
controls at all time points - 24 h, 48 h, 96 h, and 15 d, as well as recruitment by TGF-
β1 treated myofibroblasts at all time points 24 h, 48 h and 96 h, with p<0.0001. 
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Figure 4.2: THP1 monocyte migration towards CM from myofibroblasts and 
senescent fibroblasts. NOFs were treated with 5 ng/ml TGF-β1, serum-free medium 
(SFM) or 10 µM cisplatin for different time durations, and fresh media was 
conditioned for 24 h before collection and used in migration assay. THP1 cells were 
allowed to migrate towards CM from myofibroblast, senescent fibroblast, their 
untreated controls, CCL2 (positive control), and SFM (negative control, later 
deducted from data as background) in a transwell assay for 4 h, and the number of 
migrated cells counted. Only 48 h TGF-β1 treated myofibroblast CM showed a 2.18 
fold increase from its 48 h control CM, while 24 h and 96 h TGF-β1 treated 
myofibroblast CM displayed reduced recruitment of THP-1. Senescent fibroblast CM 
recruited THP-1 cells with a fold increase of 1.6 from its 15 d control CM, and was 
significant compared to myofibroblast CM at 24 h, 48 h, 96 h, and control CM at 24 
h, 48 h, 96 h and 15 d by p<0.0001. Statistical analysis - One Way ANOVA where # 
indicates migration towards 15d cisp treated NOF343 significant to all other 
conditions (24, 48, 96 h control, and TGF-β1 treated, and 15 d control) with 
p<0.0001; data are mean +/- SEM, n=3 biological repeats. 
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4.4  Peripheral blood monocyte migration in response to factors secreted by 
myofibroblast and senescent fibroblast 
THP1 is a cell line originating from acute monocytic leukaemia, and therefore results 
using it can be used to design and optimise conditions of initial experiments but are 
not directly translatable to primary monocytes. Consequently, monocytes from 
peripheral blood, isolated from the buffy coats of healthy volunteers (as described in 
chapter 2, section 2.8) were next used. Migration towards CM from myofibroblasts at 
24 h was higher (1.27 fold increase) than 24 h control, but not statistically 
significantly (Fig. 4.3 A). At 48 h time point, recruitment of PBM by myofibroblast CM 
showed fold increase of 1.54 from its 48 h control CM (again, this didn’t reach 
significance), while migration at 96 h time point showed a fold increase of 1.48 from 
its control CM (Fig. 4.3 A).  
PBM migration towards CM from senescent fibroblasts exhibited a fold increase of 
1.82 from its 15 d control (Fig 4.3 A). However, this increase was not statistically 
significant compared to recruitment by its control or by the myofibroblasts at any time 
point (Fig. 4.3 A). This is possibly due to patient-to-patient variability present in the 
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PBMs isolated from different buffy coat for each biological repeat of the experiment 
as shown in Fig. 4.3 B. 
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Figure 4.3: Peripheral blood monocyte (PBM) migration towards CM from myofibroblasts 
and senescent fibroblasts. PBMs were isolated from multi-donor buffy coats, and migrated 
towards CM from myofibroblast, senescent fibroblast, their untreated controls, CCL2 
(positive control), and SFM (negative control, later deducted from data as background) A) 
Monocytes were recruited by myofibroblasts at 24 h with 1.27 fold increase from its timed 
untreated control, gradually declining with increase in TGF-β1 treatment duration. Although 
fold increases at 48 h and 96 h time points were 1.54 and 1.48 from their timed untreated 
controls, respectively. Senescent fibroblast CM recruited the most number of monocytes and 
highest fold increase of 1.82. B) Monocyte migration trend from each buffy coat showing 
variation in number recruited during each biological repeat, resulting in insignificant statistical 
analysis. Statistical analysis – Two way ANOVA, data are mean+/- SEM with n=3 biological 
repeats. 
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4.5  Expression of CCR2 by THP-1 and peripheral blood monocytes 
CCR2 is a heptahelical transmembrane, G-protein coupled receptor, and it is the 
main receptor for chemokine CCL2 but can also bind CCL7, and CCL13 (Li et al., 
2002). CCR2 is highly expressed on the classical subset (CD14hiCD16low) of 
monocytes, but can also be found on haematopoietic cells such as macrophages, 
and on non-haematopoietic cells like fibroblasts, endothelial, and mesenchymal stem 
cells (Zhang et al., 2010). The CCR2 gene has two splice variants, CCR2A and 
CCR2B, where CCR2B accounts for 90% of the CCR2 expressed on monocytes, 
and facilitates monocyte recruitment into sites of inflammation and also facilitates 
their maturation into tissue macrophages (Van Coillie et al., 1999, Wong et al., 
1997).  
In order to assess whether the CCL2/CCR2 axis was involved in the observed 
monocyte responses to fibroblast-derived signals, expression of CCR2 transcript 
was examined in THP1 cells and PBM using qRT-PCR for both CCR2A and CCR2B 
isoforms. The CCR2B isoform transcript was readily detectable in both PBM and 
THP-1, with THP-1 showing higher expression than PBM relative to CCR2A (Fig. 4.4 
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A).  Next, protein expression of CCR2B was investigated using flow cytometry on 
both THP1 cells and PBMs (Fig. 4.4 B & C). CD14 was used as a classic monocyte 
marker to confirm that the cells isolated and purified from buffy coats to be used 
were monocytes (Fig.4.4 D). Flow cytometry showed that only 14.2% of THP1 cells 
expressed CD14 (Fig. 4.4 B), while a much smaller population of these cells (1.19%) 
expressed CCR2 (Fig. 4.4 C). Conversely, 91.9% of PBMs expressed CD14 (Fig. 4.4 
D), of which 78.6% expressed CCR2 receptor (Fig. 4.4 E). 
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Figure 4.4: CCR2 expression in PBM and THP1 cells. RNA was isolated from both 
PBM and THP1 cells, followed by generation of cDNA, used in qPCR normalised to 
β2 microglobulin (B2M). Flow cytometry was used to validate expression of monocyte 
marker CD14, and CCR2 on THP1 cells and PBMs, depicted by the red histogram, 
while blue depicts the isotype control. A) PBM and THP1 cells express higher levels 
of CCR2B variant transcript relative to CCR2A B)  and C) show that only 14.2% and 
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1.19% of THP1 cells express classic monocyte marker CD14, and CCR2B receptor, 
respectively. D) Red histogram with higher peak shows 91.9% of the monocytes 
purified expressed CD14, with a smaller peak on the left showing monocyte subset 
with low CD14 expression. E) Of the PBMs positive for CD14 expression, 78.6% of 
them expressed CCR2 receptor. N = 1. 
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4.6  CCL2 secretion by myofibroblasts and senescent fibroblasts 
Both myofibroblasts and senescent fibroblasts have been reported to develop 
secretory phenotypes, and produce a gamut of factors, some of which are 
chemokines that might be responsible for the monocyte migration observed in fig. 
4.2 and 4.3. Having confirmed the expression of CCR2 receptor on PBM (Fig. 4.4), 
the next step was to examine levels of CCL2 in both myofibroblast and senescent 
fibroblasts by qPCR and ELISA (in conditioned medium) to test the hypothesis that 
the CCL2/CCR2 axis is the mechanism responsible for the fibroblast-induced 
migration observed in this study (Fig. 4.5 A and B). The qPCR results from 
fibroblasts treated with TGF-β1 for 24 h showed almost no change in CCL2 transcript 
levels compared to its control at 24 h, whereas transcript levels in 48 h and 96 h 
TGF-β1 treated myofibroblast showed a decrease in expression of CCL2 transcript 
compared to their respective controls (Fig. 4.5 A). In contrast, at the protein level, 
TGF-β1 treated fibroblasts showed a 7.4 fold increase in secreted CCL2 at 24 h, a 
1.7 fold increase at 48 h, and a 2.7 fold increase at 96 h compared to their timed 
controls (Fig. 4.5 B). The highest concentration of CCL2 secreted by myofibroblasts 
was at the 48 h time point (133.1 pg/ml), followed by 129.6 pg/ml at 24 h time point, 
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finally decreasing to 97.82 pg/ml at 96 h time point. Senescent fibroblasts showed 
the highest expression of CCL2 transcripts, both in comparison to its control and 
myofibroblasts and their controls at all time points (Fig. 4.5 A). Surprisingly, the 15 d 
(untreated) control also expressed higher levels of CCL2 than other controls and 
TGF-β1 treated fibroblasts. There was no significant difference between CCL2 
expressions in the cisplatin treated cells and their respective untreated (15 d) control. 
In terms of CCL2 secretion, senescent fibroblasts secreted 825.6 pg/ml, a 0.58-fold 
increase from its 15 d control (p=0.032) as shown in Fig. 4.5 B. CCL2 secretion 
levels were significantly higher from senescent fibroblasts than myofibroblasts and 
their controls at all time points (p<0.0001; Fig. 4.5 B). CCL2 secretion by 15 d 
untreated control was also higher than TGF-β1 treated NOFs and their untreated 
controls at all time points with a significance of p<0.008 (Fig. 4.5 B). 
 
 
 
 
157 
 
 
Figure 4.5 Expression of mRNA and secreted levels of CCL2 in myofibroblast and 
senescent fibroblast. A) Myofibroblast showed a decrease in mRNA expression of 
CCL2 compared to its untreated controls, while both senescent fibroblast and its 
control showed an upregulation in comparison. B) Myofibroblast initially showed an 
increase in secretion of CCL2 at 24 h – 7.4 fold, 2.7 fold at 48 h and 2.6 fold at 96 h, 
declining with increase in duration of TGF-β1, while senescent fibroblast showed a 
1.27 fold increase. Statistical analysis – Two way ANOVA, where # is 15 d cisp 
significant to control & TGF-β1 NOFs at 24, 48, and 96 h with p<0.0001, and * is 15 
d cisplatin significant to 15 d control with p=0.032, and $ is 15 d control significant to 
TGF-β1 treated NOFs and their controls at 24, 48, and 96 h with p<0.008. Data are 
mean +/- SEM with n=3 biological repeats. 
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4.7  Targeting CCR2 receptor  
Having established the presence of CCR2 on PBM and the ability of both 
myofibroblasts and senescent fibroblasts to secrete its ligand, CCL2, it was next 
decided to examine the effect of using a small molecule inhibitor of CCR2, RS 
504393, on monocyte migration, to elucidate whether CCL2 was wholly or partly 
responsible for the observed effects on monocyte recruitment. 
PBMs were pre-treated with 10 µM of the CCR2-specific small molecule inhibitor RS 
504393 (CCR2i) for one hour; this concentration was based on the study by (Carmo 
et al., 2014). CCR2i was then removed and PBMs suspended in fresh SFM before 
migrating towards CM from myofibroblasts or senescent fibroblasts (section 2.12). 
However, before proceeding with the migration assay, monocyte cell viability was 
examined at 5, 10, and 20 µM by treating cells with the inhibitor for 1 h (SFM was 
used as negative control), followed by incubation in SFM for 4 h at 37°C, mimicking 
the conditions of the transwell migration assay used in this study. This experiment 
was performed to ensure that the inhibitor did not cause toxicity that might lead to 
artefactual results in the migration assay. Trypan blue was used to calculate the 
159 
 
percentage of dead cells out of total cells; there was 33% less cell death at 10 µM 
compared to normal SFM as shown in Fig. 4.6 A. Upon treating PBMs with 10 µM 
CCR2 inhibitor (+CCR2i), migration towards recombinant CCL2 showed a 0.52 fold 
decrease with p=0.01 compared to migration by PBMs with uninhibited CCR2 
(control; Fig 4.6 B). After treating PBMs with CCR2 inhibitor, they migrated towards 
CM from myofibroblasts, senescent fibroblasts and their untreated and time controls 
(Fig. 4.6 C); migration observed to be reduced by 91%, 97.3%, 94.78%, and 92.57%  
towards CM from 24 h, 48 h, 96 h and 15 d untreated control respectively, while 
migration towards CM from 24 h, 48 h, and 96 h TGF-β1 treated myofibroblasts was 
reduced by 79.4%, 83.6%, and 89.8% respectively, and migration towards CM from 
15 d cisplatin senesced fibroblasts showed least reduction amongst all with a 76.3% 
decrease as shown in Fig. 4.6 C.  
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Figure 4.6: Effect of CCR2 inhibition on monocyte migration. PBMs were treated with 10 µM 
CCR2 inhibitor (CCR2i) RS 504393 for 1 h, followed by 4 h in a transwell assay set up at 37°
C and 5% CO2, n=1. A) Trypan blue exclusion was used to examine cell viability 4 h after 
treatment with CCR2i for 1 h. CCR2i induced 33% less death at 10 µM concentration 
compared to serum free media. B) After inhibiting CCR2, migration towards recombinant 
CCL2 showed a 0.52 decrease with p=0.01 from student t test with n = 3 biological repeats. 
C) Treatment with CCR2i also decreased migration towards CM from 24 h, 48 h, 96 h and 
15 d untreated control fibroblasts by 91%, 97.3%, 94.78%, and 92.57%, respectively, while 
migration towards CM from 24 h, 48 h, 96 h TGF-β1 treated myofibroblasts, and 15 d 
cisplatin senesced fibroblasts decreased by 79.4%, 83.6%, 89.8% and 76.3%, respectively. 
Statistical analsyis – two way ANOVA with no significance with n = 3 biological repeats. All 
data are mean +/- SEM. 
 
161 
 
4.8  Inhibition of chemokine receptors on monocytes with pertussis toxin 
As presented in fig. 4.6 B, it was observed that PBM migration towards CM from 
myofibroblast and senescent fibroblasts was not completely abolished upon 
inhibiting CCR2. Evidence exists suggesting monocytes possess numerous 
chemokine receptors that are promiscuous in nature and interact with more than one 
ligand/chemokine (summarised in Table 9), which can compensate for the loss of 
one receptor to some degree (Anders et al., 2003, Sandblad et al., 2015).  
Table 9. Chemokine receptors present on monocytes, and their interacting ligands 
(Anders et al., 2003, Sandblad et al., 2015). 
Receptor Ligand Alternative name 
CCR1 CCL3,5,7,8,13,14,15,16,23 MIP-1α, Rantes, MCP-3,2,4, HCC-1,2,4, 
MPIF-1 
CCR2 CCL2,7,8,13 MCP-1,3,2,4 
CCR3 CCL5,13,24,26 Rantes, MCP-4, Eotaxin-2,3 
CCR4 CCL17,22 TARC, MDC 
CCR5 CCL3,5,8 MIP-1α, Rantes, MCP-2 
CCR6 CCL20 LARC 
CCR7 CCL19,21 ELC, SLC/6Ckine 
CCR8 CCL1,16 I-309, HCC-4 
CCR9 CCL25 TECK 
CCR10 CCL27 CTAK/Eskine 
CXCR1 CXCL1,4,6,8 Groα, PF4, GCP-2, IL-8 
CXCR2 CXCL1,4,5,6,7,8 Groα, PF4, ENA-78, GCP-2, NAP-2, IL-8 
CXCR3 CXCL9,10,11 Mig, IP-10, I-TAC 
CXCR4 CXCL12 SDF-1 
CXCR5 CXCL13 BCA-1 
CXCR6 CXCL16 SR-PSOX 
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CXCR7 CXCL11,12 I-TAC, SDF-1 
XCR1 XCL1 Lymphotactin 
CX3CR1 CX3CL1 Fractalkine 
ChemR23  RARRES2/Chemerin 
  
To investigate whether other chemokine receptors were compensating for the 
inhibition of CCR2, PBMs were treated with Pertussis toxin (PTX) that inhibits most 
G-protein coupled receptors by ADP-ribosylation of Gαi/o proteins resulting in 
uncoupling of receptors from G-proteins (Mangmool and Kurose, 2011).   
PBMs pre-treated with 1 µg/ml PTX for 30 min where it did not affect cell viability 
(Malik et al., 2009, Sano et al., 2000), showed a 0.71 fold decrease in migration from 
untreated PBM with p=0.03 (Fig. 4.7 A). When PTX treated PBMs were migrated 
towards CM from 24 h, 48 h, 96 h, and 15 d untreated controls, migration decreased 
by 77%, 19.7%, 47.29%, and 71% compared to untreated PBMs, respectively; while 
migration towards CM from 24 h, 48 h, and 96 h TGF-β1 treated myofibroblasts, and 
15 d cisplatin senesced fibroblasts decreased by 55.5%, 72.4%, 32.4% and 75.85% 
respectively (Fig 4.7 B). 
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Figure 4.7: Effect of PTX treatment on migration of PBM. PBMs were treated with 1 
µg/ml of PTX for 30 min prior to migration towards CM. A) After treatment migration 
towards recombinant CCL2 decreased with a fold change of 0.71. B) Migration of 
PTX treated PBMs towards CM from 24 h, 48 h, 96 h, and 15 d untreated controls, 
decreased by 77%, 19.7%, 47.29%, and 71% compared to untreated PBMs, 
respectively; while migration towards CM from 24 h, 48 h, and 96 h TGF-β1 treated 
myofibroblasts, and 15 d cisplatin senesced fibroblasts decreased by 55.5%, 72.4%, 
32.4% and 75.85% respectively. Data are mean +/- SEM with n=3. 
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Between CCR2 inhibition and PTX treatment (Fig. 4.8), CCR2 inhibition reduced 
overall recruitment of PBMs more efficiently, in response to 24 h myofibroblast CM 
(p=0.0349), 48 h myofibroblast CM (p=0.0332) and 24 h control CM with p= 0.0309 
(Fig. 4.8). The most significant decrease in recruitment was seen by senescent 
fibroblasts when CCR2 was inhibited, compared to untreated PBMs, with p=0.008. 
Pertussis toxin is known to be a broad spectrum inhibitor of GPCRs which comprise 
of most chemokine receptors, surprisingly PTX was not as efficient in preventing 
PBM migration towards the CM from myofibroblast, but reduced migration towards 
CM from senescent fibroblast significantly with p=0.008 (Fig. 4.8). This is discussed 
further in section 6.3. 
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Figure 4.8: Comparison of migration of untreated, CCR2 inhibited (CCR2i), and 
pertussis toxin (PTX) treated PBMs towards CAF CM. CCR2 inhibitor decreased 
migration of PBMs the most, with significant decrease by 24 h control CM 
(p=0.0309), 24 h TGF-β1 CM (p=0.0349), 48 h TGF-β1 CM (p=0.0332), and 15 d 
cisp (p=0.0008). Decrease in migration by PTX was not as effective as CCR2 
inhibition but showed a significant decrease towards 15 d cisp CM with p=0.00083. 
Statistical analysis – Two way ANOVA, data are mean +/- SEM with n=3. 
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4.9  Monocyte recruitment by patient CAFs  
Next, OSCC patient-derived CAFs were examined to compare similarities and 
differences between myofibroblasts and senescent fibroblasts in the context of 
monocyte recruitment. For this study, senescence associated β-galactosidase assay, 
CCL2 secretion and monocyte recruitment by CAF cultures BICR18, BICR69, 
BICR73, BICR78, (kindly provided Professor Stephen Prime and Professor Eric 
Parkinson from the Blizard Institute, QMUL) and CAF002 (generated in Sheffield by 
Amy Harding, Ref 13/NS/0120, STH17021, approved by Sheffield research ethics 
committee) were investigated. CAFs BICR18 and BICR78 were isolated from 
genetically unstable (GU) OSCC, while BICR69 and BICE73 were isolated from 
genetically stable (GS) OSCC (Hassona et al., 2013b).  
Both Hassona et al and Kabir et al provided evidence that CAFs from GU OSCC are 
more senescent in comparison to CAFs from GS OSCC (Hassona et al., 2013b, 
Kabir, 2015). Senescence associated β-galactosidase assay was performed on the 
CAFs used in this study (Fig. 4.9); CAFs from GS OSCC, BICR69  and BICR73 
showed 0% and 4% positively stained cells, respectively. While CAFs from GU 
OSCC, BICR78 and BICR18 exhibited 100% and 70% positively stained cells, in 
167 
 
agreement with previous evidence. Genetic status of the tumour from which CAF002 
was isolated was unknown at the time of this study, but it showed less than 2% 
positive staining, suggesting lack of presence of senescent fibroblasts. 
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Figure 4.9. Senescence associated β-galactosidase assay on CAFs: CAFs from 
genetically stable OSCC, BICR69 and BICR73 showed 0% and 4% positively 
stained cells, respectively. CAFs from genetically unstable OSCC, BICR78 and 
BICR18 showed 100% and 70% positively stained CAFs. CAF002 exhibited only 
less than 2% positively stained cells; n=1 biological repeat. 
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NOF343 produced very little CCL2 (14.67 pg/ml) but  CAF002, BICR18, and BICR78 
(both from GU OSCC) secreted elevated levels (p<0.0001), with slightly lower levels 
secreted by BICR73 (GS OSCC) (p<0.0005) as shown in fig. 4.10 A. Amongst the 
patient CAFs, BICR69 from GS OSCC produced the lowest levels of CCL2 (20.58 
pg/ml), significantly lower than BICR73 with p<0.0005 and from BICR78, BICR18, 
and CAF002 with p<0.0001 (Fig. 4.10 A). BICR78 from GU OSCC secreted the 
highest amount of CCL2 (1054 pg/ml), significantly higher with p<0.0001 than 
NOF343, BICR69, BICR73, BICR18, and CAF002. Genetic status of the tumour from 
whose stroma CAF002 was isolated is not known, but it still exhibited higher 
secretion of CCL2 ((435.7 pg/ml) compared to CAFs from GS OSCC – BICR69 and 
BICR73, as well as NOF343 (Fig 4.10 A).  
An important observation to note is that CAFs from GU OSCC are more senescent 
(Fig. 4.10) and secreted more CCL2 in comparison to CAFs from GS OSCC. This 
corresponds to result in Fig. 4.5 B which reports senescent fibroblasts generated for 
this study also secreted more CCL2 than myofibroblasts. 
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When Pearson’s correlation was determined between data from fig. 4.10 A & B, a 
positive trend was suggested between monocyte recruitment between CCL2 
secretion and PBM recruitment by CAFs with r = 0.39 (Fig 4.10 c).  
Monocyte recruitment by BICR18 was significantly higher compared to recruitment 
by NOF343, BICR69, BICR73, BICR78, and CAF002 with p<0.0001. NOF343, 
BICR69, and CAF002 exhibited significantly low monocyte recruitment compared to 
BICR73 and BICR78 with p<0.0005 and p<0.0001, respectively. Even though 
BICR18 secreted less CCL2 than BICR78, it recruited more monocytes, raising the 
possibility of other chemokines and factors having a role in monocyte recruitment. 
 
 
 
 
 
 
171 
 
 
 
172 
 
Figure 4.10. Levels of CCL2 secretion and monocyte migration by patient CAFs: 
CAFs from patients were cultured as described in section 2.6 until 80% confluency, 
followed by change of medium to serum free medium to be conditioned for 24 h. 
Levels of CCL2 were measured in the collected CM, and PBMs were migrated 
towards the same CM. A) Normal oral fibroblast NOF343 (14.67 pg/ml,) and BICR69 
(20.58 pg/ml) from genetically stable OSCC (GS OSCC) secreted significantly low 
amounts of CCL2 compared to BICR73 (235.7 pg/ml, p<0.04), BICR78 (1054 pg/ml), 
BICR18 (314 pg/ml) and CAF002 (435.7 pg/ml) with p<0.0001. BICR78 secreted the 
highest amount of CCL2 with p<0.0001 significance to NOF343, BICR69, BICR73, 
BICR18, and CAF002. Secretion of CCL2 by BICR73 and BICR18 were also 
significant to secretion by CAF002 with p<0.0005, and p<0.04, respectively. B) 
NOF343 and BICR69 recruited significantly fewer number of monocytes with 
p<0.0001 compared to BICR73, BICR78, and BICR18. While BICR18 significantly 
recruited more monocytes than BICR73, BICR78 and CAF002 with p<0.0001 even 
though it secreted lower levels of CCL2. Recruitment by CAF002 compared to 
BICR73 and BICR78 was significantly low as well, with p<0.0005 and p<0.0001, 
respectively. C) Pearson’s correlation coefficient suggests a trend between CCL2 
secretion and PBM recruitment with r = 3.9. Statistical analysis – ANOVA & 
Pearson’s correlation. Data are mean +/- SEM, n=3 biological repeats. 
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4.10 Monocyte recruitment by fibroblasts cultured in cancer cell line CM 
Normal oral fibroblasts were also cultured for 24 h in CM derived from OSCC cancer 
cell lines (H357, a non-metastatic line from the tongue with mutant p53, which 
produces high levels of TGF-β1, and undergoes EMT in response to it TGF-β1. 
While SCC4 is a metastatic line, also from the tongue.), CM was washed off 
thoroughly and fresh serum free media was added to the NOF culture to be 
conditioned by them for 24 h. The resulting CM from NOF was collected and 
examined for CCL2 and used in migration assays to recruit PBMs to examine 
whether cancer cells can influence fibroblast secretome in a paracrine manner, in 
relation to monocyte recruitment (Fig. 4.11 A and B). Both indirect co-cultures, 
NOF343 with H357 CM (5906 pg/ml) and NOF343 with SCC4 (3357 pg/ml) exhibited 
a high level of secretion of CCL2 with p<0.0001, compared to NOF343 (14.67 pg/ml) 
on its own. Significantly greater recruitment of monocytes by H357 co-culture 
(p=0.0007) and SCC4 co-culture (p<0.0001) was observed compared to NOF343 
(Fig. 4.11 A and B).  H357 co-culture exhibited significantly higher levels of CCL2 
than SCC4 co-culture, but the numbers of monocytes recruited was not statistically 
different, perhaps suggesting saturation of receptors. 
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Figure 4.11. Soluble factors from cancer cell line (H357 & SCC4) increased 
subsequent secretion of CCL2 and monocyte recruitment by resulting NOF CM: 
NOF343 was cultured with CM from cancer cell line H357 and SCC4 for 24h, 
washed and changed to fresh SFM to be conditioned. The subsequent media from 
NOF343 was examined for CCL2 and monocyte recruitment. A) Both indirect co-
cultures, H357+NOF343 and SCC4+NOF343 lead to a significant increase, with 
p<0.0001 in secretion of CCL2 compared to NOF343 alone. There was significant 
difference in effects of H357 and SCC4 on CCL2 secretion after co-culture where 
secreted factors from H357 caused more CCL2 secretion than SCC4 secretory 
factors (p<0.0001). B) CM from both, H357+NOF343 and SCC4+NOF343 co-culture 
recruited more monocytes compared to NOF343 alone, but SCC4+NOF343 recruited 
more monocytes than H357+NOF343. Statistical analysis – ANOVA, data are mean 
+/- SEM, n=3 biological repeats. 
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4.11 Effect of soluble factors from polarised macrophages on fibroblast activation: 
The TME hosts numerous cells surrounding the malignant cells, including a variety of 
immune cells, and macrophages being one of the many (section 4.9). Macrophages 
possess the plasticity to polarise towards an M1 or M2 phenotype in response to 
cytokines in the surrounding microenvironment (Pollard, 2009). It is important to note 
that macrophages also secrete cytokines and other factors; therefore after being 
recruited to TME it was hypothesised here that they may be capable of influencing 
differentiation of normal fibroblast into developing a CAF-like phenotype before or 
after their own polarisation. To investigate this possibility, PBMs were differentiated 
in to M0, M1, and M2 macrophages (as described in section 3.9.2), CM was 
prepared and collected, and normal oral fibroblast (NOF343) were cultured in 
macrophage CM for 24 h while TGF-β1 and SFM were used as positive and negative 
controls, respectively. Immunocytochemistry was then used to examine α-SMA 
expression as a marker of fibroblast activation/myofibroblast differentiation (Fig. 
4.12). Highest SMA expression was induced by M0 CM, followed by M1 and M2 (Fig. 
4.12 A-C, F). In comparison to SFM, α-SMA expression showed a trend toward 
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being induced by M0-derived CM, but this didn’t reach significance (p<0.065; Fig. 
4.12 F). 
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Figure 4.12: Validation of SMA expression in NOF induced by macrophage CM. A) 
SMA expression in NOF343 after culturing with M0 macrophage CM for 24 h. B) 
SMA expression in NOF343 after culturing with M1 macrophage CM for 24 h. C) 
SMA expression in NOF343 after culturing with M2 macrophage CM for 24 h. D) 
SMA expression in NOF343 after TGF-β1 treatment for 24 h. E) SMA expression in 
NOF343 after culturing in SFM for 24 h. F) Graph comparing SMA expression 
between different conditions, with p<0.065 between SMA induced by M0 CM and 
SFM. Statistical analysis performed – ANOVA, error bars indicate SEM, with n = 3 
wells. 
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4.12 Examination of the existence of any correlation between the presence of CAFs and 
the number of TAMs in tumour tissue ex vivo  
Based on results from figs. 4.3 A, 4.4, 4.5, 4.10 and 4.11, highlighting monocyte 
recruitment capabilities displayed by myofibroblasts, senescent fibroblasts, patient 
CAF, and NOF following cancer cell line co-culture, the next step was to begin to 
examine the in vivo relevance of these findings by assessing the existence of any 
correlation between the presence of CAFs and macrophages in tumour and stroma 
in sections from a cohort of OSCC cases. Using immunohistochemistry on a cohort 
OSCC tumours (appendix 3), Histoquest software, and CAF marker-α-SMA and 
macrophage marker-CD68 (as described in section 2.21), to observe a correlation 
between presence of α-SMA positive CAFs and CD68 positive TAMs, as shown in 
Fig. 4.13 A. Pearson’s correlation coefficient was applied to measure correlation 
between the presence of α-SMA positive CAFs in TME/stroma (tissue surrounding 
tumour mass) and at tumour invasive front, and CD68 positive TAMs in TME/stroma 
and tumour mass. As seen from Fig 4.13 B, presence of CAFs in TME/stroma 
negatively correlated with presence of TAMs in TME and in tumour mass with r = -
0.3461 and r = -0.09594, respectively (Fig. 4.13 B and C). On the other hand, 
presence of CAFs near the tumour invasive front suggested a positive correlation 
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with presence of TAMs in TME and in the tumour with r = 0.1192, and r = 0.5666, 
respectively (Fig. 4.13 D and E). 
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Figure 4.13: Immunohistochemical analysis of CAF marker α-SMA and macrophage 
marker CD68. Adjacent OSCC sections were stained for α-SMA and CD68 
immunohistochemically, and percentage (%) of positively stained cells in the tumour, 
in stroma/tumour microenvironment (TME) and at tumour invasive front were 
examined for any correlation. A) Both, CAF (α-SMA marker) and tumour associated 
macrophage (TAM, CD68 marker) antibodies were able to detect their respective 
protein when sparse or abundant. B) and C) Graphs show a negative Pearson’s 
correlation between CAFs in TME and TAMs in TME (r = -0.3461) as well as CAFs in 
TME and TAMs in tumour (r = -0.0959). D) Graph shows no correlation between 
presence of CAFs at the tumour invasive front and presence of TAMs in the tumour, 
with r = 0.1192 E) Pearson’s correlation coefficient showed a trend between 
presence of CAFs at the tumour invasive front and presence of TAMs in the tumour 
with r = 0.5556. Statistical analysis – Pearson’s correlation coefficient, data are mean 
+/- SEM, n = 10 
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4.13 Summary 
In this chapter, monocyte recruitment capabilities of senescent fibroblasts, treated 
with a chemotherapeutic drug-cisplatin, and myofibroblasts, generated by exposure 
of NOF to TGF-β1 for different durations (24 h, 48 h, and 96 h), was studied. In 
addition the recruitment capabilities of NOF exposed to cancer cell-derived media 
and CAF isolated from tumours were analysed. Comparing senescent fibroblasts 
and myofibroblasts, CM from senescent fibroblasts recruited the most number of 
THP-1 cells and peripheral blood monocytes (PBM), while 24 h TGF-β1 treated 
myofibroblasts recruited the most number of THP-1 cells and PBMs between the 
three time points (24 h, 48 h and 96 h), however, the recruitment by 24 h 
myofibroblast was still less than by senescent fibroblasts. 
It was found that cisplatin treatment induced secretion of high amounts of CCL2 (a 
well-documented monocyte chemoattractant), in addition 24 h treated TGF-β1 
myofibroblast also secreted high levels of CCL2 compared to untreated controls, 
which again declined with longer TGF-β1 treatment. PBMs also exhibited high 
expression of CCR2. Therefore, it could be surmised that PBMs were mostly 
recruited through CCL2/CCR2 axis; this was confirmed by inhibiting CCR2 receptor 
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(CCR2i) as migration of PBM towards senescent fibroblast CM and 24 h TGF-β1 
treated myofibroblast CM was reduced significantly by addition of CCR2i. Migration 
was not abolished completely after CCR2 inhibition, suggesting other promiscuous 
chemokine-receptors may compensate and interact with CCL2 and other 
chemokines present in the CM. Promiscuity of chemokine receptors has been 
described before (Zlotnik and Yoshie, 2012) 
To test this hypothesis, PBMs were then treated with pertussis toxin (PTX) to block 
G-protein coupled chemokine receptors. Treatment of PBMs with PTX reduced their 
migration towards CM but not as efficiently as CCR2 inhibition. A possible 
explanation for this is discussed further in section 6.3. 
Patient CAFs were also examined from both genetically stable OSCC (GS OSCC) 
(BICR69 and BICR73) and genetically unstable OSCC (GU OSCC) (BICR78 and 
BICR18), and CAF002 from tumour of unknown genetic status at the time of study. It 
was found that CAFs from GU OSCC were more senescent compared to CAFs from 
GS OSCC and CAF002, and correspondingly secreted more CCL2.  
CAFs from GU OSCC also recruited more PBMs compared to CAFs from GS OSCC 
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and CAF002, however, BICR18 recruited more PBMs in spite of secreting lower 
levels of CCL2 compared to BICR78, suggesting other secreted factors may be 
involved; this is investigated further in chapter 5. 
NOF were also co-cultured with CM from cancer cell lines – H357 and SCC4, and 
exhibited high levels of CCL2 and recruitment more PBMs compared CM from NOF 
alone.   
Once recruited, monocytes differentiate in to macrophages and are polarised based 
on the cytokine environment present around (Qian and Pollard, 2010). The effect of 
this polarisation on fibroblast phenotype was examined. It was found that 
unpolarised M0 macrophages activated NOF the most, a surprising finding 
discussed further in section 6.3. 
Immunohistochemical analysis of tumour sections for CAF marker SMA, and TAM 
marker CD68 revealed no correlation between presence of CAFs in TME and 
presence of TAM in TME and tumour. However, CAFs present near the tumour 
invasive front suggested a correlation to presence of TAM in the tumour, further 
discussed in section 6.3.  
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Since PBMs migrated towards CM in spite of CCR2 blockage, evidently blocking 
CCL2/CCR2 axis, and the fact that, BICR18 recruited more PBMs than BICR78 in 
spite of secreting lower levels of CCL2 suggests secretion of other chemokines by 
myofibroblast, senescent fibroblast, and a patient CAFs, which lead to further 
analysis of the same using mass spectrometry. 
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Chapter 5  
5. Secretome of CAF phenotypes  
Secreted proteins play an important role in intra- and intercellular communication; 
therefore they hold a key to understanding cancer progression and metastasis. 
Some of these secreted proteins are also found in the bloodstream, saliva or 
lymphatic system, sometimes far from the site of disease and so may serve as a 
diagnostic biomarker for early cancer diagnosis, or as a measure of cancer 
progression or response to treatment.  
As mentioned in section 1.4, CAFs promote cancer progression by secreting factors 
that modify the ECM, promote angiogenesis, metabolism, replication, and metastasis 
of cancer cells. They are also instrumental in recruiting and manipulating immune 
cells such that cancer cells are able to evade the body’s immune system.  But CAFs 
are made up of different sub-populations, therefore it is important to narrow down 
and identify factors secreted by different CAF phenotypes to examine whether each 
phenotype has a specific role in cancer progression and may therefore provide 
therapeutic targets. This chapter sheds light on the secretome of CAF phenotypes 
using mass spectrometry for further scrunity. 
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5.1. Hypothesis: 
 
Myofibroblasts and senescent fibroblasts develop distinct secretomes to differentially 
influence their microenvironment. 
5.2. Aims: 
 Analyse concentrated and purified conditioned media from 
myofibroblasts, senescent fibroblasts, and patient CAF by mass 
spectrometry. 
 Compare expression of cytokines in the conditioned media from 
myofibroblasts, and senescent fibroblasts. 
 Examine the effects of conditioned media from myofibroblasts, 
senescent fibroblasts, and patient CAF on macrophage polarisation 
through qPCR for CD80, CD86, CD163, and CD206 
5.3. Mass spectrometry 
A mass spectrometer (MS) is generally composed of three basic components, 
namely the ioniser, the mass analyser, and the mass detector. The function of the 
ioniser is to ionise molecules/peptides being tested and imparting a charge to them 
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with each peptide having a unique mass to charge (m/z) ratio. The mass analyser 
then evaluates the mass to charge ratio, and the mass detector counts peptides for 
each m/z ratio reported by the mass analyser; the resulting output is a mass spectra.  
For this investigation, conditioned media was concentrated, digested with trypsin, 
tertiary structures denatured by urea, cysteine residues modified using 
iodoacetamide, and purified to remove inorganic salts (Wysocki et al., 2005). 
Subsequently, label-free quantification was selected to expand the range of 
discovery of peptides. This method also requires lower quantities of samples, which 
were run with the settings described in section 2.23. The samples tested were: 24 h 
control (24 h ctrl), 24 h TGF-β1-induced myofibroblast (24 h TGF-β1), 15 d control 
(15 d ctrl), 15 d cisplatin treated senescent fibroblast (15 d cisp), and tumour-derived 
CAF002 (CAF). 
After the data was processed, principal component analysis revealed the technical 
repeats clustered together but proteins from CM from different conditions clustering 
separately (Fig. 5.1). Both 24 h TGF-β1-treated NOF (myofibroblast) and 15 d 
cisplatin-treated NOF (senescent) cluster away from 24 h control (component 1 
axis), and from each other (component 2 axis) highlighting the difference in protein 
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expression between the three. However, CAF triplicates cluster further along the 
component 1 axis from 24 h TGF-β1 and 15 d cisp, with a larger difference in protein 
reads from 15 d cisp on component 2 axis, further validating its non-senescent 
phenotype from Fig. 4.9.  
A remarkable observation in the principal component analysis of CM is the difference 
between 24 h control and 15 d control. Throughout this study it was observed that 15 
d control secreted increased quantities of IL-6 (Fig. 3.6), CCL2 (Fig. 4.5), and 
exhibited elevated mRNA expression of FNEDA and COL1A1 (Fig. 3.7) and even 
recruited more monocytes than 24 h control CM as seen in Fig. 4.2 and 4.3. 
However, 15 d control did not show an increased expression of p16INK4A mRNA, and 
stained negatively in SA β-gal assay, confirming that these fibroblasts were not 
senescent; the low levels of p21 mRNA also make quiescence unlikely (Adomako et 
al., 2015, Sharpless and Sherr)., but further experiments would be required to 
determine the phenotype of these cells  
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Figure 5.1. Principal component analysis (PCA) of MS analysis: PCA plots variations 
present within a data set, increasing distance between any two data points denotes 
increasing variation based on multiple variables (various protein secretions in this 
case). The graph shows technical repeats (3 boxes) processed in MS clustered 
together, representing similarity between technical repeats. CM from myofibroblast 
(24 h TGF-β1) and senescent fibroblast (15 d cisp) showed distinct difference 
between each other (component 2 axis) and from both 24 h control and CAF on 
component 1 axis. Proteins expressed by CAFs varied more from 15 d cisp than 24 
h TGF-β1 (based on component 2 axis). Another discrete set of proteins were 
secreted by 15 d control, with most variation compared to 24 h control, followed by 
CAF, 24 h TGF-β1, and 15 d cisp. N = 3 biological repeats pooled together and then 
divided in to 3 as technical repeats for MS. 
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From a list of thousands of protein hits (signal intensities), pairs of fibroblast 
phenotypes were statistically compared one at a time using T test due to absence of 
one way ANOVA test in Perseus software; highlighting significantly different proteins 
expressed between two phenotypes compared (Angi et al., 2016). From the 
statistical analyses, 193 proteins were identified as significantly expressed between 
the five samples. Proteins from 24 h TGF-β1 transdifferentiated myofibroblast, 15 d 
cisplatin induced senescent fibroblast and patient CAF002 were filtered for 5-fold 
increase from 24 h control secreted protein and putative pathways they may be 
engaged in analysed using reactome-database for biological pathways (Reactome). 
The majority of proteins secreted by myofibroblasts were predicted to participate in 
metabolism (19 proteins; 21% of total), followed 17% (16 proteins) in ECM 
organisation, and 15% (14 proteins) in signal transduction (Fig. 5.2). Only 8% (7 
proteins) of the secreted proteins engaged in the immune system, while the others 
participate in vesicle transportation of molecules, homeostasis, cell-cell adhesion, 
cell cycle, gene expression and disease (Fig. 5.2).  
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About 31% (26 proteins) of the secreted proteins from senescent fibroblasts up-
regulated from 24 h control fibroblasts (24 h control fibroblasts were chosen as the 
comparator to negate effects of 2D culture has on primary cells) participated in ECM 
organisation, followed by 25% (19 proteins) in metabolism and 16% (13 proteins) as 
seen in Fig. 5.3. About 9 secreted proteins, making up 11% from senescent 
fibroblasts engaged in immune system (Fig. 5.3). The majority of CAF secreted 
proteins with a fold increase from normal 24 h fibroblast are known to participate in 
ECM organisation (21 proteins making up 29%), followed by 20% (14 proteins) in 
signal transduction, and 18% (13 proteins) engaged in metabolism as seen in Fig. 
5.4.  Roughly, 7% (5 proteins) participated in pathway from the immune system (Fig. 
5.4).  
From this comparison we speculate that there were more variety of proteins secreted 
from senescent fibroblasts that modulated the ECM compared to the plethora of 
ECM related proteins from myofibroblast. Senescent fibroblast proteins also 
engaged heavily in metabolism as well as in pathways involved in the immune 
system, compared to both patient CAF and myofibroblast.  
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Figure 5.2. Biological pathways myofibroblast secreted proteins have previously 
been found to engage in: The pie chart represents proteins with fold increase 
compared to 24 h control CM and the pathways they engage in. A majority of 
proteins secreted by 24 h TGF-β1 transdifferentiated myofibroblast participate in 
metabolism (21%), followed by 17% of proteins playing a role in ECM organisation 
and 15% in signal transduction leading to various other functions. Pathways 
engaged in vesicle transportation, homeostasis and the immune system included 
11%, 9% and 8% of the secreted proteins. N = 3  
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Figure 5.3. Biological pathways senescent fibroblast secreted proteins have 
previously been found to engage in: The pie chart represents proteins with fold 
increase compared to 24 h control CM and the pathways they engage in. With a 
majority of 31%, proteins secreted by senescent fibroblast participate in ECM 
organisation, followed by 23% of proteins playing a role in metabolism and 16% in 
signal transduction leading to various other functions. Pathways engaged in immune 
system, homeostasis and vesicle transportation included 11%, 5% and 8% of the 
secreted proteins. N=3  
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Figure 5.4. Biological pathways patient CAF secreted proteins have previously been 
found to engage in: The pie chart represents proteins with fold increase compared to 
24 h control CM and the pathways they engage in. With a majority of 29%, proteins 
secreted by patient CAF participate in ECM organisation, followed by 20% of 
proteins playing a role in signal transduction and 18% in metabolism. Pathways 
engaged in immune system, homeostasis and vesicle transportation included 7%, 
6% and 11% of the secreted proteins. N=3. 
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Scatterplots were then used to validate differential expression of secreted proteins 
between patient CAF (CAF002), senescent fibroblasts, myofibroblasts, and controls 
after 24 h in culture. Comparing NOF (24 h control) vs. patient CAF generated a total 
of 126 significantly different proteins, highlighting the change in secretome of normal 
fibroblast compared to the CAF secretome (Fig. 5.5). Comparison between secreted 
proteins from myofibroblasts and patient CAF (Fig. 5.6) also generated a large 
number of significantly different proteins (96 in total). Comparison between 
senescent fibroblasts and CAF, however, highlights only two differentially detected 
proteins; insulin-like growth factor binding protein (IGFBP) 2 and plectin (PLEC) (Fig. 
5.7) suggesting that the two have a very similar secretory profile. A large number of 
significantly differentially detected proteins were identified when CM from 
myofibroblasts and senescent fibroblast were compared, 76 in total (Fig. 5.8), 
indicating profound differences between their secretory profiles. 
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Figure 5.5. Scatterplot displaying differential expression of proteins between 24 h 
control fibroblast and patient CAF secretory profiles: Comparison of secretory 
proteins between 24 h control (normal oral fibroblast) and patient CAF generated the 
most number of significant proteins – 126, highlighting the effect TME has on 
fibroblasts and their secretory phenotype. The scatterplots calculate q-value which is 
p-value adjusted for false discovery rate where a small sample is run for hundreds 
and thousands of tests (proteins, in this case), therefore q-value of 5% means 5% of 
total significant results will result in false positives. Statistical analysis performed – 
Student T test, q < 0.009, n = 3 
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Figure 5.6. Scatterplot displaying differential expression of proteins between 
myofibroblast and patient CAF secretory profiles: Comparison of secretory proteins 
between myofibroblasts CM to CAF CM generated 96 significantly differentially 
expressed proteins, highlighting differences in concentration and variety of proteins 
secreted. Statistical analysis performed – Student T test, q <0.0097, n = 3. 
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Figure 5.7. Scatterplot displaying differential expression of proteins between 
senescent fibroblast and patient CAF secretory profiles: Secretory profile of 
senescent fibroblasts vs. CAF generated only 2 significant proteins, suggesting 
similarities in variety and concentrations of proteins secreted. Statistical analysis 
performed – Student T test, q = 0, n = 3. 
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Figure 5.8. Scatterplot displaying differential expression of proteins between 
myofibroblast and senescent fibroblast secretory profiles: Comparison of CM from 
myofibroblasts to CM from senescent fibroblast revealed differential expression of 76 
significant proteins, accentuating the difference in their secretory proteins. Statistical 
analysis performed – Student T test, q < 0.006, n = 3. 
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A threshold of 5 fold increase from 24 h was applied to reduce the number of 
proteins sufficiently to interrogate in more detail (summarised in Table 10). 
Table 10: Secreted proteins up-regulated more than 5 folds in MF, SF, and CAF 
Accession 
no. 
Secretory protein Up-regulated in (fold 
increase from 24 h 
ctrl) 
Pathway associated with 
P98160 Basement membrane-
specific heparan sulfate 
proteoglycan core protein 
(HSPG2) 
SF (5.15), CAF (7.4) Metabolism 
P21810 Biglycan (BGN) MF (28.5), CAF 
(13.11) 
Metabolism 
P49747 Cartilage oligomeric matrix 
protein (COMP) 
MF (2.9x108), SF 
(6.7x105), CAF 
(9.3x105) 
ECM 
Q76M96 Coiled-coil domain-
containing protein 80 
(CCDC80) 
CAF (5.7) Cell-cell communication, 
ECM 
P02461 Collagen alpha-1(III) chain 
(COL3A1) 
MF (17.23), SF (7.21), 
CAF (102.73) 
ECM, Immune system, 
signal transduction, 
vesicle mediated transport 
P02462 Collagen alpha-1(IV) chain 
(COL4A1) 
MF (4.1x107), CAF 
(6.4x106) 
ECM, signal transduction, 
vesicle mediated transport 
P20908 Collagen alpha-1(V) chain 
(COL5A1) 
MF (61.42), CAF 
(18.19) 
ECM, signal transduction 
Q02388 Collagen alpha-1(VII) chain 
(COL7A1) 
MF (1.9x107) ECM, protein metabolism, 
vesicle mediated transport 
Q05707 Collagen alpha-1(XIV) 
chain (COL14A1) 
SF (4.4x107), CAF 
(9.4x105) 
ECM 
P08572 Collagen alpha-2(IV) chain 
(COL4A2) 
MF (61), CAF (10.3) ECM, signal transduction, 
vesicle mediated transport 
P05997 Collagen alpha-2(V) chain 
(COL5A2) 
MF (19.97), CAF 
(54.94) 
ECM 
P00736 Complement C1r 
component (C1R) 
SF (7.57), CAF (18.04) Immune system 
202 
 
P00746 Complement factor D 
(CFD) 
SF (8.6x106) Immune system 
Q12805 EGF-containing fibulin-like 
extracellular matrix protein 
1 (EFEMP1) 
SF (4.7x107), CAF 
(8.1x107) 
ECM 
Q4ZHG4 Fibronectin type III domain-
containing protein 1 
(FNDC1) 
MF (5) Signal transduction 
P17936 Insulin-like growth factor 
binding protein 3 (IGFBP3) 
MF (2.1x107), CAF 
(3.9x107) 
Gene expression, protein 
metabolism 
P24593 Insulin-like growth factor 
binding protein 5 (IGFBP5) 
SF (10.4) Protein metabolism 
Q16363 Laminin subunit alpha-4 
(LAMA4) 
SF (18.79), CAF 
(44.79) 
ECM, signal transduction 
P55268 Laminin subunit beta-2 
(LAMB2) 
SF (39.87) ECM, signal transduction 
Q15063  Periostin (POSTN) MF (8.8x106), SF 
(1.4x106), CAF 
(4.1x106) 
ECM, signal transduction, 
response to external 
stimuli 
Q92626 Peroxidasin homolog 
(PXDN) 
MF (4.3x107), SF 
(3.2x106), CAF 
(1.5x107) 
ECM 
P05121 Plasminogen activator 
inhibitor 1 (SERPINE1) 
MF (12.82) ECM 
O14818 Proteasome subunit alpha 
type-7 (PSMA7) 
MF (5.8) Cell cycle, response to 
external stimuli, DNA 
replication, disease, gene 
expression, immune 
system, metabolism, 
signal transduction, 
molecule transport 
Q99969 Retinoic acid receptor 
responder protein 2 
(RARRES2) 
SF (3.3x106), CAF 
(2.8x107) 
Signal transduction, 
metabolism 
Q6FHJ7 Secreted frizzled-related 
protein 4 (SFRP4) 
SF (8.5x106), CAF 
(4.4x106) 
Cell cycle, signal 
transduction 
P09486 SPARC MF (7.5) Signal transduction, ECM 
Q9HCB6 Spondin 1 (SPON1) SF (1.1x107) Protein metabolism 
Q15582 Transforming growth factor- MF (9.23) Protein metabolism 
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beta-induced protein ig-h3 
(TGFBI) 
P06753 Tropomyosin alpha-3 chain 
(TPM3) 
MF (3.4x106) Cell movement 
 
The proteins highlighted in blue in table 10 were found to not be expressed at all in 
the untreated normal oral fibroblasts but were present in TGF-β1 and cisplatin 
treated counterparts, suggesting these secreted proteins might be unique to the 
phenotype. Table 11 presents evidence from the literature of how these unique 
proteins might participate in cancer progression. 
Table 11. List of proteins from current MS data showing association with cancer 
progression previously 
Protein Function 
COMP/TSP5 Protects cells against apoptosis (Gagarina et al., 2008), promotes breast 
cancer development & metastasis by boosting metabolism & cell survival 
(Englund et al., 2016) 
COL7A1 Modifies ECM. Correlates with tumour and lymphatic invasion in esophageal 
SCC (ESCC) (Kita et al., 2009). 
COL14A1 Modifies ECM. High methylation of COL14A1 gene correlation with tumour 
stage in ESCC (Li et al., 2014c). 
EFEMP1 Binds to EGF receptor, plays a role in invasion of osteosarcoma via NF-κB 
signaling pathway (Wang et al., 2015c), ovarian cancer (Yin et al., 2016), and 
cervical cancer (En-lin et al., 2010). 
POSTN Aids incorporation of BMP1 in fibronectin matrix, and activates lysyl oxidase 
to modify ECM to promote cell migration (Gillan et al., 2002). Associated with 
colon cancer (Xiao et al., 2015), esophageal adenocarcinoma (Underwood et 
al., 2015), pancreatic cancer (Liu and Du, 2015), and prostate cancer (Tian et 
al., 2015). 
PXDN Metabolises H2O2 (Cheng et al., 2008), and modifies ECM produced by 
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myofibroblasts (Peterfi et al., 2009). 
RARRES2 Recruits M1 macrophages possessing receptor CMKLR1 (Herova et al., 
2015), and stimulates angiogenesis (Bozaoglu et al., 2010) and adipogenesis 
(Roh et al., 2007) 
SFRP4 Wnt-signalling antagonist (Pohl et al., 2015) 
SPON1 Cell adhesion protein, and upregulated in osteosarcoma and correlates 
expression of MMP9 to promote cell migration and invasion (Chang et al., 
2015b) 
 
A noteworthy observation is that even after applying 5 fold increase threshold the 
patient CAF had 11 highly expressed proteins (biglycan, cartilage oligomeric matrix 
protein, COL3A1, COL4A1, COL5A1, COL4A2, COL5A2) in common with 
myofibroblast, while compared to senescent fibroblast there were 13 proteins 
(basement membrane specific heparin sulphate proteoglycan core protein, cartilage 
oligomeric matrix protein, COL3A1, COL4A1, COL5A1, COL14A1, complement C1r 
component, EGF-containing fibulin like extracellular matrix protein1, lamini α4, 
periostin, retinoic acid receptor responder protein 2, secreted frizzled related protein 
4) in common  suggesting some similarities between in secretory profiles of lab-
generated CAF phenotypes (myofibroblast and senescent fibroblast) and CAFs 
obtained from cancer patients.   
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5.4. Cytokine array 
As described in this chapter in section 5.3, most of the protein hits by MS played a 
major role in metabolism, ECM organisation and the immune system, however not 
many cytokines were detected using MS. The reason for this could be that cytokines 
are low molecular weight proteins, and potentially lost during concentration and 
processing of CM, also observed previously (Chevallet et al., 2007). The data 
presented in chapter 3 (Fig. 3.6) and chapter 4 (Fig. 4.5) confirmed robust secretion 
by fibroblasts of two cytokines, IL-6 and CCL2, which has been established in 
literature previously (Kabir et al., 2016). In light of this discrepancy between the MS 
data and the apparent abundance of these cytokines detected using other methods, 
a cytokine array panel was carried out to identify differences in cytokines present in 
the CM from myofibroblast and senescent fibroblast. Cytokines detected using the 
array are detailed in table 12, where CM from myofibroblast (24 h TGF-β1) (Fig. 5.9) 
exhibited a wider range of cytokines compared to CM from senescent fibroblasts 
(Fig. 5.10). The panel also detected the following chemokines: Eotaxin-1, 2, 3, GCP-
2, I-309, CCL2, Rantes, CCL13, SCF, SDF-1α, and TARC, which serve as 
chemoattractants for monocytes, eosinophils, neutrophils, mast cells, B cells and T 
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cells secreted by myofibroblasts (Fig. 5.9 B) (Moore et al., 2015). While Eotaxin 2/3, 
chemoattractants for eosinophils, neutrophils, and basophils, fibroblast growth factor 
6/7 in CM from senescent fibroblast were down-regulated (Fig. 5.10 F). 
The cytokine array also reported a down-regulation of anti-inflammatory cytokines 
like IL-10 and IL-13 by myofibroblast (Fig. 5.9 C). 
The cytokine array also indicates elevated secretion of both IL-6 and CCL2 from both 
myofibroblasts and senescent fibroblasts, in keeping with the ELISA data presented 
in sections 3.1.2 and 4.5. 
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Figure 5.9. Cytokine array analysis of CM from myofibroblast: NOFs were treated 
with TGF-β1 for 24 h, and serum free media was conditioned by the resulting 
myofibroblast and its untreated control for 24 h, which was incubated on a cytokine 
array. A) Radiographic film depicting change in cytokine expression after 24 h TGF-β
1 treatment via chemiluminescence. B) Thirty cytokines up-regulated in 24 h TGF-β1 
treated myofibroblast compared to its control, out of which 9 are chemokines 
responsible for macrophage recruitment and others promote inflammation, 
angiogenesis, matrix remodelling, and cell proliferation. C) Anti-inflammatory 
cytokines like IL-10 and IL-13 were downregulated, and so were other 
chemoattractants like MCP 2/3/4 (CCL8/7/13). 
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Figure 5.10. Cytokine array analysis of CM from senescent fibroblast: NOFs were 
senesced with cisplatin over 15 d, and serum free media was conditioned by the 
resulting senescent fibroblast and its untreated control for 24 h, which was incubated 
on a cytokine array. A) Radiographic film depicting change in cytokine expression 
after 15 d cisp treatment via chemiluminescence. B) Four chemokines (CCL2, 
CCL13, Rantes, Eotaxin-1) for macrophage migration were up-regulated compared to 
its control, while others were responsible for angiogenesis, inflammation, matrix 
remodelling, and cell proliferation. C) While other chemo-attractants like eotaxin 2/3 
209 
 
for eosinophils, neutrophils, and basophils, and fibroblast growth factors 6/7 were 
down-regulated. 
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Table 12. Cytokines from array panel in cancer progression 
Accession no. Cytokine Function 
P03950 ANG Promotes angiogenesis, cell proliferation, ECM remodelling 
malignant tissues (Barcena et al., 2015, He et al., 2015, 
Kishimoto et al., 2014, Shu et al., 2015) 
P23560 BDNF Promotes cell survival and angiogenesis (Lin et al., 2014, 
Vanhecke et al., 2011, Yang et al., 2012) 
P12644 BMP4 Implicated as both pro-tumorigenic (Ivanova et al., 2013, Kim 
et al., 2015) and anti-tumorigenic (Li et al., 2014a, Tsuchida 
et al., 2014) 
P01133 EGF Promotes cell growth, and implicated in cell invasion in 
ovarian, prostate, colorectal cancer and HNC (Bae et al., 
2014, Bhat et al., 2014, Chang et al., 2015c, Qiu et al., 2014) 
P10767 FGF6 Promotes cell growth, differentiation, angiogenesis. 
Responsible for cell proliferation in prostate cancer (Ropiquet 
et al., 2000) 
P80162 GCP2 Chemoattractant for neutrophils and implicated in cell 
invasion and angiogenesis (Otomo et al., 2014, Tian et al., 
2014) 
P39905 GDNF Implicated in cell invasion and conferring chemoresistance in 
cancers (Chuang et al., 2013, Ding et al., 2014a, Ferranti et 
al., 2012, Huang et al., 2014, Liu et al., 2012, Ng et al., 2009) 
P04141 GM-CSF Stimulates growth and differentiation of macrophage. 
Promotes tumour inflammation (Bayne et al., 2012, Mueller et 
al., 1999) 
P05112 IL-4 Supports metastasis, metabolism, and inflammation in TME 
(Bankaitis and Fingleton, 2015, Venmar et al., 2014, Venmar 
et al., 2015) 
P05231 IL-6 Facilitates monocyte to macrophage differentiation, 
angiogenesis, inflammation in TME (Caetano et al., 2016, 
Nowak et al., 2015, Patel and Gooderham, 2015, Pinciroli et 
al., 2013, Zou et al., 2016, Castellana et al., 2015, Eligini et 
al., 2013, Kojima et al., 2013, Mia et al., 2014, Nguyen et al., 
2014) 
P41159 LEP Maintains body weight and fat. Promotes growth, ECM 
remodelling, EMT, inflammation, cell migration (Alshaker et 
al., 2015, Catalano et al., 2015, Chang et al., 2015a, Kato et 
al., 2015, Lee et al., 2014b, Newman and Gonzalez-Perez, 
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2014, Wang et al., 2015a) 
P21583 SCF Promotes cell proliferation, stemness, and metastasis in 
cancers (Chen et al., 2015, Krasagakis et al., 2011, Kuonen 
et al., 2012, Park et al., 2013b, Perumal et al., 2014) 
P10600 TGF-β3 Involved in cancer metastasis (Petrella et al., 2012, Qin et al., 
2016, Tang et al., 2015) 
P01374 TNF-β Associated with tumour proliferation, invasion, and 
inflammation in TME (Bauer et al., 2012, Bjordahl et al., 
2013, Lau et al., 2014, Villanueva et al., 2009) 
 
 
5.5. Effects of CAF secretome on macrophage polarisation 
Keeping in line with the hypothesis that CAFs have capability to recruit immune cells, 
specifically monocytes, the CAF secretome (fig. 5.9 and 5.10) also demonstrated 
expression of IL-4 and IL-6 which are known to promote macrophage polarisation 
towards M2 (Mauer et al., 2014, Casella et al., 2016, Sanmarco et al., 2017). This 
observation led to the hypothesis that fibroblast-derived secretions, as well as 
recruiting monocytes, might influence the macrophage phenotype. To examine this, 
monocytes were isolated and differentiated into unpolarised M0 macrophages (as 
described in section 2.8) and cultured in CM from myofibroblast, senescent fibroblast 
and a patient-derived CAF (as used for MS) for 24 h. Polarisation markers CD80 and 
CD86 for M1 macrophage, and CD163 and CD206 for M2 macrophage, were 
examined at the mRNA level by RT qPCR (Fig. 5.11) (Bertani et al., 2017). 
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Macrophages cultured with CM from 24 h TGF-β1 treated NOF (myofibroblast), 15 d 
cisplatin treated NOF (senescent fibroblast), and CAF002 (patient CAF) exhibited 
higher level of M2 marker CD206 (in blue boxes) transcripts compared to the 24 h 
and 15 d control (Fig. 5.11), but this did not reach significance due to variation in 
results obtained using the different cultures. CD86 (in orange boxes), an M1 marker, 
was elevated at the transcript level in indirect co-cultures of macrophages with either 
24 h TGF-β1 treated (myofibroblast), 15 d cisplatin treated (senescent fibroblast), 
and CAF002 (patient CAF) compared to 24 h and 15 d controls, but this change was 
lower than observed for CD206 transcripts (Fig. 5.11). 
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Figure 5.11. Effect of macrophage incubation with CAF CM on macrophage 
polarisation: Macrophages were incubated for 24 h with CM from lab generated 
myofibroblast, senescent fibroblast, their untreated controls, and a patient CAF. RNA 
from these macrophages was isolated to generate cDNA which was used in qPCR, 
normalised to B2M, to look at polarisation markers (CD80, CD86, CD163 and 
CD206). M2 marker CD206 transcript was expressed in higher quantity when 
macrophages were cultured in CM from myofibroblast, senescent fibroblast, and 
patient CAF compared to their respective controls. Amongst the 3, incubation with 
patient CAF CM expressed the highest level of CD206 transcript followed by CM 
from senescent fibroblast. Statistical analysis – not significant, TWO way ANOVA, 
data are mean with +/- SEM, n = 3 biological repeats. 
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5.6. Summary 
To conclude, MS technique was used in this project to examine differences as well 
as similarities between the secretomes of lab-generated CAF phenotypes, 
myofibroblasts and senescent fibroblasts, and a tumour-derived CAF. Principal 
component analysis validated that each control, phenotype, and one patient CAF 
was different from the other and spread out, yet technical repeats of each condition 
clustered together. 
Out of the thousands of protein hits in the CM tested, the analysis revealed a total of 
193 significant proteins hits, out of which most (26%) proteins; HSPG2, BGN, 
COMP, COL7A1, IGFBP3 & 5, MDH1, PSMA7, RARRES2, SPON1, TGFBI, ALDOA, 
TKT, EEF2 were highly upregulated and are observed previously to participate in 
metabolism in other studies based on Reactome database. Possible signal 
transduction proteins involved COL3A1, COL4A1, 5A1, 4A2, FNDC1, LAMA4, 
LAMB2, POSTN, PSMA7, RARRES2, SFRP4, SPARC which were highly 
expressed, especially in myofibroblast CM. 
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Only few highly expressed proteins participated in the immune system; COL3A1, 
C1r, CFD and PSMA7, most of these proteins were expressed by senescent 
fibroblast according to reactome database. 
A well-known characteristic of fibroblast is to modify the ECM; COMP, CCDC80, 
COL3A1, COL4A1, COL5A1, COL7A1, COL14A1, COL4A2, COL5A2, EFEMP1, 
LAMA4, LAMB2, POSTN, PXDN, SERPINE1, SPARC were found to upregulated 
above the 5 fold threshold applied, and again most of these proteins were expressed 
by myofibroblast. 
Even though MS analysis exhibited some uncommon, it didn’t show any cytokines. 
MS requires higher concentration of proteins to achieve hits, and literature shows 
evidence of cytokines like IL-6, IL-8, CCL2, and the like being secreted from CAFs. 
And the cytokine array validated secretion of cytokines by both myofibroblast and 
senescent fibroblast.  
Similar to MS analysis, myofibroblast CM displayed a wider range of cytokine 
cocktail secreted compared to senescent fibroblast. However, not all cytokines 
secreted by the myofibroblasts maybe of biologically effective concentration as some 
of the antibodies on the panel detect protein levels at pg/ml range. 
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Many of the upregulated cytokines were responsible for promoting angiogenesis, cell 
proliferation, survival, cell invasion and most importantly maintaining inflammatory 
environment, yet providing immune evasion; namely ANG, BDNF, BMP4, EGF, 
FGF6, GCP2, GDNF, GMCSF, IL-4, IL-6, LEP, SCF, TGF-β, TNF-β (Ivanova et al., 
2013, Owens et al., 2013, Kim et al., 2015, Vanhecke et al., 2011, Yang et al., 2012, 
Lin et al., 2014, Pozzi and Weiser, 1992, Riedel et al., 2005, Lin et al., 2007, Duffy et 
al., 2008, Sullivan et al., 2009, Ara and Declerck, 2010, Rose-John, 2012).  
As seen in chapter 4, CM from both myofibroblast and senescent fibroblast recruited 
monocytes, the cytokine array also showed other chemokines like eotaxin-1, 2, 3, 
GCP-2, I-309, CCL2, Rantes, CCL13, SCF, SDF-1α, and TARC which recruit 
monocytes, eosinophils, mast cells, neutrophils, T cells, and B cells. With proof in 
hand that CAFs are able to recruit monocytes, effects of co-culture with CAF CM 
with macrophage on polarisation were observed. 
qPCR results from the co-culture showed that CM from myofibroblast, senescent 
fibroblast, and patient CAF up-regulated transcripts of M2 macrophage marker 
CD206 compared to their controls. However, the same macrophages also showed a 
slightly higher transcription of CD86 compared to the controls, which is an M1 
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marker suggesting that M1 and M2 phenotypes are not rigid phenotypes, but the 
expression of the markers (M1 – CD80 and CD86, M2 – CD163 and CD206) lie on a 
spectrum and their expression is influenced by the cytokine environment around 
them. Therefore can express varying levels of each polarisation marker across the 
span of the tumour to serve varying purposes. 
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Chapter 6 
6. Discussion 
6.1 Introduction 
Cancer associated fibroblasts (CAFs) found in tumour microenvironment (TME) are 
commonly the most prominent cell type in solid tumours and secrete a multitude of 
soluble factors promoting ECM changes, angiogenesis, tumour growth, invasion, and 
immune cell infiltrate (Lim et al., 2011a). CAFs are thought to comprise a 
heterogeneous mix of activated fibroblasts arising from local fibroblasts, 
epithelial/tumour cell through EMT, pericytes, endothelial cells, adipocytes, bone-
marrow derived mesenchymal stem cells in response to the local paracrine 
environment; this may differ depending on the tissue in which the tumour grows 
(Augsten, 2014a).  
With the existence of different sub-populations of CAFs, one of the questions that 
arise is whether there is any difference in their role of tumour progression. Two of the 
many sub-populations of CAFs identified are myofibroblastic CAF and senescent 
CAF, both of which are α-SMA positive (Routray et al., 2014b, Davalos et al., 2010b, 
Mellone et al., 2017).  α-SMA is the most common marker used in CAF studies, but it 
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fails to recognise distinguish between sub-populations, and differences/similarities 
between those sub-populations. Perhaps certain sub-populations are more tumour 
promoting than another, when identified can serve as a prognostic marker, and as a 
possible treatment target. This study was designed to examine and compare the 
secretome of myofibroblasts and senescent fibroblasts, and their capabilities to 
recruit monocytes. Monocytes which differentiate in to macrophages were chosen as 
the immune cell of interest as there is evidence of monocyte chemoattractants being 
secreted by CAFs (Mueller et al., 2010, Wu et al., 2011, Ohgo et al., 2015, Li et al., 
2014b, Tsuyada et al., 2012b), and evidence suggests the presence of these tumour 
associated marcophages often leads to poor prognosis in most solid tumours, 
including oral cancers (Gajewski et al., 2013, Bingle et al., 2002, Chen et al., 2005, 
Ryder et al., 2008, Zhu et al., 2008). 
6.2  Generation of CAF like phenotype 
This study used normal oral fibroblasts (NOFs) isolated from buccal or gingival tissue 
extracted during routine oral surgeries. NOFs were treated with TGF-β1, a very 
prominent soluble factor present in TME, to induce myofibroblast transdifferentiation 
as previously reported (Melling, 2015, Elmusrati et al, 2017), and cisplatin was used 
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to induce senescence in the same NOFs (Melling, 2015, Kabir et al., 2016). CAFs 
isolated from OSCC patients were also used to compare their phenotypes with the 
lab-generated myofibroblasts and senescent fibroblasts. Myofibroblastic 
transdifferentiation from NOFs was confirmed by up-regulation of myofibroblastic 
markers like α-SMA, FNEDA, COL1A1, as previously reported (Melling, 2015, 
Dugina et al., 2001, Desmouliere et al., 1993).  
During initial stages of the project, three separate NOF cultures (NOF316, NOF320, 
and NOF343) were treated with TGF-β1 (5 ng/ml) for 24 h, 48 h, and 96 h. The ideal 
duration of TGF-β1 for myofibroblastic transdifferentiation had previously been 
reported in the lab to be 48 h (Melling, 2015) but two more time points were selected 
– half and double the ideal duration - to examine effects of TGF-β1 on secretory 
factors, especially cytokines.  
All three NOFs showed an increase in α-SMA transcripts at 24 and 48 h post 
treatment but this declined with longer treatment duration, suggesting that 
continuous production of α-SMA mRNA is not required for protein production as seen 
in NOF316 and NOF343 showed an increasing expression of α-SMA protein with 
longer treatment of TGF-β1. Both the control and TGF-β1 treated NOF320, however, 
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exhibited similar expression of α-SMA protein, indicating a lack of responsiveness to  
TGF-β1. This could be due to extraction of NOF320 from an inflamed site which is 
usually rich in TGF-β1, desensitizing cells including fibroblasts in the vicinity (Hasan 
et al., 1997). Finally, NOF343 was selected for further experimentation due to its 
clear response to TGF-β1 and availability in the lab. Immunocytochemistry of 
NOF343 after TGF-β1 treatment also confirmed the expression of α-SMA stress 
fibers as seen previously in other studies (Melling, 2015, Mellone et al., 2017).  
Senescence was induced in fibroblasts (NOF343) using cisplatin. These cells 
displayed an enlarged and flattened cell morphology; showed an up-regulation of 
p16INK4a, p21 mRNA, and stained positive in senescence associated β-
galactosidase assay in agreement with previous studies (Kabir et al., 2016, Dimri et 
al., 1995, Ben-Porath and Weinberg, 2004, Sedelnikova et al., 2004, Passos et al., 
2010, Overhoff et al., 2014). CAFs are also reported to display increased secretion 
of ECM components; here myofibroblasts displayed a significant increase in 
transcript levels of FNEDA, and a non-significant trend towards an increase in 
COL1A1 transcripts. Senescent fibroblasts, however, did not show an increase in 
either FNEDA or COL1A1 transcripts; this is in agreement with similar data reported 
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in a study by (Mellone et al., 2017). This suggests that perhaps myofibroblasts are 
more responsible than senescent fibroblasts for modifying the ECM in the TME.  
The next secreted factor examined was IL-6, known to be a notorious cytokine; it has 
been linked to chronic inflammation initiating cancer, and subsequent progression 
and metastasis. IL-6 signalling promotes survival and proliferation of immune cells 
such macrophages and Th17 cells, and in neighbouring cancer cells activates 
transcription of cell cycle regulator cyclin D1, proto-oncogene c-myc, 
JAK/STAT3/PI3AK, angiogenic factors – VEGF & FGF, anti-apoptotic proteins like 
survivin, bcl2 and  bcl-XL (Yao et al., 2014, Middleton et al., 2014, Ara and Declerck, 
2010, Rose-John, 2012, Tanaka et al., 2014, Fisher et al., 2014). Previously, 
senescent fibroblasts have been reported to exhibit secretion of IL-6 in our lab (Kabir 
et al., 2016), and this finding was extended in this study, with both 24 h TGF-β1 
treated myofibroblast and senescent fibroblasts shown to secrete significant 
amounts of IL-6, with latter secreting more than the former. This suggests that CAF 
with a myofibroblastic phenotype, as well as senescent fibroblasts, may contribute to 
an inflammatory TME. 
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In the literature, IL-6 shows conflicting roles in relation to CAFs, on one hand it 
down-regulated p16INK4a, p21, and p53 in normal fibroblasts through paracrine 
signalling, and increased expression of α-SMA, SDF-1, and TGF-β1 after 24 h 
(Hendrayani et al., 2014), while another study (Kojima et al., 2013) provided 
evidence of IL-6 inducing senescence in fibroblast by activating STAT3, inducing 
expression of IGFBP5 which in turn produces ROS. When this axis is constantly 
activated, ROS induced senescence as a DNA damage response leading to further 
secretion of IL-6, subsequently senescing neighbouring fibroblasts.  
It was also observed that IL-6 secretion reduced with increasing duration of TGF-β1, 
suggesting that myofibroblasts produce IL-6 in short bursts, which along with a 
previous study showing short exposure (24 h) to IL-6 induced myofibroblastic 
activation (Hendrayani et al., 2014) indicates that myofibroblasts may form 
segregated clusters where neighbouring normal fibroblasts maybe activated to 
myofibroblasts farther away from other sources of IL-6. 
Senescent fibroblasts, in contrast, are capable of maintaining secretion of IL-6 
suggesting that they can overpower myofibroblasts, along with other cancer cells, 
224 
 
and macrophages (which also produce IL-6) and senesce them through the IL-
6/STAT3/IGFBP5 loop. 
6.3  Monocyte/macrophage recruitment by myofibroblasts and senescent fibroblasts 
Once the myofibroblastic and senescent fibroblastic phenotypes were characterised, 
the next aim of the study was to examine their capability to recruit monocytes. A 
monocytic cell line, THP-1 was migrated towards secreted factors from both 
myofibroblasts and senescent fibroblasts. Significant migration was observed 
towards conditioned media (CM) from senescent fibroblasts compared to minimal 
migration towards myofibroblast CM. THP-1 migration towards CM from cisplatin 
induced senescent fibroblasts corroborates and extends preliminary data from 
(Kabir, 2015). 
Since THP-1 is a monocytic cell line, and does not accurately represent the 
phenotype or functions of primary cells, monocytes from peripheral blood were 
isolated (confirmed by expression of CD14) and migrated towards CM from 
myofibroblasts and senescent fibroblasts. Secreted factors by senescent fibroblasts 
again showed the highest recruitment of peripheral blood monocytes (PBM), but 
myofibroblasts showed recruitment of PBMs too, especially 24 h TGF-β1 treated 
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myofibroblasts, and declining towards CM from myofibroblasts treated with TGF-β1 
longer, unlike THP-1 cells. However, the results from PBM migration were not 
statistically significant, most likely due to patient to patient variability as each 
biological repeat used PBMs from a different buffy coat. 
In the case of both THP-1 cells and PBMs, senescent fibroblasts recruited the 
highest number of monocytes, but only PBMs (not THP-1) migrated towards 
myofibroblast CM. In light of this finding the presence and function of the most 
common chemokine/receptor axis for monocytes, CCL2/CCR2, was investigated to 
examine the underlying mechanisms.  
CCR2 is found to have two isoforms, CCR2A and CCR2B, where the latter is the 
most commonly found isoform biologically. Levels of the transcripts of both isoforms 
were examined in THP-1 and PBMs; both showed high expression of CCR2B which 
was higher in THP-1. However, at protein level, only PBMs exhibited expression of 
CCR2B, which agrees with the study by (Tanaka et al., 2002), suggesting that 
perhaps migrating THP-1 cells use a different chemokine or express another variant 
of CCR2 that the antibody used in this study does not bind to.  
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Next, expression of CCL2 was investigated in both myofibroblasts and senescent 
fibroblasts. At transcript level, 24 h TGF-β1 treated myofibroblasts showed a small 
increase, only to decline with longer TGF-β1 treatment, but senescent fibroblasts 
expressed very high levels of CCL2 transcripts compared to control cells. ELISA 
showed that myofibroblasts secreted increased levels of CCL2 after 24 h of TGF-β1 
treatment but slowly declined with time suggesting that CCL2 mRNA is transcribed 
and translated swiftly after a short exposure to TGF-β1, but senescent fibroblasts 
expressed high levels of CCL2 transcripts, as well as significantly high levels of 
secreted CCL2 protein as observed in (Kabir et al., 2016) suggesting that production 
of CCL2 is a sustained activity, similar to IL-6 production as described in section 6.2. 
Subsequently, CCR2 (the CCL2 receptor) was inhibited on PBMs to investigate 
whether this discouraged migration in response CCL2 from CM. Although it did not 
abolish migration, it did decrease migration towards CM 24 h TGF-β1 treated 
myofibroblasts and senescent fibroblast significantly as shown by the use of same 
CCR2 antagonist in a different context ((Carmo et al., 2014). Nonetheless, 
monocytes express a variety of chemokine receptors as described in (Sandblad et 
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al., 2015), which could possibly compensate for the inhibition of CCR2, permitting 
the residual minimal migration observed in this study.  
To further inhibit these remaining chemokine receptors, Pertussis toxin (PTX) was 
employed which is known to inhibit most G-protein coupled receptors, in this case 
chemokine receptors, and suppress monocyte migration as verified by various 
studies (Ogawa et al., 1983, Malik et al., 2009, Syrovets et al., 1997, Kang et al., 
2014). Compared to untreated monocytes, the migration of PTX treated monocytes 
was reduced but surprisingly, migration was still higher compared to migration of 
monocytes with CCR2 inhibited. The reason for this anomaly could be explained by 
the activation of proline rich tyrosine kinase 2 (Pyk2), which is a non-receptor 
tyrosine kinase known to be activated by chemokines, GPCR ligands, and growth 
factors (Dikic et al., 1996, Dikic and Schlessinger, 1998). It is also one of the 
signalling mediators of GPCRs including CCR5 and CXCR4 leading to activation of 
MAPK, calcium induced regulation of ion channels and  c-Jun N-terminal kinase, and 
is known to participate in cell motility and migration   (Del Corno et al., 2001, Ganju 
et al., 1998, Avraham et al., 2000). A group studying activation of Pyk2 in primary 
macrophages by HIV-1 gp120 and chemokines found that Pyk2 was activated by 
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CCL4 (MIP-1β) binding to CCR5 in spite of treatment with PTX (100 ng/ml for 18 h), 
suggesting migration through activation of CCR5 is either only partially or not G-
protein (Gαi) mediated  (Del Corno et al., 2001). Even though CCR2 is the most 
prominent chemokine receptor on monocytes and there aren’t any studies looking at 
Pyk2 subsequent to CCR2 activation, it could be possible that CCR2 migration is not 
fully G-protein mediated either, hence complete inhibition of CCR2 had more of an 
impact on migration than PTX treated inhibition of GPCR component of CCR2. It is 
also possible that the dose of PTX used here was not sufficiently high to completely 
inhibit receptor function. 
Next, CCL2 secretion and monocyte recruitment by patient CAFs were examined. A 
study by (Hassona et al., 2013a)  suggested that genetically unstable OSCC first 
activates, then senesces CAFs through TGF-β1 and ROS dependent pathways. This 
senescence was not observed in CAF isolated from genetically stable tumours. Four 
CAFs from the same study were used in this study; BICR18 and BICR78 are derived 
from genetically unstable (GU) OSCC, and BICR69 and BICR73 from genetically 
stable (GS) OSCC. Senescent associated β-galactosidase assay on these CAFs 
showed BICR18 and BICR78 from GU OSCC staining positively, while BICR69 and 
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BICR73 developed little to no staining; similar results using BICR18 and BICR69 
were obtained in the same lab (Kabir, 2015).  In accordance with the results reported 
earlier in this thesis with senescent fibroblasts generated in the lab, the naturally 
senescent BICR18 and BICR78 from GU OSCC also secreted high levels of CCL2 
with high levels of monocyte recruitment, compared to BICR69 and BICR73 which 
secreted low levels of CCL2 and recruited fewer monocytes.  
However, a peculiarity was observed in this case; BICR78 produced very strong 
staining in SA β-gal assay, and secreted the highest level of CCL2, yet it recruited 
fewer monocytes than BICR18; both CAFs are from GU OSCC. It is possible that 
BICR18, along with senescent fibroblasts contains myofibroblasts or a 3rd sub 
population of CAF that secreted other chemokines responsible for monocyte 
recruitment. Due to lack of time further characterisation of BICR18 was not pursued. 
Another CAF, CAF002, which was isolated recently in the same Sheffield lab where 
this study took place, didn’t show positive staining for senescence, and recruited 
fewer monocytes compared to the more senescent fibroblasts CAFs in the group – 
BICR78 and BICR18. Except for BICR69, all the other CAFs examined – BICR73, 
BICR78, BICR18, and CAF002, irrespective of the type of tumour they were isolated 
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from displayed higher secretion of CCL2 and recruitment of monocytes compared to 
normal oral fibroblast NOF343 confirming that both activated/senescent CAF are 
capable of recruiting monocytes. 
Subsequently, NOF343 was co-cultured with CM from cancer cell lines: H357 and 
SCC4 for 24 h to examine whether cancer cells can influence the secretome of 
fibroblasts in a paracrine manner. CM from NOF343 after the co-culture resulted in 
higher secretion of CCL2 and recruitment of monocytes. An experiment similar to 
this was conducted previously in the same lab, where the NOFs were co-cultured 
with cancer cell line for 48 h in an attempt to generate a myofibroblast phenotype in 
keeping with previous findings (Lewis et al., 2004, Marsh et al., 2011). Only a very 
small increase in α-SMA expression at both mRNA and protein level was identified, 
suggesting perhaps a longer incubation period with cancer cell line CM or co-
culturing with cancer cells directly is required to generate a myofibroblastic 
phenotype (Melling, 2015). Here, however, novel evidence is provided that indirect 
coculture of fibroblasts with cancer cells generates a rapid secretion of pro-
inflammatory cytokines, which recruit monoctes. Melling’s suggestion of longer 
incubation is justified as α-SMA protein expression increased with longer incubation 
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with TGF-β1 in this study, however, high expression of α-SMA may not necessarily 
equate to an active secretome; IL-6 and CCL2 secretion was highest after 24 h 
incubation with TGF-β1. 
At this stage, it was evident from this study that CAF phenotypes: myofibroblasts and 
senescent fibroblasts are capable of recruiting monocytes. Immunohistochemical 
analysis of OSCC tissue sections were therefore undertaken to validate the 
existence of any correlation between the presence of α-SMA+ CAFs and CD68+ 
TAMs as previously been reported (Marsh et al., 2011, Lewis et al., 2004, Takahashi 
et al., 2017). A trend was found between presence of CAFs close to the invasive 
tumour front, and presence of tumour associated macrophages (TAMs) in the tumour 
but not in the stroma. There was no trend or correlation seen between presence of 
CAFs and TAMs in the stroma. However, this could be due to a small sample size of 
only 10 sections being analysed, while other studies which found correlation 
between their presences used a much larger sample size (Marsh et al., 2011, Lewis 
et al., 2004, Takahashi et al., 2017). 
Macrophages are known to be secretory in nature, and influence inflammation by 
both causing and resolving it. This power to cause and resolve inflammation also 
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exists in the TME and depends on their polarised phenotypes – M1 and M2, which is 
attained after differentiation from monocyte to M0 macrophage in tissue, and 
subsequent polarisation based on the cytokine environment around them. (Sica et 
al., 2006a, Bayne et al., 2012, Chen et al., 2005, Ueno et al., 2000, Zhang et al., 
2013, Mantovani and Locati, 2013, Bingle et al., 2002, Shi and Pamer, 2011, Biswas 
and Mantovani, 2010, Sanmarco et al., 2017). After confirming paracrine activation 
of fibroblasts by cancer cells, effect of polarised macrophages on fibroblast activation 
was examined. Surprisingly, the study showed that CM from unpolarised M0 
macrophages activated the fibroblasts to the greatest extent compared to CM from 
M1 and M2. This result requires further validation, however, by examination of other 
markers of the myofibroblast phenotype. Unfortunately, there are not many studies 
on M0 phenotype and its secretome, however, a transcriptome profiling study 
(Gabrusiewicz et al., 2016, Liu et al., 2016) showed that M0 macrophages from 
glioblastoma patients express markers CD163 and CD206, similar to M2, and 
CD204 hinting at an active secretome. They also overexpressed miR-223 which can 
activate NF-κB signalling in M0 macrophages resulting in inflammatory secretions 
(Haneklaus et al., 2013). Another study found that M0/M2 macrophages respond in 
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similar ways to M1 macrophages when Rho pathway was inhibited suggesting that 
M0 may have subtle similarities to M2 (Liu et al., 2016). Based on these limited 
evidences and suggestions, it is possible M0 macrophages secrete factors to 
activate fibroblasts, but further analysis of M0 secretome and the fibroblast 
phenotype in co-culture is required to validate this. 
6.4  Differential expression of proteins in myofibroblast, senescent fibroblast and CAF 
secretome.  
The importance TME in tumour progression and metastasis has been widely 
accepted, however, the molecules involved in crosstalk between cancer and stromal 
cells is still far from fully understood. With a diverse selection of stromal cells; 
fibroblasts, adipocytes, endothelial cells, lymphocytes, inflammatory cells including 
macrophages communicate through a network of signalling molecules (Yang and 
Lin, 2017, Kise et al., 2016, Scharping and Delgoffe, 2016, Raffaghello and Dazzi, 
2015, Lyssiotis and Kimmelman, 2017). Amongst these stromal cells cancer 
associated fibroblasts remain a poorly characterised heterogeneous population. In 
order to shed more light on their phenotypes and function, this study examined the 
secretome of two previously described sub-populations of CAFs, myofibroblasts and 
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senescent fibroblasts using mass spectrometry and a cytokine array. Previously, 
Mellone et al compared the transcriptome of myofibroblasts and senescent 
fibroblasts, giving us a preliminary insight in to genetic differences between the two 
sub-populations of CAFs from OSCC (Mellone et al., 2017). 
In this thesis, principal component analysis (PCA) revealed the degree of variation in 
the types and levels of proteins secreted by 24 h control NOF, 24 h TGF-β1 
myofibroblast, 15 d control NOF, 15 d cisplatin induced senescent fibroblast, and 
patient CAF-CAF002. 
The largest variation was seen between 24 h control NOF and CAF002, as 
expected, highlighting the active secretory phenotype CAFs possess. A difference 
was observed between the secretome of myofibroblasts and senescent fibroblasts 
on PCA, a finding in meeting one of the aims of this study, that is to examine 
differences between the secretomes of these two phenotypes. Differences between 
myofibroblast and senescent fibroblasts were also observed by (Mellone et al., 2017) 
at a whole cell transcriptional level. Out of 193 significantly expressed proteins 
reported in this thesis, changes in transcripts encoding 63 of those proteins were 
found in the study by (Mellone et al., 2017), where 45 proteins expressed by 
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myofibroblasts were consistent with their gene expression, while 18 weren’t. In case 
of senescent fibroblasts, 29 proteins were consistent with their gene expression, and 
34 were not (Mellone et al., 2017). Table 13 compares protein regulation with gene 
regulation data from the study conducted by Mellone et al (Mellone et al., 2017). 
Table 13: Comparison between gene regulation and protein regulation in 
myofibroblast (MF) and senescent fibroblast (SF) compared to their controls. 
 
Protein  Protein regulation 
in MF compared 
to NOF 
Gene regulation 
in MF compared 
to NOF 
Protein regulation 
in SF compared 
to NOF 
Gene regulation in 
SF compared to 
NOF 
COL1A1 Up-regulated Up-regulated Up-regulated Down-regulated 
COL1A2 Up-regulated Up-regulated Up-regulated Down-regulated 
COL3A1 Up-regulated Up-regulated Up-regulated Down-regulated 
COL5A1 Up-regulated Up-regulated No change Down-regulated 
COL5A2  Up-regulated Up-regulated Up-regulated Down-regulated 
COL6A3 Up-regulated Up-regulated Up-regulated Up-regulated 
COL4A1 Up-regulated Up-regulated No change Down-regulated 
COL4A2 Up-regulated Up-regulated Down-regulated Down-regulated 
COL7A1 Up-regulated Up-regulated No change Down-regulated 
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COL11A1 Down-regulated Up-regulated Up-regulated Up-regulated 
COL14A1 No change Up-regulated Up-regulated Up-regulated 
HSPG2 No change Up-regulated Up-regulated Up-regulated 
BGN Up-regulated Up-regulated Up-regulated Up-regulated 
COMP Up-regulated Up-regulated Up-regulated Up-regulated 
CTSB Down-regulated Down-regulated Up-regulated Up-regulated 
CRABP2 Down-regulated Up-regulated Up-regulated Down-regulated 
CCDC80 Up-regulated Down-regulated Down-regulated Up-regulated 
C1R Down-regulated Down-regulated Up-regulated Down-regulated 
C1S Down-regulated Down-regulated Up-regulated Down-regulated 
CFD No change Down-regulated Up-regulated Down-regulated 
DCN Down-regulated Down-regulated Up-regulated Down-regulated 
EFEMP1 No change Down-regulated Up-regulated Down-regulated 
EFEMP2 Down-regulated Up-regulated Up-regulated Up-regulated 
FNDC1 Up-regulated Up-regulated Down-regulated Down-regulated 
FBN1 Down-regulated Up-regulated Up-regulated Down-regulated 
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FBN2 Down-regulated Up-regulated Up-regulated Up-regulated 
FSTL1 Up-regulated Up-regulated Up-regulated Up-regulated 
ISLR Up-regulated Up-regulated Up-regulated Down-regulated 
IGFBP2 Down-regulated Down-regulated Up-regulated Up-regulated 
IGFBP3 Up-regulated Up-regulated No change Up-regulated 
IGFBP4 Down-regulated Down-regulated Up-regulated Down-regulated 
IGFBP5 Down-regulated Down-regulated Up-regulated Down-regulated 
ITGBL1 Up-regulated Down-regulated Up-regulated Up-regulated 
MMP1 Down-regulated Up-regulated Up-regulated Up-regulated 
LAMA4 Down-regulated Down-regulated Up-regulated Up-regulated 
LAMB1 Down-regulated Down-regulated Up-regulated Up-regulated 
LAMB2 Down-regulated Up-regulated Up-regulated Up-regulated 
LAMC1 Down-regulated Down-regulated Up-regulated Up-regulated 
LTBP4 Down-regulated Down-regulated Up-regulated Up-regulated 
LUM Down-regulated Down-regulated Up-regulated Down-regulated 
MDH2 Up-regulated Up-regulated Down-regulated Up-regulated 
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TIMP1 Down-regulated Up-regulated Down-regulated Up-regulated 
YBX1 Up-regulated Up-regulated Down-regulated Down-regulated 
NME1 Up-regulated Up-regulated Down-regulated Up-regulated 
POSTN Up-regulated Up-regulated Up-regulated Down-regulated 
PXDN Up-regulated Up-regulated Up-regulated Up-regulated 
SERPINE
1 
Up-regulated Up-regulated Down-regulated Up-regulated 
PCOLCE Down-regulated Up-regulated Up-regulated Down-regulated 
PSMA7 Up-regulated Up-regulated Up-regulated Up-regulated 
RARRES
2 
No change Up-regulated Up-regulated Down-regulated 
PRSS23 Up-regulated Up-regulated Up-regulated Up-regulated 
SPARC Up-regulated Up-regulated Up-regulated Up-regulated 
SPON1 No change Down-regulated Up-regulated Down-regulated 
QSOX1 Down-regulated Down-regulated Up-regulated Up-regulated 
SVEP1 Up-regulated Up-regulated Up-regulated Up-regulated 
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THSB1 Up-regulated Up-regulated Up-regulated Down-regulated 
THSB2 Up-regulated Up-regulated Up-regulated Down-regulated 
TGFBI Up-regulated Up-regulated Up-regulated Down-regulated 
TAGLN Up-regulated Up-regulated Down-regulated Up-regulated 
TPM1 Up-regulated Up-regulated Down-regulated Up-regulated 
TPM3 Up-regulated Down-regulated No change Up-regulated 
TPM4 Up-regulated Up-regulated Down-regulated Down-regulated 
VCAN Up-regulated Up-regulated Down-regulated Down-regulated 
 
From table 13, it is clear that more proteins correlate with their cellular gene 
expression (as determined by RNA-seq) in myofibroblasts than senescent 
fibroblasts. From their Gene Set Enrichment Analysis of the transcriptomes, Mellone 
et al also suggested that myofibroblasts have genes associated with ECM deposition 
upregulated which correlates with the protein data from this study showing over-
expression of COL1A1, COLA1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, 
COL6A3, and COL7A1. According to Mellone et al, the same genes were observed 
to be down-regulated in senescent fibroblasts in comparison (Mellone et al., 2017), 
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however, the data in this thesis identified confounding protein results where fold 
increases were observed in expression of COL1A1, COLA1A2, COL3A1, COL4A2, 
COL5A1, COL5A2, COL6A3, COL11A1, and COL14A1 showing a negative 
correlation with their gene expression. COL6A3, also known as endotrophin, was 
found to be over-expressed in both myofibroblast and senescent fibroblasts, and has 
been implicated in several cancers like melanoma, ovarian cancer, lung cancer, 
oesophageal cancer, breast cancer, pancreatic cancer and colon cancer (Arafat et 
al., 2011, Sherman-Baust et al., 2003, Nanda et al., 2004, Motrescu et al., 2008, 
Iyengar et al., 2005, Park and Scherer, 2012). COL6A3 is also known to promote 
fibrosis, endothelial cell migration, alternate activation of macrophages with high 
expression of M2c marker – CD150, IL-10, IL-12 and TGF-β, and impart 
chemoresistance to tumour cells (Park et al., 2013a, Park and Scherer, 2012, 
Spencer et al., 2010). As mentioned previously, COL6A3 not only activates 
macrophages alternatively, it also serves as a chemoattractant for macrophages, 
and is actively secreted by M2 macrophages as well (Park and Scherer, 2012, 
Schnoor et al., 2008). Therefore, it could be hypothesised that both myofibroblasts 
and senescent fibroblasts recruit macrophages via COL6A3, as well as by the 
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cytokines identified functionally earlier in this thesis, and reported by others. Similar 
to COL6A3, type I collagen has also been reported to prevent monocytes 
differentiation in to M1 macrophage (Kaplan, 1983).  
Other types of collagen secreted by both myofibroblasts and senescent fibroblasts, 
such as, collagen type V has shown to promote malignant behaviour of pancreatic 
ductal adenocarcinoma (Berchtold et al., 2015), collagen type IV feeds proliferative, 
migratory and survival behaviour of pancreatic cancer cells in an autocrine loop 
(Ohlund et al., 2013); collagen type VII, especially COL7A1 increased PI3K and 
MAPK resulting in cell migration and invasion in cutaneous SCC (Pourreyron et al., 
2014), COL7A1 mRNA expression was also found to be up-regulated in malignant 
esophageal tissue.  
COL11A, secreted by senescent fibroblasts but not by myofibroblasts, promoted 
tumour cell migration and invasion in ovarian cancer, correlated with metastasis in 
invasive carcinomas, and promoted HNSCC growth and invasion (Sok et al., 2013, 
Cheon et al., 2014, Vazquez-Villa et al., 2015).  
Several proteins and glycoproteins known to interact with collagen fibres, such as 
DCN, HSPG2, EFEMP1, EFEMP2, FBN1, FBN2, LAMA4, LAMB1, LAMB2, LAMC1, 
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LTBP4, LUM were over-expressed in senescent fibroblasts compared to 
myofibroblasts (also correlating their gene expression with (Mellone et al., 2017), 
while some ECM interacting proteins like BGN, THBS1, and THBS2 were over-
expressed by both myofibroblasts and senescent fibroblasts. Many of these proteins 
have been implicated in cancer, although some have shown conflicting roles, for 
example, decorin modulates endothelial cell motility on type 1 collagen through 
activation of IGF1 receptor (Fiedler et al., 2008), but it also interferes with angiogenic 
activities of THBS1 and VEGFA to attenuate angiogenesis in several cancers 
including OSCC (Grant et al., 2002, de Lange Davies et al., 2001). However, decorin 
often associates with HNC positively (Stylianou et al., 2008, Dil and Banerjee, 2011, 
Wu et al., 2010, Nayak et al., 2013, Dil and Banerjee, 2012, Skandalis et al., 2006, 
Kasamatsu et al., 2015, Banerjee et al., 2003). Thus, targeting decorin or its source 
could have a positive impact on prognosis in HNC. 
Another heavily researched ECM component is perlecan (HSPG2), shown in this 
study to be secreted by senescent fibroblasts but not by myofibroblasts, and has 
been positively associated with cancers of the head and neck, and promotes 
invasion of HNC cells and its knockdown reduces cell migration (Maruyama et al., 
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2014, Kimura et al., 2000, Mishra et al., 2011, Tilakaratne et al., 2009, Ikarashi et al., 
2004, Hasegawa et al., 2016, Ahsan et al., 2011, Kawahara et al., 2014, Chen et al., 
2006). Targeting senescent fibroblasts, thus eliminating an important source of 
perlecan in the TME, might therefore be beneficial to treating cancers of the head 
and neck. 
An interesting protein secreted by senescent fibroblasts but not myofibroblasts is 
quiescin sulfhydryl oxidase 1 (QSOX1). It has shown tumour promoting functions in 
breast and pancreatic cancer, by preventing oxidative stress induced apoptosis, 
activates MMP2/9 promoting invasion, and is overexpressed in both cancers serving 
as a potential biomarker (Katchman et al., 2011, Poillet et al., 2014, Morel et al., 
2007, Sobral et al., 2015, Shi et al., 2013, Lake and Faigel, 2014, Hanavan et al., 
2015). The expression and function of QSOX1 has not been examined in HNC; this 
is worth further analysis as it has a potential role which could be abolished by 
targeting senescent fibroblasts.  
The final protein to mention secreted only by senescent fibroblasts, and not 
myofibroblasts, is retinoic acid receptor responder protein 2 (RARRES2) RARRES2, 
also known as chemerin, is a chemokine for ChemR23 receptor expressed on 
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dendritic cells and macrophages (Samson et al., 1998). Chemerin promotes 
angiogenesis through activation of MAPK, Akt and MMP2/9 supporting endothelial 
cell proliferation, migration and new capillary formation (Bozaoglu et al., 2010). M1 
macrophages lose their expression of ChemR23 upon polarisation via TLR ligands, 
and cytokines (IFN-γ and TNF-α), while M2 macrophages up-regulate their 
expression of ChemR23 after polarisation by TGF-β, suggesting chemerin may 
facilitate further movement of M2 macrophages within the TME (Zabel et al., 2006), 
which could also go towards explaining the IHC results reported here; α-SMA 
positive CAFs (especially senescent fibroblasts) at the tumour margin and tumour 
cells could themselves secrete chemerin to recruit M2 macrophages within the 
tumour but further confirmation with senescent fibroblast markers and M2 markers 
are required. Chemerin has also shown evidence of recruiting other immune cells 
like dendritic cells and neutrophils via ChemR23 receptor, suggesting an influential 
role in tailoring the inflammatory environment of the tumour stroma (Parolini et al., 
2007). This again suggests senescent fibroblasts, a potential source of chemerin in 
the TME, may be a good target to reduce recruitment of macrophages. 
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6.5  Limitations of the study 
The majority of the study has been conducted using one particular NOF culture, 
NOF343,  due to its distinct response to TGF-β1, and time constraints; it is possible 
that other NOFs may give different results, as initially seen in NOF316 and NOF320, 
therefore. These experiments need to be conducted with more normal fibroblast 
samples, perhaps even from different locations (dermal, liver, pancreas) of the body 
to reinforce the data gathered from this study.  
CAFs arise from many sources which might include bone marrow derived 
mesenchymal stem cells from a distant location, or resident fibroblasts, pericytes, or 
even cancer cells themselves via EMT. Perhaps as a result of these variable origins, 
CAFs display numerous markers, such as, α-SMA, FNEDA, COL1A1, podoplanin, 
FAP, and FSP1 (Augsten, 2014a, Paulsson and Micke, 2014). This study only used 
α-SMA as a marker for myofibroblast activation at protein level, and FNEDA and 
COL1A1 at mRNA level. Other markers, could be be examined to further interrogate 
the myofibroblast and senescent CAF like phenotypes.  
The migration assays were conducted using monocytes from different buffy coats 
each time, increasing patient to patient variability with each repeat leading to non-
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significant result. However, a migratory trend was suggested from the results which 
could prove significant with more biological repeats. 
The immunohistochemical staining sample size contained sections from 10 patients 
due to time and tissue availablility constraints. A trend was observed between 
presence of CAFs near the tumour invasive front and presence of macrophages in 
the tumour, however a larger cohort needs to be analysed to reach a significant 
conclusive result.  
6.6 Future work 
The data gathered in this study has raised many new questions for which extra 
experimentation might provide answers. First of all, further characterisation of the 
patient CAF (CAF002) used in mass spectrometry is needed, as it had some 
similarities to myofibroblast (8 secreted proteins in common above the applied 
threshold), and some to senescent fibroblasts (10 secreted proteins in common 
above the applied threshold), and yet, not staining positively in SA β-gal assay. The 
patient CAF used could possibly be a third sub-population, and characterising it 
would open doors to new questions and theories.  Increasing the number of CAF 
cultures analysed would also increase confidence in the results obtained. 
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It would also be interesting to investigate whether normal fibroblasts from other parts 
of the body, such as dermal, liver, and pancreatic fibroblasts, when activated to 
myofibroblastic or senescent phenotype attract macrophages in similar manner, and 
other secretory differences between them, as resident fibroblasts have a different 
genetic profile based on their location in the body suited specifically the homing 
tissue. 
With limited literature existing on M0 macrophages, a cytokine array on the 
secretome comparing CM from M0, M1, and M2 macrophages could possible give 
us a hint on why secretory factors from M0 macrophages activated NOF the most, 
expressing α-SMA. Having said that, when NOFs were cultured in CM from cancer 
cell lines, they secreted more CCL2 and recruited more macrophages compared to 
NOFs cultured in normal medium, suggesting activation of the said NOFs. Further 
investigation is required to characterise the phenotypical changes those NOFs 
underwent in response to secretory factors from cancer cell lines, which in turn 
needs analysis as well, to give us a picture of the secretome of the cancer cell lines 
and what activated the fibroblasts. Subsequently, the effect on secretory factors from 
myofibroblasts, senescent fibroblasts and CAF002 (patient CAF) on M0 
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macrophages indicated polarisation towards an M2 phenotype (up-regulation of 
CD206), but this was examined at mRNA level. Macrophage polarisation markers 
could also be examined at protein level, perhaps using flow cytometry to examine 
CD80, CD86, CD163, and CD206. 
Finally, phenotypes of normal, myofibroblasts and senescent fibroblasts should be 
examined in 3D models to see how a 3D environment, more akin to that encountered 
in the body, affects these cells and their secretome. 
6.7 Conclusion 
The data described in this thesis identifies differences between the secretome of 
myofibroblasts and senescent fibroblasts, and their capabilities to recruit 
macrophages based on those differences. Senescent fibroblasts secreted the main 
chemokine responsible for macrophage recruitment – CCL2, in greater quantities 
than myofibroblasts along with other factors responsible for macrophage chemotaxis, 
such as CCL5, CCL13 IL-6, and chemerin/RARRES2. An important observation to 
note is that myofibroblasts also secreted CCL2 and IL-6, however the highest 
secretion was seen 24 h post TGF-β1 treatment, and these secretions declined with 
increase in treatment duration, even though expression of α-SMA kept increasing 
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with time and treatment suggesting perhaps, maintenance of TGF-β1 exposure by 
additional administration may attenuate the secretion of cytokines from 
myofibroblast.  
The recruitment of macrophages mostly occurred via the CCL2/CCR2 axis, which 
was confirmed by a substantial reduction in migration of monocytes when CCR2 on 
their surfaces were antagonised. However, due to the presence of other chemokines 
in the CM and expression of numerous other promiscuous chemokine receptor, low 
levels of migration was still observed in the presence of inhibitor. Nonetheless, 
targeting the CCR2 receptor might reduce infiltration of macrophages, improving 
prognosis as well. 
Through mass spectrometry, it was also found that both myofibrobasts and 
senescent fibroblasts secrete collagen of various types, implicated in several 
cancers but myofibroblasts secreted higher levels than senescent fibroblasts. 
However, senescent fibroblast secreted a plethora of factors (proteoglycans and 
laminins) that interact with collagen fibres, therefore suggesting that both phenotypes 
work in synchronisation to create an ECM which might be permissible for tumour cell 
survival, proliferation, growth of new capillaries, chemo-resistance, and modulating 
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immune cell polarisation towards immune-suppression. Hence, targeting either 
fibroblast phenotype or collagen or the proteins that interact with it would disrupt the 
ECM, possibly directly impacting upon tumour viability or invasive ability, or 
increasing bioavailability of cancer-targeting drugs in the TME. 
Finally, this study found the hypothesis that CAFs of different phenotypes have 
different macrophage recruitment capability holds true to a great extent, with 
senescent fibroblasts secreting and recruiting more macrophages via chemokines 
than myofibroblasts in head and neck cancer. 
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Appendix 1: Lab equipment 
Equipment Manufacturer 
Applied Biosystems 7900HT Fast Real-Time PCR System Life Technologies 
Applied Biosystems 2720 Thermal Cycler Life Technologies 
3 – 18k SciQuip centrifuge Sigma Aldrich 
Class II Safety Cabinets Walker 
Compact X4 Automatic X-ray Film Processor Xograph 
Dri-Block Heater Techne 
Electromagnetic Stirrer FALC 
Galaxy CO2 Incubators Eppendorf 
Inverted Tissue Culture Microscope AmScope 
Microplate Reader BMG POLARstar Galaxy 
Microplate Reader Tecan infinite M200 
Microtube Centrifuge Sigma Aldrich 
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NanoDrop 1000 Thermo-Fisher 
PureLab Option Water De-ioniser Elga 
SteriMate Autoclave Astell 
Rotor Gene Q Qiagen 
 
Appendix 2: Buffers and solutions: 
Buffer/Solution Contents 
Laemmli buffer 4% Sodium dodecyl sulphate, 20% glycerol, 10% β-
mercaptoethanol, 0.004% bromophenol blue, 0.125 M Tris HCl 
Running buffer 25 mM Tris base, 190 mM glycine, 0.1% SDS, pH – 8.3 
TBS  2.423 g Trizma HCL, 8.006 g NaCl, 800 ml ultra-pure water, pH 
to 7.6 using HCL 
TBS-Tween TBS + 1 ml Tween 
Macs buffer 0.5% BSA and 2 mM EDTA in PBS, pH 7.2 
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Appendix 3: Stages of tumour section: 
Tumour sections Stage 
10/46 B2 C5P T1 
07/1996 A18 A3P T3 
12/0016 B1 T4 
07/1396 B7 A2P T1 
12/0763 A1 T2 
06/2300 A2 C4P T1 
12/1009 D2 T2 
12/1911 C3 T1 
12/0641 D2 T1 
12/0763 E2 T2 
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